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Design of foldamers, unnatural backbone oligomers that mimic the structure of proteins, is an important 
field of research as these species can bind to natural proteins but are resistant to proteolytic degradation.  
We have focused on developing strategies for the design of unnatural oligomers that adopt β-sheet 
secondary structures like those commonly found in protein tertiary folds. Our approach is to modify 
natural peptide sequences that encode for β-sheet folds with various unnatural amino acid building blocks 
to produce hybrid-backbone peptides that fold like the parent sequence in aqueous solution.  
Through evaluation of β-hairpin model systems using multidimensional NMR, we have 
discovered several design strategies that may be applicable to mimicry of sheets found in larger protein 
tertiary structures and have ranked unnatural monomer types in order of increasing sheet propensity: β-
amino acid  <  N-methyl-α-amino acid  ≤  vinylogous γ4-amino acid < cyclic γ-amino acid. These 
substitutions require a 2:2 or 2:1 α- to β-residue substitution or 1:1 α- to γ- or α- to N-methyl-α-residue 
substitution to maintain native-like folding behavior.  
We applied these unnatural backbone substitutions to protein GB1, a 56 residue protein with a 
complex tertiary fold consisting of a four stranded β-sheet packed against an α-helix. Using thermal 
denaturation melts and circular dichroism spectroscopy, we have determined that the trend of sheet 
propensity seen in the hairpin peptide is similar in a tertiary fold with the caveat that the position of the 
unnatural residues matters greatly. Substitution strategies that lengthen the strands of the β-sheet have 
varying effects on the stability of the folded structure depending on their placement; substitutions near the 
center of the strands are significantly more destabilizing than those placed near the termini. Use of N-
methylated α-amino acids is not limited in this fashion, but their positioning must be chosen so as to 
avoid disruption of inter-strand hydrogen bonding.  
v 
Overall, we have determined that several types of unnatural amino acids can be used to promote 
sheet formation with limited destabilization; these amino acids could potentially be used in other proteins 
with tertiary folded structures. 
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1.0  INTRODUCTION TO BETA-SHEET FOLDAMERS 
1.1 PEPTIDE THERAPEUTICS 
Proteins are responsible for a wide variety of natural processes within the body and misfunction of these 
processes is the root cause of many diseases.1 Small molecules have been the focus of the majority of 
research in drug design, but these therapeutics are limited in their ability to target proteins with large 
surface areas.2 Peptide therapeutics offer an attractive alternative to small-molecule drugs because they 
are often target-specific, do not elicit immune responses, and can bind to large surface areas.3  
Design of peptide therapeutics relies on the ability of short peptide fragments to successfully 
mimic key structural features, such as turns, helices, or sheets, of well-folded proteins. One example of 
such structural mimicry is found in inhibition of HIV-1 protease (HIV-1 PR). Crystal structures of HIV-1 
PR show that the sheet-like regions of the N-terminal and C-terminal domains of two monomer units 
associate, driving formation of a dimer (Figure 1).4 Upon dimerization, HIV-1 PR acts as an aspartyl 
protease used for processing of polypeptide chains, a process necessary for viral infection.5 Studies have 
shown that using a fragment of the C-terminal sheet can disrupt dimerization and prevent formation of the 
active site.6 
2 
 
Figure 1. Cartoon of the HIV-1 protease dimer from PDB: 3HVP. 
Grey box highlights the N- and C-terminal sequences necessary for dimerization. 
 
 
 While the HIV-1 protease dimerization inhibitor described above uses a sheet-like structure, α-
helical structures have also seen wide applicability as peptide therapeutics. One example is enfuvirtide, a 
peptide that prevents HIV fusion between the virion and host cell.7 When HIV virus binds to a target cell, 
the viral membrane protein gp41 undergoes a conformational change from an extended three-helix bundle 
to form a compact six-helix bundle (Figure 2).8 This rearrangement brings the host cell and viral 
membrane into contact and creates a fusion pore, allowing viral infection of the host.9  Enfuvirtide, a 36-
residue fragment from the C-terminus of gp41, can disrupt this process by binding to the N-terminal 
three-helix bundle of gp41 and preventing formation of the six-helix bundle.   
3 
 
Figure 2. Cartoon of the six-helix bundle formed by gp41 during HIV infection from PDB: 1AIK. 
N- and C-terminal helices are shown as yellow and green, respectively. 
 
 
 
A third example of secondary structure mimicry in peptides can be found with somatostatins. 
These peptides have a β-turn region necessary for binding to G-protein coupled receptors. Somatostatins 
are responsible for inhibition of endocrine secretion, a potential area for therapeutic exploitation for 
diseases such as diabetes.10 Studies of SRIF-14, a 14-residue cyclic peptide found in the somatostatin 
family, show that it has a half-life less than three minutes in plasma.11 The short life-span of this peptide 
highlights one of the key drawbacks of protein therapeutics: their rapid degradation by endogenous 
proteases.  
1.2 FOLDAMERS AND SEQUENCE-BASED DESIGN 
Small peptide and protein therapeutics, because of their hydrophilic nature and high solubility in aqueous 
media, are often are cleared from the body during circulation through proteolysis by enzymes found 
dissolved in the blood or bound to cell membranes.12 To circumvent the issue of proteolysis and to 
provide mimics of specific secondary structures, one direction of research has focused on design of 
4 
foldamers, defined as “polymers with a strong tendency to adopt a specific compact conformation.”13 
Foldamers, while able to mimic the structures of natural proteins, have backbones built using unnatural 
building blocks, thereby imparting resistance to proteolytic degradation and longer half-lives compared to 
natural backbone therapeutics.14-16 Backbone homologation of an α-peptide to a β-peptide, for example, 
can increase stability from degradation by a variety of proteases from <10 minutes to >48 hours.14  
The source of proteolytic resistance of foldamers has been examined on several fronts. Studies of 
peptides containing fluorinated α- and β-residues show that electronics do not affect proteolytic 
stability.17 It has been suggested that changing the placement of amide bonds via inclusion of β- or γ-
amino acids can prevent recognition by proteases.14 N-Methylation of peptides provides a similar avenue 
of protection by providing steric disruption of potential recognition sites.18 An alternative, and possibly 
additional, source of increased proteolytic stability of foldamers is their ability to manifest well-folded 
structures. Work with well-folded β-hairpin peptides has shown that as the folded stability of these 
peptides increases, they become less susceptible to proteolysis,19 likely due to prevention of a single 
strand conformation necessary for enzyme recognition.20 This finding suggests that if inclusion of 
unnatural backbones is able to promote a well-folded structure in a foldamer, it may prevent formation of 
an extended conformation necessary for amide cleavage. Similarly, if an unnatural backbone element is 
found in a larger disordered structure, it may be able to provide a degree of local protection to proteolysis 
by preorganizing nearby sections of the backbone to a specific fold.  
Regardless of the cause of proteolytic stability, foldamers provide an interesting area of study for 
mimicry of structures found in nature. Early studies of foldamers focused largely on the design of mimics 
of α-helices.13,21-24 These studies have provided the foundation for design strategies that can applied to the 
other secondary structures. One such strategy, sequence-based design, involves substitution of α-residues 
with unnatural residues at carefully selected sites within a parent peptide sequence. Sequence dictates the 
secondary structures (helices, sheets, turns, loops) of peptide segments, judiciously applying substitutions 
to a sequence that dictates a specific type of fold can be a valuable tool for design of secondary structure 
mimics. Studies of helical systems have shown that sequence-based design incorporating β-amino acids, 
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backbone lengthened homologs of α-amino acids, can be applied to generate α/β-hybrid peptides that fold 
into discrete helical structures as well as more complex quaternary structure assemblies mimicking those 
formed by the parent α-peptides.25-28  
In some cases, peptides require only secondary structure, such as the helices described above, for 
activity, but most proteins require tertiary folds to function. Larger proteins have a more complex tertiary 
structure where several different secondary structures combine to form a folded structure, in turn dictating 
the function of the protein. Foldamer design has been focused almost exclusively on mimicry of 
secondary structures, thereby excluding the active folded conformations found in tertiary folds. Our goal 
is to provide strategies for mimicry of tertiary folds using unnatural backbones, but to mimic the tertiary 
structure of larger proteins, sequence-based design strategies for all secondary structure types need to be 
developed. While design strategies for design of α-helical foldamers are well-established, similar 
strategies for mimicry of other secondary structure types, such as β-sheets, are not. Our research focuses 
on designing substitution strategies suitable for application in β-sheets and then applying these strategies 
to a tertiary fold. 
1.3 PROTEIN BETA-SHEETS 
1.3.1 Beta-Hairpins 
The β-strand is a type of secondary structure where the amino acid backbone adopts an extended 
conformation. β-Sheets are formed as two or more β-strands associate with one another through inter-
strand hydrogen bonds and contacts between hydrophobic side chains. Many investigations of β-sheet 
folding utilize smaller systems such as the β-hairpin, the simplest form of a β-sheet consisting of two anti-
parallel strands connected by a tight turn (Figure 3). 
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Figure 3. β-Hairpin structure with hydrogen bond contacts shown in red. 
 
 
When removed from the context of an intact protein, many β-sheet peptides aggregate or lose all 
folded structure in solution. While limited in number, some examples of short sequences that encode 
sheets exist, such as the N-terminal hairpin fragment of the protein ubiquitin29,30 and the C-terminal 
hairpin fragment of the protein GB1.31,32 One drawback of these sequences is that their folds are also 
minimally stable in aqueous solution. 
 
1.3.2 Amino Acid Identity and its Impact on Beta-Hairpin Formation 
Because short peptide fragments are often unstable in terms of folded structure, studies have focused on 
how to improve the folded stability of these peptides, showing the identity of the residues involved in the 
hairpin plays an important role in the stability of the fold.33 
A survey of various residue mutations in the C-terminal hairpin of GB1 suggests that the β-
branching seen in amino acids such as threonine, valine, and isoleucine restrict the torsional preferences 
of the amino acid backbone and support sheet formation more than flexible amino acids such as alanine or 
glycine.34 In addition to sheet propensity of amino acids, the side chains themselves can play an important 
role in sheet stability. The folding of the C-terminal fragment of GB1 is partially driven by packing of the 
side chains of four hydrophobic residues: valine, phenylalanine, tyrosine, and tryptophan (Figure 4).31  
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Figure 4. Hairpin structure of the C-terminal fragment of protein GB1. 
Side chains of hydrophobic packing residues are colored grey. 
 
 
 
Mutation of valine to tryptophan results in a new side chain cross-strand pairing with the tryptophan 
residue naturally found in the parent, thereby significantly stabilizing the hairpin of the new “trpzip” 
mutant.35 Removal of any of the three aromatic residues, tyrosine, phenylalanine, or tryptophan, in this 
fragment abolishes folding completely.36 
Aside from stabilizing aromatic interactions, other side chain interactions can also promote sheet 
formation. Adding terminal salt-bridge interactions,37 adding a Trp-Thr-Gly capping motif,38 or creating a 
cation-pi interaction between tryptophan and N-methyl lysine residues39 can also stabilize hairpin 
peptides. 
The stability of hairpins is not only impacted by identity of strand residues but also by the 
residues involved in forming the turn. Replacing the turn segment of the C-terminal hairpin fragment of 
GB1 with D-Pro-Gly40 or Asn-Pro-Ala-Thr-Gly-Lys41 can pre-organize the peptide backbone with a well-
defined turn region and dramatically improve the overall stability of the system. Turn mutations are not 
limited to natural residues either; other artificial loop designs such as Aib-Gly42 have proven to be 
successful as sheet promoters.  
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1.4 BETA-SHEET FOLDAMERS 
As described above, the folded stability of hairpin peptides can be increased by applying modifications in 
a variety of ways. While mutation of sequences with naturally occurring amino acids has been thoroughly 
investigated, our goal is to apply sequence-based design to a protein using unnatural amino acids. We 
surveyed the types of unnatural backbones previously examined in sheets to provide a basis for backbone 
modification in a tertiary fold. 
1.4.1 Beta-Sheet Foldamers Derived from Cyclic Beta-Amino Acids 
One of the original design strategies for β-sheet foldamers is use of a single unnatural amino acid building 
block in synthesis of a β-peptide. Studies have shown that three different types of cyclic β-amino acids 
can be used to generate sheets in this fashion (Figure 5).43-45 
 
 
 
Figure 5. An α-amino acid (yellow) and cyclic β-amino acids cis-ACBC, cis-ACPC, and trans-ACPC (blue). 
 
 
A tetramer containing (1R,2S)-2-amino-cyclobutanecarboxylic acid (ACBC) assembles into 
sheet-like structures which form long fibrils visible by TEM.43 Oligomers of (1R,2S)-2-amino-
cyclopentanecarboxylic acid (cis-ACPC) form sheet structures in organic solvent44 and alternating the two 
enantiomers of trans-ACPC in a hexamer also initiates formation of sheet-like fibrils.45 While all three of 
these cyclic β-monomer types allow for formation of sheet-like structures, they lack the side chain 
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diversity of α-residues. Because folded stability can be highly dependent on side chain interactions, 
removal of side chain functionality could significantly impact the folded stability of a hybrid peptide 
incorporating cyclic amino acids. 
1.4.2 Beta-Sheet Foldamers Derived from Pyrrolinone-Based Scaffolds 
One of the earliest investigations of sheet mimics bearing side chain functionality involved 
pyrrolinones.46 In this work, a sequence of natural α-amino acids was replaced with pyrrolinones with 
similar side chain functionalities (Figure 6) as a means to eliminate the amide bond cleaved by proteases 
while still maintaining side chain and carbonyl placement.  
 
 
 
Figure 6. Tetramer conversion to a pyrrolinone-based scaffold. 
 
 
Crystal structures of a compound with a pyrrolinone-based scaffold with alkyl side chains show 
that it is able to form sheets similar to those of the parent sequence.46 Since this work was published, new 
synthetic routes have been developed to allow other side chain functionalities to be incorporated47 and to 
allow for N-methylation backbone nitrogen atoms.48 Using peptide therapeutics as templates for amide 
and side chain display, these pyrrolinone scaffolds have shown the ability to act as structural mimics.49,50  
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1.4.3 Beta-Sheet Foldamers Templated by Methoxybenzamide 
Rather than using a single unnatural amino acid type to template sheet formation, an alternative strategy is 
to use a sheet-forming scaffold while introducing unnatural backbone elements in a limited number of 
sites. Oligourea scaffolds (Figure 7) have shown utility in templating sheet formation.51,52 
 
 
 
Figure 7. Sheet formation templated by an oligourea scaffold. 
 
 
 Placing one or more unnatural sheet-promoting elements such as 5-amino-2-methoxybenzamide 
(Figure 8) on one of the strands of an oligourea scaffold can template β-sheet formation on its 
neighboring strand in organic solvent.53,54  
 
 
 
Figure 8. Sheet-promoting backbones containing 5-amino-2-methoxybenzamide. 
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Combining 5-amino-2-methoxybenzamide with a hydrazine and oxalic acid generates an 
unnatural backbone unit which can mimic a tripeptide.55,56 Use of the this unit in a two-strand scaffold can 
template sheet formation on the opposite strand while disrupting aggregation56,57 and allowing mimicry of 
biologically relevant systems,58,59 potentially leading to important discoveries regarding protein-protein 
interactions.  
1.4.4 Beta-Sheet Foldamers Containing Alpha-Amino Acid Homologs  
The design strategies discussed above involve either repetition of unnatural amino acids or use of an 
unnatural scaffold to mimic natural sheets. While these strategies are effective for examining small 
systems, they do not allow for backbone modification in a larger protein. Incorporation of α-amino acid 
homologs at a limited number of positions can limit the degree of unnatural character of the peptide 
backbone while adding enhanced proteolytic stability as inclusion of even a single unnatural amino acid 
in a peptide can protect nearby residues from proteolysis.60 
1.4.4.1 Beta-Sheet Foldamers Containing Beta-Amino Acids 
One homolog of a natural α-amino acid is a β-amino acid which incorporates an additional 
methylene carbon in the backbone. Side chain functionality can be introduced in various positions to 
generate β2-, β3-, or β2,3-amino acids (Figure 9). 
 
 
 
Figure 9. An α-amino acid (yellow) and several β-amino acids (blue). 
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The first study reporting β-amino acids in a sheet-like fold compared the sheet-forming 
propensity of unsubstituted β-, monosubstituted β3-, and disubstituted β2,3-amino acids in a tetramer 
containing two β-residues linked by a D-Pro-Gly turn.61 NMR studies in organic solvent (dichloromethane 
and methanol) as well as solid-state structures showed that β-residues are capable of forming a short 
hairpin, although eliminating substituents on the backbone destabilizes the structure. Further work with a 
tetramer consisting of a different short turn and β2,3-residues formed a hairpin in methanol and in the solid 
state.62 It was later demonstrated that a β-peptide hexamer consisting only of β2-, β3-, and β2,3-residues is 
able form a hairpin in methanol63 and this structure was further supported by MD simulations.64 
Additionally, crystal structures of a hexamer with a D-Pro-Gly turn and two β-residues on either strand 
can adopt a sheet structure.65 
With evidence of hairpin formation from turn units in combination with β-residues, further 
research was performed using mixed α/β-hairpins. Crystal structures66-68 and NMR in organic solvent,67,68 
showed that peptides containing a combination of α- and β3-residues can form hairpin structures. 
1.4.4.2 Beta-Sheet Foldamers Containing Gamma-Amino Acids  
Study of α-amino acid analogs is not limited in scope to β-amino acids; γ-amino acids (Figure 10) such as 
vinylogous γ4-amino acids, (1R,3S)-3-aminocyclohexanecarboxylic acid (Acc), and meta-aminobenzoic 
acid (mABA) have also shown the potential to template β-sheet formation. 
 
 
 
Figure 10. An α-amino acid (yellow) and several γ-amino acids (green). 
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Crystal structures and NMR of short tetrapetides containing two-residue turns attached to two 
vinylogous γ4-residues have shown short hairpin structure formation.69 A mixed α/γ-hybrid peptide 
including vinylogous γ4-amino acids has also been shown to form a hairpin structure in organic solvent, 
although it also shows removing the α,β-unsaturation destabilizes the folded structure of the peptide.70 
Using cyclic γ-amino acids in sheets can also be effective. NMR in organic solvent has shown 
that α/γ-hybrid peptides containing mABA residues can form hairpins.71 A saturated form of mABA, Acc, 
can also form sheet-like structures. Alternating D-α-residues and L-α-residues has been shown to promote 
formation of cyclic sheet structures.72 Acc residues can be used in place of the natural L-α-residues to 
promote similar cyclic sheet structures.73-75 
 
1.5 SOLVENT CHOICE AND ITS EFFECT ON BETA-SHEET FORMATION 
As described above, a variety of backbone modification strategies can be applied to hairpin systems with 
minimal change in folded structure. A significant drawback of many studies, however, is the use of 
organic, rather than aqueous, solvent. Solvent choice can have a dramatic impact on the folded stability of 
peptides. Inclusion of trimethylamine n-oxide (TMAO) in aqueous solvent, for example, has been shown 
to increase the free energy of the unfolded state of proteins,76 forcing equilibrium towards the folded state. 
Mechanistically, inclusion of TMAO co-solvent increases the number and strength of hydrogen bonds 
between water molecules,77 preventing water from acting as a hydrogen bond donor or acceptor to the 
amides found in the protein backbone. When the amide bonds in a protein backbone are unaffected by 
solvent molecules, they can form the inter-residue hydrogen bonds necessary to stabilize folded structure. 
Other solvents affect protein folding in a similar manner. 2,2,2-Trifluoroethanol (TFE) will 
surround a protein backbone, preventing water from accessing hydrogen bond sites.78 The reverse is true 
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in the case of urea co-solvent; addition of urea provides a preferential hydrogen bond donor and acceptor 
relative to the backbone and allows solvation of the backbone amides.79 
As shown above, the ability of the solvent to form hydrogen bonds with backbone amides within 
a protein plays a large role in the folded stability of a protein. Water, due to its ability to form hydrogen 
bonds, does not promote inter-residue hydrogen bonding in a protein.80 Organic solvents, such as 
methanol or dimethylsulfoxide (DMSO), however, have weaker hydrogen bond capacity and can enhance 
folded stability relative to water. 
1.6 GOALS 
Many systems discussed above rely on artificial scaffolds that are difficult to synthesize or are impossible 
to incorporate into a protein with a complex folded structure. Additionally, the folded structures of hybrid 
peptides where unnatural amino acids are incorporated alongside natural α-amino acids have only been 
examined in context of organic solvents.  In cases where structural data is available, thermodynamic 
consequences of unnatural backbone modifications have not been evaluated. To design foldamers that 
mimic natural proteins, both the structural and thermodynamic impacts of such substitutions in a 
biologically relevant aqueous environment need to be examined. It is the goal of this work to develop 
general design rules for the incorporation of unnatural amino acids in natural sheet forming sequences to 
generate heterogeneous backbone mimics. 
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1.6.1 Model System Selection 
As a model system, we have chosen to examine protein GB1, a 56 residue B1 domain of protein G, an 
immunoglobin binding protein from Streptoccoccus bacteria.81 GB1 has a compact tertiary fold with four 
β-strands packed against an α-helix (Figure 11).82-84 
 
 
 
Figure 11. Cartoon structure and sequence of protein GB1. 
 
 
GB1 is small enough to be accessible by solid-phase peptide synthesis while still maintaining a compact 
tertiary folded structure with folding driven by packing of hydrophobic side chains found both on the 
sheets and helix (Figure 12).  
 
 
16 
 
Figure 12. Cartoon structure of protein GB1 with core packing residues displayed in grey. 
Coordinates derived from PDB: 2QMT. 
 
 
While GB1 can be used as a model protein for examining the structural and thermodynamic 
effects of backbone modification in tertiary systems, it is too large a system to be practical for initial 
screening of appropriate monomers for use in backbone modification. For these purposes, we have chosen 
to use a smaller model system, the C-terminal fragment of GB1 (Figure 13), shown to form a hairpin 
folded structure in water,32 and several of its derivatives. 
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Figure 13. Sequence and structure of the C-terminal fragment of protein GB1. 
Side chains of hydrophobic packing residues are colored grey. 
 
 
1.6.2 Outline 
1.6.2.1 Analysis of α- to β-Residue Substitution 
This document is laid out into three chapters of data. The first details the structural and thermodynamic 
consequences of β-residue substitutions in derivatives of the C-terminal hairpin fragment of GB1. In this 
work, we first examined 1:1 α- to β-residue substitution by incorporating 16 different β-amino acids of 
varying side chain position, stereochemistry, and backbone ring constraint in a 12-residue hairpin peptide. 
Multidimensional NMR analysis revealed use of 1:1 α- to β-residue substitution leads to inversion of the 
hydrogen bond pattern and side chain display.  
To prevent the inversion seen with 1:1 substitution, we next examined the effects of 2:1 or 2:2 α- 
to β-residue substitutions with a combination of β2-, β3, and β2,3-amino acids in a 16-residue hairpin 
peptide. Again using NMR analysis, we found that three of the substitution strategies applied can prevent 
inversion and maintain native-like folding of the hairpin, although at a significant cost to folded stability. 
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1.6.2.2  Analysis of α- to γ-Substitution and N-Methylation 
To find other monomer types that might allow native-like folding while not compromising the stability of 
the hairpin fold, we next examined the effects of 1:1 α- to γ-residue substitution using two types of cyclic 
γ-amino acids and a vinylogous γ4-amino acid in the context of a 16-residue hairpin peptide. Unlike the 
case of 1:1 α- to β-residue substitution, use of γ-amino acids not only allows for native-like folding, but is 
also less destabilizing when vinylogous γ4-amino acids are used. The hairpin fold is stabilized when 
cyclic γ-amino acid are used. 
As an alternative to homologs of α-residues, the impact of N-methylation of specific residues was 
also examined. We determined the individual effects of N-methylation on the four hydrophobic core 
residues of a 16-residue hairpin. This work showed that N-methylated residues can be used directly in 
place of α-residues with varying degrees of destabilization. When substitution occurs away from the 
hairpin turn, this destabilization is decreased. 
1.6.2.3 Unnatural Residue Substitutions Applied to Protein GB 1 
In the final chapter, the various backbone modification strategies examined in chapters two and three are 
applied to the β-sheet of full-length protein GB1. Mutant analogs containing β-, γ-residues, and N-methyl 
amino acids were examined using circular dichroism spectroscopy and thermal denaturation melts to 
determine the thermodynamic effects of these substitutions on the stability of the folded structure. These 
experiments revealed that the sheet propensities of the unnatural amino acids predicted by the hairpin 
peptides can be applied to a larger protein with the caveat that the site of substitution plays an important 
role in the overall stability of the tertiary fold. 
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2.0  IMPACT OF BETA-AMINO ACID INCORPORATION ON FOLDING OF BETA-
HAIRPINS IN AQUEOUS SOLUTION 
The results detailed in this chapter have been published in: 
1. Lengyel, G.A.; Frank, R.C.; Horne, W.S., “Hairpin Folding Behavior of Mixed α/β-Peptides in 
Aqueous Solution,”; Journal of the American Chemical Society, 2011, 4246-4249. 
2. Lengyel, G.A.; Horne, W.S., “Design Strategies for the Sequence-Based Mimicry of Side-
Chain Display in Protein β-Sheets by α/β -Peptides,” Journal of the American Chemical Society, 
2012, 15906-15913. 
 
As discussed in Chapter 1, work has been done investigating unnatural residue substitution in designed β-
sheet peptides; however, guidelines for the use of such elements to mimic larger proteins have not been 
described. With an eventual goal of modifying a protein sheet in the context of a well-defined tertiary 
fold, we first sought to compare unnatural residue substitution strategies in the context of a minimal sheet 
model system: a hairpin peptide consisting of two anti-parallel β-strands connected by a tight turn.  
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2.1 1:1 ALPHA- TO BETA-RESIDUE SUBSTITUTION 
2.1.1 Hairpin Peptide Design 
To determine the structural impact of backbone modification in β-sheets, we first examined unnatural 
residue substitutions in peptide 1a, derived from the C-terminal hairpin of protein GB1.85 Peptide 1a has 
two strands connected by a turn-promoting D-Pro-Gly sequence (Figure 14).86,87 As in the case of the C-
terminal hairpin fragment of GB1,32 hydrophobic packing of core residues Trp3, Tyr5, Phe9, and Val11 
found in the strands of peptide 1a drives the formation of a short hairpin structure in water. An 
approximate folded population of 61% at 275 K allows peptide 1a to be a sensitive tool for measurement 
of either increases or decreases in folded population resulting from unnatural residue substitutions.  
 
 
 
Figure 14. Sequence and NMR solution structure of hairpin peptide 1a. 
 
 
Based upon the utility of β-amino acid substitutions shown in prior work (see Chapter 1), we 
chose to use a 1:1 α- to β-residue substitution strategy. As β-amino acids contain an additional carbon 
atom in the backbone, they are generally more flexible than their shorter α-amino acid analogs and can 
exhibit a wider range of conformations. To screen for specific amino acid types that might be 
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accommodated into a sheet structure in water, we examined sixteen different α/β-hybrid peptides 
(peptides 2a-17a) with β-residues incorporated in place of residues Gln3 and Thr10 of the α-peptide 
sequence, 1a (Figure 15). Positions 3 and 10 were chosen because they are found in the center of each 
strand in the hairpin and are not involved in the hydrophobic core of the hairpin structure. Compounds 1a-
17a were synthesized using standard Fmoc-protected solid-phase peptide synthesis techniques. Unnatural 
monomers were synthesized in Fmoc protected form by known routes28,88-106 as detailed in Section 2.3. 
Compounds 1b-17b, epimers of 1a-17a, were also prepared; these incorporate L-Pro used in place of D-
Pro at position 7 for use as unfolded control peptides in population analysis. 
 
 
 
Figure 15. Sequences of peptides 1a-17a and 1b-17b. 
Locations of unnatural residues are highlighted blue. 
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The structures of the unnatural residues were systematically varied to evaluate the impact of side 
chain stereochemistry, backbone substitution pattern, and preorganization of backbone dihedrals by ring 
constraint in both five- and six-membered rings. The impact of side chain stereochemistry on folding was 
analyzed by incorporating each possible stereoisomer for each monomer class (β2, β3, acyclic β2,3, and 
cyclic β2,3) in oligomers 2a-17a. Side chain substitution site within the unnatural residues was analyzed 
comparing α/β3-hybrid peptides (2a, 3a) to the corresponding α/β2-hybrid peptides (4a, 5a), each bearing 
an isopropyl side chain, or α/β2,3-hybrid peptides (6a-9a), functionalized with both an isopropyl and a 
methyl side chain. The effect of backbone preorganization on folding was measured using peptides with 
backbones including β-residues with five-membered (10a-13a) or six-membered (14a-17a) ring 
structures.  
2.1.2 Qualitative NMR Analysis 
Peptides 1a-17a were analyzed using 2D 1H-NMR spectroscopy (TOCSY, NOESY, and COSY) at 278 K 
in aqueous buffer. From the NMR data, chemical shifts of backbone protons were assigned using 
sequential NOE analysis and the chemical shifts of the protons of Gly7 were used as a measure of 
folding.107-110 Glycine residues have two diastereotopic Hα protons; when these protons are found in a 
well-folded environment, they resonate at distinct frequencies leading to separate peaks. There is a direct 
correlation between the separation of glycine resonances by NMR and hairpin folded population and 
glycine separation analysis has been used to gauge hairpin folded population.110  
The separation of the Gly7 Hα protons (∆δ Gly7 Hα/α′) in peptides 1a-17a was calculated to 
qualitatively measure the impact of unnatural residue substitution on folded stability (Figure 16). Values 
for hybrid peptides 2a-17a ranged from 0.03 to 0.34 ppm compared to a value of 0.23 ppm for peptide 1a. 
Of significance is that the glycine protons of peptides 8a and 9a, containing the two enantiomers of the 
syn β2,3-residues, have the highest overall separation, even when compared to those found in parent 
peptide 1a. Peptide 16a shows a similar value to peptide 1a, suggesting a similar folded population. 
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Figure 16. Glycine separation values for hybrid α/β-peptides 1a-17a. 
 
 
 As another means to gauge folded population, the chemical shift deviation (CSD) between 
peptides 1a-17a and their unfolded analogs 1b-17b was analyzed.30,32,110-112 Peptides 1b-17b served as 
unfolded controls as they contain a turn-abolishing L-Pro-Gly segment in place of turn-promoting D-Pro-
Gly (Figure 17).40 As in the case of the diastereotopic protons of glycine, the chemical shifts of backbone 
amide and Hα protons change significantly when found in a folded hairpin conformation compared to an 
unfolded conformation; the larger the magnitude of the change, the larger the difference in folded 
population. The chemical shifts of the α-protons (Hα) and amide protons (HN) for each residue except turn 
residues Pro6 and Gly7 were tabulated. The difference in Hα or HN chemical shifts between folded 
peptides 1a-17a and unfolded peptides 1b-17b were subtracted. The absolute values of these differences 
were summed to determine the total CSD values (Figure 17).  
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Figure 17. Chemical shift deviation between unfolded and folded peptide pairs 1-17. 
 
 
 From the CSD analysis, peptide pairs 8 and 9 show similar values to that of model hairpin peptide 
pair 1, agreeing with the glycine separation data that also suggest peptides containing syn β2,3-residues 
allow folding in a hairpin conformation. Peptide pair 16, unlike in the case of glycine separation analysis, 
shows a much smaller CSD value than the parent peptide pair, suggesting the higher glycine separation in 
this case might not be indicative of a hairpin-like fold but the beginnings of an alternative folded 
structure. 
2.1.3 Structural Analysis by NMR 
With two peptides demonstrating potentially higher folded population than model peptide 1a, each α/β-
hybrid peptide was analyzed using NOE analysis.30,31,113,114 A well-folded hairpin will demonstrate inter-
strand NOE’s across the entire length of the backbone. When analyzed for cross-strand NOE signals, only 
peptides 1a, 2a, 8a, and 9a showed evidence of hairpin folding (Figure 18). 
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Figure 18. Cross-strand NOE’s of peptides 1a, 2a, 8a, and 9a. 
Ambiguous NOE’s are shown as dotted lines. α-Residues are colored yellow while β-residues are colored blue. 
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 In each case, similar to parent peptide 1a, α/β-hybrid peptides 2a, 8a, and 9a showed cross-strand 
NOE’s along the entire length of the backbone. Of note, however, is the apparent inversion of both side 
chain and hydrogen bond display of any residues beyond the site of β-residue incorporation. This type of 
inversion has been seen previously,61,66 but in the case of this peptide it is surprising that the hairpin 
maintains a folded structure in water. Inversion forces the Trp2 and Val11 side chains out of the 
hydrophobic core and likely decreases the energetic favorability of folding. One possible explanation of 
the hybrid peptides’ ability to remain folded despite this disruption is the incorporation of the isopropyl 
group of the unnatural residue at position 3 into the hydrophobic core in place of the side chain of Trp2. 
 To further analyze the structural impact of β-residue substitution, 3D solution structures were 
generated using simulated annealing with NOE distance restraints using the CNS software package. The 
proton resonances of peptides 1a, 2a, 8a, and 9a were fully assigned and each peptide was examined for 
inter-residue NOE’s which were tabulated and used as described in Section 2.3.4 to generate a list of 
NOE distance restraints. Simulated annealing was performed to arrive at the 20 lowest energy 
conformations (Figure 19) consistent with the experimental data and an average NMR structure (Figure 
20) for each peptide. In each case, the average NMR structure of the α/β-hybrid peptides closely 
resembles the hairpin structure of the parent peptide. As was suggested by cross-strand NOE analysis, the 
side chains of residues beyond unnatural residue insertion in hybrid peptides 2a, 8a, and 9a are inverted 
relative to parent peptide 1a (Figure 21).  
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Figure 19. Ensembles of 20 lowest energy conformations of peptides 1a, 2a, 8a, and 9a. 
Structures calculated using NOE distance restraints from NMR. Samples consisted of ~1 mM solution of peptide 
and 0.1 M deuterated acetate buffer in 90% H2O/D2O, pH 3.8. Unnatural residues are shown in blue. 
 
 
 
Figure 20. Average structures of peptides 1a, 2a, 8a, and 9a. 
Structures calculated from the average of 20 lowest energy conformations determined using NOE distance restraints 
from NMR. Samples consisted of ~1 mM solution of peptide and 0.1 M deuterated acetate buffer in 90% H2O/D2O, 
pH 3.8. Unnatural residues are shown in blue. 
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We overlaid the average coordinates of peptides 2a, 8a, and 9a with 1a, giving calculated RMSD 
values of 1.959, 1.540, and 1.740 Å, respectively (Figure 22). Peptide 2a, relative to 1a, has significant 
twisting of the backbone, likely due to the enhanced flexibility resulting from the unsubstituted methylene 
unit found in the β3-residues. Introducing functionalization at this site, as in the case of an additional 
methyl group with the β2,3-residues used (peptide 8a), significantly decreases the RMSD of overlays as 
well as the twisting of the backbone, likely due to preorganization resulting from steric constraints of the 
Cα-Cβ axis. Reversing the stereochemistry of the syn β2,3-residue, as with the unnatural residue used in 
peptide 9a, introduces a kink in the backbone, likely caused by a corresponding reversal in torsional 
preferences of the residue. Previous work has shown that incorporation of D-α-residues with similar 
stereochemistry to that of the monomer used in 9a causes kinking in the backbone of β-sheets.115 
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Figure 21. NMR solution structures of α-peptide 1a and a/b-hybrid peptides 2a, 8a, and 9a.  
Hydrophobic side chains are displayed as spheres. 
 
 
 
Figure 22. Overlays of NMR solution structures of α-peptide 1a (white) with α/β-hybrid peptides 2a, 8a, and 9a 
(yellow). 
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2.1.4 Analysis of 2:1 α- to β-Residue Substitution Strategies 
Based on the NOE analysis of the 16 α/β-hybrid peptides, three β-amino acids promoted folding: the β3-
amino acid with stereochemistry that mimics the natural L-configuration of α-amino acids and both 
enantiomers of the syn β2,3-amino acids used. Glycine separation and CSD analysis suggested that the two 
hybrids containing syn β2,3-residues template hairpin formation most strongly and of the two, the peptide 
containing the monomer with a natural L-configuration most closely mimics the natural hairpin sequence.  
These results suggest that the sheet propensities of acyclic β-amino acids are affected by the 
number of substituents in the β-residue backbone; functionalizing both carbon atoms in the backbone, as 
with an L-configured syn β2,3-residue, increases the folded stability of the hairpin relative to a 
monosubstituted β3-residue. The peptides including anti β2,3-amino acids do not have hairpin folded 
structures, suggesting that in addition to number of substitutions, relative stereochemistry also plays an 
important role in the sheet propensity of β-residues. Backbone torsional preferences could be used to 
explain these differences in β-residue sheet propensities (Figure 23). 
 
 
 
Figure 23. Extended conformations of acyclic β-residues and their resulting Newman projections. 
Newman projections are drawn along the C3-C2 bond. 
 
 
 Comparing the Newman projections of extended conformations (such as those found in a β-
strand) along the C3-C2 bond of β2- and β3-residues shows only minor differences; both residues have 
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only one substituent and can therefore adopt extended conformations without creating gauche 
interactions, perhaps accounting for the low sheet propensity of these monomers. In the extended 
conformation, the position of the isopropyl moiety differs only in its position relative to the carbonyl 
carbon or amide nitrogen; the subtle change in steric repulsion between the isopropyl group and these two 
atoms may be enough to shift folded stability from marginally stable as with β3-residue substitution to 
wholly unstable with β2-residue substitution.  
A less subtle difference is the folded stability of hairpins containing the syn versus anti 
configurations of β2,3-residues. Newman projections show that to form an extended backbone 
conformation, anti β2,3-residues force the isopropyl and methyl substituents gauche to one another. The 
syn configuration, however, allows these two substituents to orient in an anti relationship, thereby 
promoting an extended backbone conformation. 
An important consequence of 1:1 α- to β-residue substitution with our chosen monomers is the 
inversion of the side chain and hydrogen bonding display of all residues beyond the site of unnatural 
residue insertion. This inversion is caused by the additional carbon atom found in the backbone of β-
residues and can be seen when the backbones of these residues are found in an extended conformation. 
None of the acyclic β-residues were able to accommodate a conformation that would prevent an extended 
conformation and side chain inversion (Figure 24).  
 
 
 
Figure 24. Bent conformations of acyclic β-residues and their resulting Newman projections. 
Newman projections are drawn along the C3-C2 bond. 
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Comparison of β2- and β3-residues once again shows a lack of any steric repulsion involving the 
isopropyl group. While these residues can adopt a “bent” conformation, they can also adopt the extended 
conformation described previously with less steric repulsion between the two R groups representing the 
peptide chain. Both the syn and anti β2,3-residues experience significant steric hindrance in forming a bent 
conformation as the isopropyl and methyl groups are gauche in both cases. As the syn β2,3-residue can 
adopt an extended conformation without this gauche interaction, an extended conformation is favored. 
While close proximity of substituents in the case of β2,3-residues can cause steric repulsion and 
prevent a bent conformation, it is not unreasonable to expect that restraining the side chain atoms in a ring 
could stabilize this conformation. It was somewhat unexpected, then, that none of the cyclic β-residues 
examined were able to promote hairpin formation. Upon closer examination, we saw that unlike α-
residues, the trans configuration of both ACPC and ACHC residues does not promote an extended 
conformation but instead acts similar to a turn promoter, forcing the two attached segments of the peptide 
chain closer together (Figure 25). α/β-Residue hybrids containing cis-ACPC and cis-ACHC also 
discouraged hairpin formation. It is possible that the change in the directionality of the amide bonds 
connected to the unnatural residues disrupts sheet formation; relative to α-residues, the amides found in 
cis-ACPC and cis-ACHC are forced closer together (Figure 26). 
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Figure 25. Two views of an α-residue, trans-ACPC, and trans-ACHC. 
α-Residues and β-residues are colored yellow and blue, respectively. 
 
 
 
 
 
Figure 26. Front view of an α-residue, cis-ACPC, and cis-ACHC.  
α-Residues and β-residues are colored yellow and blue, respectively. Dotted lines highlight the deviation of cyclic β-
residue amide directionality by showing the directionality found with α-residues. 
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In summary, this work has shown that the backbone torsional preferences of β3- or β2,3-residues 
can promote hairpin formation in water, a solvent that does not typically support folded conformations of 
short peptides. This observation is however limited by a subtle change in side chain display.  
2.2 2:1 OR 2:2 ALPHA- TO BETA-RESIDUE SUBSTITUTION 
2.2.1 Design of Alpha- to Beta-Residue Substitution Strategies 
As described in Chapter 2.1, application of a 1:1 α- to β-residue substitution strategy, while supportive of 
hairpin folding, caused inversion of hydrogen bonding and side chain display (Figure 27A). As this 
inversion could potentially disrupt the structure of larger proteins with more complex folding behavior, 
we sought alternative strategies for backbone modification. We hypothesized a 2:1 α- to β-residue 
substitution could be used (Figure 27B) without causing the inversion seen with a 1:1 substitution. This 
substitution strategy, essentially an amide deletion, would allow for retention of functionality from a 
single side chain with a β2- or β3-residue or both side chains with a β2,3-residue substitution. Alternatively, 
the backbone could be lengthened using a 2:2 α- to β-residue substitution strategy (Figure 27C). Both side 
chain functionalities can be maintained using either a combination of β2- and β3- residues or a pair of syn 
β2,3-residues. Use of syn β2,3-residues in place of β2- or β3-residues allows incorporation of an extra methyl 
group, which should enforce an extended backbone conformation. 
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Figure 27. Possible α- to β-residue substitution strategies. 
A. 1:1 α- to β-residue substitution. B. 2:1 α- to β-residue substitution resulting in backbone contraction. C. 2:2 α- to 
β-residue substitution resulting in backbone expansion. 
 
2.2.2 Selection of Hairpin Model System 
Peptide 1a, due to its small size and ease of synthesis, is useful for screens of unnatural backbone 
residues, but it is limited in several ways. While it is derived from the 16-residue C-terminal hairpin of 
GB1, peptide 1a is a shorter 12-residue sequence; the natural Asp-Ala-Thr-Lys turn of peptide of GB1 is 
replaced by an unnatural D-Pro-Gly turn, modifying two residues while eliminating two more. D-Pro-Gly 
turns also display an increased glycine separation relative to what would be expected in natural turns as 
they enforce some degree of turn regardless of hairpin formation.109 Because of these factors, a model 
system was sought after with several new requirements: 1) a length corresponding to that of the C-
terminal hairpin of GB1, 2) a natural turn segment, and 3) a folded population of roughly 50% to 
accurately measure any thermodynamic changes affected by unnatural residue substitution. 
The C-terminal hairpin fragment of GB1, peptide 18 (Figure 28), was synthesized and examined 
by NMR as it was previously reported to have a folded population of ~40% at 278 K.32 We synthesized 
this peptide and collected NMR in aqueous buffer and found that, while meeting the guidelines for 
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selection as a model, this peptide demonstrated poor chemical shift dispersion of the threonine proton 
resonances, preventing their unambiguous assignment. As these signals are vital for determining folded 
population using CSD analysis, we were forced to look for a different model system.  
 
 
 
Figure 28. Sequence of GB1 C-terminal fragment, peptide 18. 
 
 
We next analyzed peptide 19a (Figure 29), a previously reported mutant of peptide 18 with a 
folded population of 86% at 298 K.41  Additionally, we examined alanine mutant 20a, where residues 
Thr4 and Thr13, potential sites for backbone modification, were mutated to alanine to simplify monomer 
synthesis. As peptide 19a has an innately high folded population, we also examined peptide 21a with a 
reported folded population of 74% at 298 K,41 and its alanine mutant, 22a. 
 
 
 
Figure 29. Model peptides 19a-22a and their derivatives (b-d). 
For each parent peptide (a), derivative b contains terminal cysteine residues connected via disulfide bridge, 
derivative c is an N-terminal fragment, and derivative d is a C-terminal fragment. 
 
 
Unlike our previous study of single α- to β-residue substitution, we wanted to quantify folded 
population. Both CSD and glycine separation analyses have been used to quantify population,110 but both 
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of these methods require both fully-folded and fully-unfolded control peptides.111,112 As folded control 
sequences, we modified peptides 19a-22a to include terminal cysteine residues which were subsequently 
oxidized to create variants cyclized via a disulfide bond (19b-22b). Additionally, we prepared unfolded 
control peptides 19c-22c and 19d-22d by synthesizing 8-residue peptides derived from the N-terminal 
and C-terminal fragments, respectively, of the parent peptides. 
We analyzed peptides 19-22 by NMR in aqueous buffer at 293 K and fully assigned the backbone 
proton chemical shifts. As detailed in Section 2.3.5, we used the chemical shifts for hydrogen-bonded 
residues remote from the turns to perform a CSD analysis and calculate folded populations (Table 1). 
Chemical shifts of non-hydrogen-bonded residues were not used as previous work has shown these 
chemical shifts are affected not only by folded structure, but also by side-chain interactions.112 As each 
parent peptide also contained a glycine residue in the turn, glycine separation analysis was used separately 
to calculate folded populations. 
 
 
Table 1. Folded populations of model peptides 19a-22a. 
Peptide 
Folded Population 
Hα CSD Gly Hα/Hα′ Separation 
19a 97 ± 6% 94 ± 6% 
20a 66 ± 5% 68 ± 6% 
21a ND* ND* 
22a 55 ± 2% 64 ± 6% 
*Aggregation rendered this sample unfit for NMR analysis. 
 
 
 The folded populations determined by CSD and glycine separation analyses were identical within 
error. Peptide 19a proved too well-folded for use as a model system for backbone modification. Peptide 
21a was also unfit for use as a model because aggregation-induced peak broadening in the NMR 
prevented population analysis. Both peptides 20a and 22a had similar folded populations within the range 
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we desired. We chose to use peptide 22a for use as a model system as it exhibited more dispersion of 
chemical shift values due to a less homogeneous sequence than peptide 20a. 
2.2.3 Application of Beta-Residue Substitution Strategies to Model Hairpin System 
In applying the design strategies discussed in Section 2.2.1 to peptide 20a, two sites for α- to β-residue 
substitution had to be selected. Three-residue sequences Trp3 -Ala4-Tyr5 and Phe12-Ala13-Val14 were 
chosen as possible substitution sites as they are found in the center of each strand of the hairpin. Residues 
Ala4 and Ala13 are not found in the hydrophobic core and were therefore selected as the first mutation 
sites. Residue Tyr5 was chosen for mutation over residue Trp3 as the phenolic side-chain of tyrosine was 
more synthetically accessible than the indole containing side-chain of tryptophan. Phe12, the cross-strand 
partner of Tyr5, was chosen for the final site of mutation.  
Four α- to β-residue substitution strategies were applied using the four chosen sites described 
above to generate peptides 23a-26a (Figure 30). A 2:1 α- to β-residue substitution was applied in Designs 
I and II while a 2:2 α- to β-residue substitution was applied in Designs III and IV. Design I eliminates the 
alanine side chain functionality found in Ala4 and Ala13 of the parent peptide while maintaining the side 
chains of hydrophobic core residues Tyr5 and Phe12. Design II retains both the alanine and hydrophobic 
core side chain functionalities found in Ala4, Tyr5, Phe12, and Ala13. Design III maintains the presence of 
all four side chains while Design IV adds additional methyl groups to help promote an extended 
conformation. Once again, disulfide cyclized peptides (23b-26b) as well as N-terminal (23c-26c) and C-
terminal (23d-26d) fragment peptides were synthesized for use as folded and unfolded controls, 
respectively. We synthesized each peptide using SPPS using Fmoc-protected monomers synthesized as 
described in Section 2.3. 
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Figure 30. Peptides 22a-26a and their derivatives (b-d). 
For each parent peptide (a), derivative b contains terminal cysteine residues connected via disulfide bridge, 
derivative c is an N-terminal fragment, and derivative d is a C-terminal fragment. 
 
 
2.2.4 Structural Impact of 2:1 and 2:2 Alpha- to Beta-Residue Substitution 
To determine if Designs I-IV were successful in preventing inversion of side chain and hydrogen-bond 
display in the hairpin peptides, cyclic peptides 22b-26b were analyzed by 2D 1H-NMR in aqueous buffer. 
Backbone Hα and amide resonances were fully assigned for each peptide and cross-strand NOE’s were 
examined (Figure 31). 
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Figure 31. Cross-strand NOE’s displayed by peptides 22b-24b. 
Ambiguous assignments are shown as dotted lines. The termini and turns are removed for clarity. 
 
 
 Peptides 23b and 24b, like model peptide 22b, displayed cross-strand NOE’s across the backbone 
consistent with hairpin formation, suggesting Designs I and II are amenable to hairpin formation. 
Additionally, these cross-strand NOE’s suggest that these designs can prevent inversion beyond the site of 
unnatural residue substitution. Design III, employed with peptide 25b, showed no NOE’s consistent with 
folding, leading us to believe the flexibility of the backbone imparted by use of two β2- or β3-residues in 
each strand significantly destabilizes the hairpin. Peptide 26b was sparingly soluble in the pH 6.3 buffer 
solution used for analysis and did not have significant enough concentration to determine the presence of 
NOE’s beyond sequential backbone NOE’s.  
 As additional support for hairpin formation in peptides 23b and 24b and to determine if hairpin 
formation resulted with peptide 26b, we performed glycine separation analysis of peptides 22b-26b at 
293 K in aqueous buffer (Figure 32). 
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Figure 32. Glycine separation values of peptides 22b-26b. 
 
 
 Peptides 22b-24b, as expected from the NOE analysis, showed similar glycine separation values. 
Accordingly, peptide 25b, which showed little NOE evidence of folding, showed a significantly 
decreased glycine separation value.  Peptide 26b, which was too dilute for NOE analysis, showed a 
similar glycine separation value to peptides 22b-26b, suggesting it also has a hairpin formation. Based on 
these data, we concluded that Designs I, II, and IV could be used to foster hairpin formation. 
 Finally, to assess the full structural impact of these designs, we fully assigned the proton 
resonance for the peptides which showed NOE evidence of folding, 22b-24b. As described in Section 
2.3.4, NOE distance restraints were used in simulated annealing to generate low energy families of 
structures for each peptide. In the case of peptide 23b, two families of structures, one depicting a hairpin 
structure, and the other a horseshoe shape with a significant kink in the backbone, were evident. We 
assigned the horseshoe conformation as a minor conformer brought upon by the presence of the disulfide 
linkage, not the presence of unnatural amino acid insertions. From the families of structures, average 
NMR structures for peptides 22b-24b were generated (Figure 33). 
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Figure 33. NMR solution structures of peptides 22b-24b with hydrophobic side chains depicted as spheres.  
Structures calculated from the average of 10 lowest energy conformations determined using NOE distance restraints 
from NMR. Samples consisted of ~1 mM solution of peptide and 50 mM phosphate in 90% H2O/D2O, pH 6.3.  
β2/β3-Residues are colored cyan while β2,3-residues are colored magenta. 
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 In each case, hairpin structures can be clearly seen for peptides 22b-26b. Overlays of the Cα and 
Cβ atoms from the hydrophobic core residues of each peptide with those from the C-terminal hairpin of 
GB1 from which the sequence was derived gives RMSD values of 1.08, 1.03, and 1.80 Å for peptides 
22b-24b, respectively. These values suggest similar agreements in fit for the two hybrid peptides to the 
model peptide. The slightly better fit for 23b relative to 24b could arise from the increased flexibility in 
the backbone allowing the increased backbone length to be more easily accommodated into a more 
native-like fold. The side chains of the four hydrophobic core residues were displayed on the same face of 
the hairpin as well, suggesting Designs I and II can be used in sheets to prevent side chain inversion seen 
in 1:1 α- to β-residue substitutions. 
2.2.5 Thermodynamic Impact of 2:1 and 2:2 Alpha- to Beta-Residue Substitution 
Designs I, II, and IV suggested native-like folding behavior, so we sought to examine the thermodynamic 
impact of the backbone modification. Acyclic peptides 23a-26a were synthesized and analyzed by NMR 
to determine the thermodynamic impact of Designs I-IV. As the folded populations calculated for 
peptides using CSD and glycine separation analysis were identical within error, glycine separation 
analysis was used to calculate folded populations for peptides 23a-26a (Table 2). In this analysis, peptides 
23b-26b were used as folded controls while a value of 0 ppm was used for unfolded peptide glycine 
separation. From folded population data, values for ∆Gfold were also calculated. 
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Table 2. Folded populations and ∆Gfold for peptide 22a and α/β-Hybrid Peptides 23a-26a. 
Peptide Folded Population (%) ∆Gfold (kcal/mol) ∆∆Gfold (kcal/mol)a 
22a 65 ± 5 −0.35 ± 0.13 --- 
23a 24 ± 5 +0.65 ± 0.15 +1.0 ± 0.2 
24a 17 ± 5 +0.90 ± 0.19 +1.4 ± 0.2 
25a <9 >1.3 >1.7 
26a 22 ± 4 0.69 ± 14 +1.0 ± 0.2 
a. Values calculated versus ∆Gfold of peptide 22a. 
 
 
Despite encouraging structural information from the cyclic variants, in each case, Designs I-IV 
destabilized the hairpin fold. Design III (25a) demonstrated minimal glycine separation, so a lower bound 
for the folded population based on the sensitivity on NMR measurements had to be used. Within error, the 
folded populations and relative values for ∆∆Gfold of peptides 23a, 24a, and 26a were identical. These 
data suggest Designs I, II, and IV are equally tolerated yet destabilizing in hairpin structures while Design 
III is not tolerated at all. 
2.2.6 Conclusions 
Of the four design strategies examined, three (a 2:1 α- to β2/β3-residue substitution, a 2:1 α- to β2,3-residue 
substitution, and a 2:2 α- to β2,3-residue substitution) were able to provide native-like folding behavior 
when applied to a model hairpin. Structurally, each of these strategies was able to prevent inversion seen 
when applying a 1:1 α- to β-residue substitution strategy, suggesting these strategies could be applied 
directly to a sheet in a larger tertiary fold. 
Only one of the strategies assessed, a 2:2 α- to β2/β3-substitution, was unable to manifest native-
like folding behavior. We attribute this instability to the lack of rigidity in the backbone that corresponds 
with β2- and β3-amino acids. While a single methylene unit can be tolerated in a hairpin (as with a 2:1 α- 
to β2/β3-residue substitution), adding an additional methylene unit in a 2:2 substitution abolishes folding. 
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Thermodynamically, the three strategies that allowed native-like folding behavior to occur were 
identical within error and each strategy resulted in destabilization of approximately 1 kcal/mol in total or 
0.25 kcal/mol per α-residue replaced. One potential cause for this destabilization is the amide deletion 
seen in the two 2:1 α- to β-residue substitution strategies which eliminates a hydrogen bond between the 
two strands (Figure 34). 
 
 
 
Figure 34. Amide deletion experience with 2:1 α- to β-residue substitution. 
Inter-strand hydrogen bonds are shown as red dotted lines. α-Residues, β-residues, and deleted amide are shown as 
yellow, blue, and magenta, respectively. 
 
 
 
The impact of hydrogen bond removal in a sheet depends on its location and the protein itself. 
One example shows that mutation of a hydrogen bond donor or acceptor in the peptide PIN WW, a three-
stranded sheet, can decrease the folded stability by 1-5 kJ/mol, similar to the 1 kcal/mol decrease seen in 
our work.116  
While the removal of a hydrogen bond can account for the destabilization with 2:1 substitution 
strategies, 2:2 substitution strategies maintain the same number of hydrogen bonds as the parent peptide. 
One alternative explanation for the destabilization seen in the 2:2 α- to β2,3- residue substitution is the 
inclusion of a β2,3-monomer with small methyl groups; perhaps increasing the bulk of the side chains 
would increase the steric hindrance to rotation and decrease the entropic penalty to folding. 
Overall, unnatural residue substitution strategies utilizing 2:1 α- to β2/β3-residue substitution, 2:1 
α- to β2,3-residue substitution, or 2:2 α- to β2,3-residue substitution may be useful for preventing inversion 
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in a protein with a larger tertiary fold, but in doing so could cause a significant destabilization of the 
folded structure. 
2.3 EXPERIMENTAL 
2.3.1 Monomer Synthesis 
2.3.1.1 General Information 
Optical rotations were measured on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at 
ambient temperature. NMR spectra of synthetic intermediates and final monomer products were recorded 
on a Bruker Avance-300 or Bruker Avance-400 spectrometer. Anhydrous ether was distilled over solid 
sodium and benzophenone. Anhydrous dichloromethane was distilled over solid calcium hydride. 
Propionyl chloride was distilled prior to use. Lithium iodide was weighed out in a glove bag under 
nitrogen atmosphere and stored under nitrogen until use. Flash chromatography was performed using 
Silicycle SiliaFlash P60 (230-400 mesh) or SorbTech silica gel (60 Å, 40-63 µm). Both trans 2-amino-1-
cylcopentanecarboxylic acid (ACPC) monomers,88 trans 2-amino-1-cyclohexanecarboxylic acid (ACHC) 
monomers,89 and O-trimethylsilylquinidine (TMS-quinidine) and O-trimethylsilylquinine (TMS-
quinine),90 were synthesized using a published route. 
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2.3.1.2 Synthesis of Fmoc-β2-Monomers 
 
 
 
Scheme 2.1. Synthesis of Fmoc-β2-monomers. 
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Compounds 27a and 27b were synthesized from commercially available aldehydes using previously 
published protocols.91,92  Compounds 30a, 33a, and 36a were synthesized from precursor compound 39 
using previously published protocols.91  
 
(R,R) β2-Ala Alcohol (29a):91,92 To 10 mL DMF under nitrogen was added 184 mg D-
proline (1.59 mmol, 0.2 equiv). The solution was stirred 2 h and then cooled to −25 
°C. To this solution was added 1.15 mL propionaldehyde (16.0 mmol, 2 equiv) and the reaction was 
stirred 15 minutes, followed by addition of 1.969 g compound 27a (7.71 mmol, 1 equiv) in 1 mL DMF. 
The reaction mixture was stirred 24 h at −25 °C and then warmed to 0 °C. To the solution was added 918 
mg sodium borohydride (24.3 mmol, 3 equiv) followed by slow addition of 10 mL methanol. The reaction 
was stirred for 30 minutes, quenched with 20 mL saturated aqueous ammonium chloride solution, and 
extracted three times with 50 mL diethyl ether. The organics were washed once with water, washed three 
times with brine, dried with magnesium sulfate, and then concentrated. The concentrate was purified 
using column chromatography (5% ethyl acetate in hexanes) and dried under vacuum to afford the 
product as a colorless oil (972 mg, 3.43 mmol, 43% yield). [α]D = −39.7 (c = 1.00, CHCl3). 1H NMR (400 
MHz, CDCl3) δ 7.23-7.38 (m, 10 H), 4.03 (q, J = 7.0 Hz, 1 H), 3.95 (d, J = 13.2 Hz, 1 H), 3.51 (m, 1 H), 
3.38 (d, J = 13.1 Hz, 1 H), 3.02 (dd, J = 10.5, 8.8 Hz, 1 H), 2.47 (m, 2 H), 2.11 (m, 1 H), 1.36 (d, J = 6.8 
Hz, 3 H), 0.69 (d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 142.7, 138.9, 129.4, 128.7, 128.3, 
127.4, 127.2, 70.0, 56.3, 56.0, 55.1, 37.2, 15.3, 9.5). HRMS m/z calculated for C19H26NO [M+H]+ 
284.2014; found 284.1987. 
 
Standard Procedure A.92 [This procedure was later optimized to improve the efficiency of the 
hydrogenolysis step. This updated procedure is detailed following this procedure.] To a stirred solution of 
alcohol precursor (1 equiv) in methanol (0.3 M) was added ammonium formate (10 equiv) and 10 wt% 
Pd/C (20% w/w). The solution was refluxed 5 h, filtered through Celite, and concentrated. The 
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concentrate was dissolved in dichloromethane (0.3 M) and to this solution was added Fmoc-OSu (1 
equiv) and DIEA (1 equiv) with stirring. The reaction was stirred 1 h, then diluted with 100 mL ethyl 
acetate. The organics were washed with aqueous 5% sodium bisulfate, aqeuous 5% sodium bicarbonate, 
and brine. The organic layer was dried with magnesium sulfate, concentrated, and purified using column 
chromatography to afford the product. 
 
Optimized hydrogenolysis: To a stirred solution of alcohol (1 equiv) in methanol (0.1 M) was added 
ammonium formate (20 equiv), glacial acetic acid (1 equiv), and 20 wt% Pd(OH)2/C (20% w/w). The 
solution was refluxed overnight, filtered through Celite, and concentrated to afford the free amine. 
 
Fmoc-(R)-β2-Val Alcohol (31a): Standard Procedure A was followed using 320 mg 
compound 28a (1.03 mmol), 649 mg ammonium formate (10.3 mmol), 198 mg 10 
wt% Pd/C, 179 μL DIEA (1.03 mmol), and 347 mg Fmoc-OSu (1.03 mmol). Column chromatography 
(33% ethyl acetate in hexanes) provided a mixture of product and residual Fmoc-OSu which was used 
directly without further purification. 
 
Fmoc-(S)-β2-Val Alcohol (31b): Standard Procedure A was followed using 485 mg 
compound 28b (1.56 mmol), 983 mg ammonium formate (15.6 mmol), 300 mg 10 
wt% Pd/C, 271 μL DIEA (1.56 mmol), and 526 mg Fmoc-OSu (1.56 mmol). Column chromatography 
(33% ethyl acetate in hexanes) provided a mixture of product and residual Fmoc-OSu which was used 
directly without further purification. 
 
Fmoc-(R)-β2-Ala Alcohol (32a): Standard Procedure A was followed using 972 mg 
compound 29a (3.43 mmol), 2.149 g ammonium formate (34.1 mmol), 104 mg 10 wt% Pd/C, 590 μL 
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DIEA (3.39 mmol), and 1.151 g Fmoc-OSu (3.41 mmol). For the hydrogenolysis, t-butanol was used in 
place of dichloromethane as solvent and the solution refluxed overnight. Column chromatography (33% 
→ 50% ethyl acetate in hexanes) provided 367 mg (~1.18 mmol) of a mixture of product and 5% 9-
fluorenemethanol byproduct which was used directly without further purification. 
 
Standard Procedure B.92 To a stirred solution of sodium dichromate in water (1 M) was added 
concentrated sulfuric acid to a final concentration of 4 M. The solution was then diluted with water to a 
final concentration of 0.5 M sodium dichromate and 2 M sulfuric acid. To a stirred solution of Fmoc-
amino alcohol (1 equiv) in acetone (0.1 M) at 0°C was added Jones reagent solution (2 equiv) slowly. The 
solution was allowed to warm to room temperature and stirred for 2 h after which isopropanol was added 
and the reaction allowed to stir for an additional 2 h. The solution was then diluted with ethyl acetate and 
washed with aqueous 5% sodium bisulfate. The organics were dried with magnesium sulfate, 
concentrated, and purified using column chromatography to afford the product. 
 
Fmoc-(R)-β2-Val-OH (34a): Standard Procedure B was followed using compound 31a 
(~1.03 mmol), 10 mL acetone, and 4 mL Jones Reagent. Column chromatography 
(25% → 33% ethyl acetate in hexanes) afforded the product as a white solid (172 mg, 0.49 mmol, 47% 
yield over 3 steps). NMR data matched previously published results.6 [α]D = −3.1 (c = 1.00, CHCl3), [α]D 
= −17.1° (c = 1.00, MeOH). 
 
 Fmoc-(S)-β2-Val-OH (34b): Standard Procedure B was followed using compound 
31b (~1.56 mmol), 10 mL acetone, and 4 mL Jones Reagent. Column chromatography 
(25% → 33% ethyl acetate in hexanes) afforded the product as a white solid (160 mg, 0.45 mmol, 29% 
yield over 3 steps). NMR data matched previously published results.6 [α]D = +3.3 (c = 1.00, CHCl3). 
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 Fmoc-(R)-β2-Ala-OH (35a): Standard Procedure B was followed using compound 
32a (~1.18 mmol), 12 mL acetone, and 4.7 mL Jones Reagent. Column 
chromatography (20% → 50% → 100% ethyl acetate in hexanes) afforded to product as a white solid 
(233 mg, 0.716 mmol, 21% yield over 3 steps). Spectra matched previously reported results.93 [α]D = −10 
(c = 1.00, CHCl3), [α]D = −5.6 (c = 1.00, CH2Cl2), [α]D, Lit = −10.85 (c = 0.273, CH2Cl2). [α]D, Lit = +9.6 (c 
= 1.00, CHCl3) for the enantiomer.94 
 
3-(4-(tert-butoxy)phenyl)propanoic acid (37):28 To a solution of 4.89 mL 4-(tert-
butoxy)-benzaldehyde (28.1 mmol, 1 equiv) in 80 mL pyridine was added 4.38 g 
malonic acid (42.1 mmol, 1.5 equiv). 830 µL piperidine (8.40 mmol, 0.3 eq) was added dropwise and the 
solution was refluxed for 3 h. The solution was then acidified with 1 M hydrochloric acid and extracted 
three times with ethyl acetate. The organics were combined, dried with magnesium sulfate, and 
concentrated under vacuum to yield the alkene addition product which was used directly. To a solution of 
alkene (28.1 mmol, 1 equiv) in 100 mL anhydrous THF was added 500 mg 10 wt% Pd/C (10% w/w). The 
reaction was stirred under a hydrogen balloon 16 h, filtered through Celite, washed with dichloromethane 
and methanol, and concentrated. The concentrate was purified using column chromatography (10% → 
20% → 50% ethyl acetate in hexanes) and dried under vacuum to afford the product as a white solid (4.29 
g, 19.3 mmol, 69% yield over two steps). 1H NMR (400 MHz, DMSO-d6) δ 12.35 (s, 1 H), 7.11 (d, J = 
8.3 Hz, 2 H), 6.86 (d, J = 8.4 Hz, 2 H), 2.76 (t, J = 7.8 Hz, 2 H), 2.48 (t, J = 7.7 Hz, 2 H), 1.26 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 153.7, 135.3, 128.7, 124.4, 78.5, 36.2, 30.2, 28.9. HRMS m/z calculated 
for C13H17O3 [M−H]− 221.1178; found 221.1167. 
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3-(4-(tert-butoxy)phenyl-N-methoxy-N-methylpropanamide (38):95 To a 
solution of 1.066 g compound 37 (4.796 mmol, 1 equiv) in 12 mL 
dichloromethane under nitrogen at 0 °C was added 657 mg N,O-dimethylhydroxylamine hydrochloride 
(6.74 mmol, 1.4 equiv), 940 µL triethylamine (6.74 mmol, 1.4 equiv), 824 mg 4-dimethylaminopyridine 
(6.74 mmol, 1.4 equiv), and 1.384 g N,N′-dicyclohexylcarbodiimide (6.708 mmol, 1.4 equiv). The 
solution was stirred for 16 h, and then filtered through Celite, eluting with ethyl acetate. The filtrate was 
washed sequentially with 1 M hydrochloric acid and saturated aqueous sodium bicarbonate. The organics 
were dried with magnesium sulfate and concentrated. The concentrate was purified using column 
chromatography (20% ethyl acetate in hexanes), and dried under vacuum to afford the product as a pale 
yellow oil (1.23 g, 4.64 mmol, 97% yield). 1H NMR (400 MHz, CDCl3) δ 7.05 (d, J = 8.3 Hz, 2 H), 6.84 
(d, J = 8.4 Hz, 2 H), 3.51 (s, 3 H), 3.10 (s, 3 H), 2.86 (t, J = 8.2 Hz , 2 H), 2.66 (t, J = 7.2 Hz, 2 H), 1.26 
(s, 9 H); 13C NMR (100 MHz, CDCl3) δ 173.5, 153.3, 135.9, 128.5, 124.0, 77.8, 60.9, 33.6, 31.9, 29.8, 
28.6. HRMS m/z calculated for C15H24NO3 [M+H]+ 266.1576; found 266.1578. 
 
3-(4-(tert-butoxy)phenyl)propanal (39):96 To a solution of 4.969 g compound 38 
(18.73 mmol, 1 equiv) in 75 mL anhydrous THF under nitrogen at −78 °C was 
added 1.41 g lithium aluminum hydride (37.2 mmol, 2 equiv). The solution was stirred for 3 h and then 
quenched by pouring into a mixture of 200 mL water/ice. The mixture was filtered through Celite, eluting 
with dichloromethane. The filtrate was then extracted three times with dichloromethane. The organics 
were combined, dried with magnesium sulfate, and concentrated to yield the crude aldehyde which was 
used directly. 
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2.3.1.3 Synthesis of anti Fmoc-β2,3-Monomers 
 
 
 
Scheme 2.2. Synthesis of anti Fmoc-β2,3-monomers. 
 
 
Standard Procedure C.97  To a stirred solution of 2.12 g lithium perchlorate (19.9 mmol, 2 equiv) in 10 
mL anhydrous ether was added O-trimethylsilyl-quinine or O-trimethylsilyl-quinidine (400 mg, 1 mmol, 
0.1 equiv) and 20 mL anhydrous dichloromethane.  The reaction mixture was cooled to −40 °C and 4.36 
mL DIEA (25.0 mmol, 2.5 equiv) and 920 μL isobutyraldehyde (10 mmol, 1 equiv) were added to the 
solution. A solution of 1.74 mL propionyl chloride (19.9 mmol, 2 equiv) in 5 mL anhydrous 
dichloromethane was added dropwise to the reaction over the course of 3 h after which time the reaction 
was allowed to stir at −40 °C for 16 h. After this time, 20 mL of ether was added to the solution and the 
resulting mixture was filtered through a silica plug, washing with ether. The solution was concentrated at 
a light vacuum (as the product is volatile) and the concentrate was purified using column chromatography 
(10% ether in pentane).   
 
(3S,4R)-4-isopropyl-3-methyloxetan-2-one (40a): Standard Procedure C was employed using 
O-trimethylsilyl-quinidine to afford the product as a colorless oil (~4.56 mmol, 46% yield) 
which was used directly. 1H NMR (300 MHz, CDCl3) δ 4.11 (dd, J = 6.07, 10.63 Hz, 1 H), 
3.73 (m, 1 H), 2.00 (m, 1 H), 1.34 (d, J = 7.97 Hz, 3 H), 1.08 (d, J = 6.45 Hz, 3 H), 0.93 (J = 6.83 Hz, 3 
H). 
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(3R,4S)-4-isopropyl-3-methyloxetan-2-one (40b): Standard Procedure C was employed 
using O-trimethylsilyl-quinine to afford the product as a colorless oil (~3.61 mmol, 36% yield) 
which was used directly. 1H NMR (300 MHz, CDCl3) δ 4.12 (dd, J = 6.07, 10.63 Hz, 1 H), 3.72 (m, 1 H), 
2.00 (m, 1 H), 1.34 (d, J = 7.59 Hz, 3 H), 1.08 (d, J = 6.45 Hz, 3 H), 0.92 (d, J = 6.83 Hz, 3 H).  
 
Standard Procedure D.98  To a stirred solution of sodium azide (2 equiv) in DMSO (0.6 M) was added 
lactone (1 equiv). The reaction mixture was stirred at 50 °C for 48 h, then allowed to cool to room 
temperature. 8 mL of saturated aqueous sodium bicarbonate was added to the solution, then water was 
added until all salts were dissolved. The aqueous layer was washed twice with ethyl acetate then acidified 
with 1 M hydrochloric acid. The acidified aqueous layer was then extracted three times with ethyl acetate. 
The organics were combined, washed twice with water, washed twice with brine, dried over sodium 
sulfate, concentrated, and dried under vacuum to afford the product. 
 
(2S,3S)-3-azido-2,4-dimethylpentanoic acid (41a):  Standard Procedure D was employed 
using 595 mg sodium azide (9.16 mmol) in 15.2 mL anhydrous DMSO and compound 40a 
(~4.58 mmol).  Drying under vacuum afforded the product as a colorless oil (523 mg, 3.06 mmol, 67% 
yield). [α]D = +11 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 3.43(dd, J = 4.52, 4.27, 9.03 Hz, 1 H), 
2.66 (m, 1 H), 2.01 (m, 1 H), 1.24 (d, J = 7.28 Hz, 3 H), 1.09 (d, J = 6.78 Hz, 3 H), 0.91 (d, J = 6.78 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 180.0, 70.6, 42.4, 29.6, 20.6, 15.8, 14.6. HRMS m/z calculated for 
[C7H13N3O2] 177.1008; found 171.1003. 
 
(2R,3R)-3-azido-2,4-dimethylpentanoic acid (41b):  Standard Procedure D was employed 
using 468 mg sodium azide (7.20 mmol) in 12 mL anhydrous DMSO and compound 40b 
(~3.61 mmol).  Drying under vacuum afforded the product as a colorless oil (466 mg, 2.72 mmol, 75% 
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yield). [α]D = −12 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 3.43(dd, J = 4.77, 4.27, 9.03 Hz, 1 H), 
2.66 (m, 1 H), 2.01 (m, 1 H), 1.24 (d, J = 7.03 Hz, 3 H), 1.09 (d, J = 6.78 Hz, 3 H), 0.91 (d, J = 6.78 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 179.9, 70.6, 42.4, 29.6, 20.6, 15.8, 14.6. HRMS m/z calculated for 
[C7H12N3O2] 170.0930; found 170.0938. 
 
Standard Procedure E.98,99 To a stirred solution of azido acid (1 equiv) in methanol (0.02 M) was added 
20 wt% Pd(OH)2/C (25% w/w) under nitrogen. The vessel was evacuated, fitted with a hydrogen-filled 
balloon, and stirred for 24 h.  The solution was then filtered through celite, washed with methanol, 
concentrated, and purified using column chromatography to afford the product.   
 
Standard Procedure F. 99 To a stirred solution of amine  (1 equiv) in water (0.8 M) was added potassium 
bicarbonate (1 or 2 equiv) and Fmoc-OSu (1 equiv) solution in acetone (0.8 M). The reaction was stirred 
48 h, then acidified 1 M hydrochloric acid. The mixture was then extracted three times with ethyl acetate. 
The organic layers were combined, dried with magnesium sulfate, and concentrated.  The concentrate was 
purified using column chromatography and dried under vacuum to afford the product. 
 
(2S,3S)-3-Fmoc-amino-2,4-dimethylpentanoic acid (42a):  Standard Procedure E 
was employed using 125 mg compound 41a (0.73 mmol), 31 mL methanol, and 31 mg 
20 wt% Pd(OH)2/C. Standard Procedure F was then employed using the resultant amino acid (0.73 
mmol), 0.9 mL water, 100 mg sodium bicarbonate (0.73 mmol), 245 mg Fmoc-OSu (0.73 mmol), and 0.9 
mL acetone.  Column chromatography (10% ethyl acetate in hexanes → 33% ethyl acetate in hexanes 
with 1% acetic acid) afforded a mixture of 9-fluorenylmethanol and the product as a white foam (85 mg, 
0.23 mmol, 32% yield over 2 steps).  [α]D = −23 (c = 1.0, CHCl3. This compound exists as a series of 
conformers in slow exchange on the NMR timescale. 1H NMR of main conformer (400 MHz, DMSO-d6) 
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δ 12.18 (s, 1 H), 7.89 (d, J = 7.53 Hz, 2 H), 7.71 (t, J = 7.78 Hz, 2 H), 7.41 (t, J = 7.53 Hz, 2 H), 7.32 (qd, 
J = 7.52, 0.97 Hz, 2 H), 7.03 (d, J = 9.79 Hz, 1 H), 4.24 (m, 3 H), 3.55 (qd, J = 7.03, 2.76 Hz, 1 H), 2.54 
(m, 1 H), 1.81 (m, 1 H), 1.04 (d, J = 7.03 Hz, 3 H), 0.84 (d, J = 6.78 Hz, 3 H), 0.80 (d, J = 6.78 Hz, 3 H); 
13C NMR (100 MHz, CDCl3) δ 176.65, 156.55, 144.45, 144.28, 141.17, 128.08, 127.55, 127.51, 125.83, 
125.74, 120.57, 65.78, 58.24, 47.26, 42.07, 29.45, 20.49, 17.77, 14.76. HRMS m/z calculated for 
[C22H24NO4] 366.1705; found 366.1718. 
 
(2R,3R)-3-Fmoc-amino-2,4-dimethylpentanoic acid (42b): Standard Procedure E 
was employed using 233 mg compound 41b (1.36 mmol), 58 mL methanol, and 20 
wt% 58 mg Pd(OH)2/C. Standard Procedure F was then employed using the resultant amino acid (1.36 
mmol), 4 mL water, 136 mg sodium bicarbonate (1.36 mmol), 456 mg Fmoc-OSu (1.36 mmol), and 4 mL 
acetone.  Column chromatography (10% ethyl acetate in hexanes → 33% ethyl acetate in hexanes with 
1% acetic acid) afforded the product as a white foam (207 mg, 0.563 mmol, 41% yield over 2 steps). [α]D 
= +18 (c = 1.0, CHCl3). This compound exists as a series of conformers in slow exchange on the NMR 
timescale. 1H NMR of main conformer (400 MHz, DMSO-d6) δ 12.18 (s, 1 H), 7.89 (d, J = 6.04 Hz, 2 H), 
7.71 (t, J = 6.78 Hz, 2 H), 7.41 (t, J = 7.20 Hz, 2 H), 7.32 (qd, J = 6.78, 0.64 Hz, 2 H), 7.02 (d, J = 10.06 
Hz, 1 H), 4.24 (m, 3 H), 3.55 (qd, J = 8.68, 1.87 Hz, 1 H), 2.54 (m, 1 H), 1.81 (m, 1 H), 1.04 (d, J = 6.36 
Hz, 3 H), 0.84 (d, J = 6.83 Hz, 3 H), 0.80 (d, J = 6.59 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 178.18, 
156.07, 143.96, 143.79, 140.69, 127.59, 127.06, 127.02, 125.35, 125.26, 120.08, 65.30, 57.75, 46.78, 
41.59, 28.96, 20.00, 17.27, 14.26. HRMS m/z calculated for [C22H24NO4] 366.1739; found 366.1705. 
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2.3.1.4 Synthesis of syn Fmoc-β2,3-Monomers 
 
 
 
Scheme 2.3. Synthesis of syn Fmoc-β2,3-monomers. 
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O-butyl carbamothioate (43):100 To a stirred solution of 13.6 g chloroacetic acid (144 mmol, 
1 equiv) in 130 mL water at 0 °C was added 5.76 g sodium hydroxide (144 mmol, 1 equiv). 
To this solution was added a solution of 27.1 g potassium butyl xanthate (144 mmol, 1 equiv) in 130 mL 
water and the reaction stirred overnight. After this time, 11.67 mL 28% aqueous ammonium hydroxide 
(173 mmol, 1.2 equiv) was added and the solution stirred overnight, then extracted five times with ether. 
The organic layers were combined, dried with magnesium sulfate, and concentrated afford the product as 
a colorless oil (17.129 g, 129 mmol, 89% yield). 1H NMR (400 MHz, CDCl3) δ 7.08 (s, 1 H), 6.27 (s, 1 
H), 4.34 (t, J = 6.78 Hz, 2 H), 1.62 (m, 2 H), 1.33 (m, 2 H), 0.88 (t, J = 7.53 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 192.69, 71.61, 30.53, 18.95, 13.69.  HRMS m/z calculated for [C10H23N2O2] (2M+H)+ 
267.1201; found 267.1225. 
 
Standard Procedure G:101 To a stirred solution of compound 43 (1 equiv) in water (0.9 M) was added 
sodium para-toluenesulfinate (1.2 equiv), aldehyde (1.2 equiv), and formic acid (6.9 equiv). This solution 
was allowed to stir for 48-72 h during which the product was formed as an oil or precipitate. The product 
was then isolated via extraction and concentrated under vacuum. 
 
Isopropyl Sulfone (44): Standard Procedure G was employed using 7.0 g compound 43 (53 
mmol), 60 mL water, 12.25 g sodium para-toluenesulfinate (63.1 mmol), 5.76 mL 
isobutyraldehyde (63.1 mmol), and 13.7 mL formic acid (362 mmol). After 48 h, the 
solution was diluted with 150 mL dichloromethane. The organics were washed twice with 
water, washed once with brine, dried over magnesium sulfate, and concentrated to afford the product as a 
white solid (16.173 g, 47.1 mmol, 90% yield). This compound exists as a series of conformers in slow 
exchange on the NMR time scale; NMR spectra are attached in Appendix D. HRMS m/z calculated for 
[C16H25NO3NaS2] 366.1198; found 366.1192. 
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Methyl Sulfone (45): Standard Procedure G was employed using 2.66 g compound 43 (20.0 
mmol), 23 mL water, 4.66 g sodium para-toluenesulfinate (24.0 mmol), 1.40 mL acetaldehyde 
(25.0 mmol), and 5.20 mL formic acid (138 mmol). The reaction was stirred for 48 h to afford 
the product as an oil. The product was dissolved in dichloromethane and washed twice with 
water and twice with brine. The organics were dried with magnesium sulfate, concentrated, and dried 
under vacuum to afford the product as a colorless oil (5.64 g, 17.9 mmol, 89% yield). This compound 
exists as a series of conformers in slow exchange on the NMR time scale; NMR spectra are attached in 
Appendix D. HRMS m/z calculated for C14H21NO3NaS2 [M+Na]+ 338.0861; found 338.0870. 
 
Benzyl Sulfone (46): Standard Procedure G was employed using 1.726 g compound 43 
(12.96 mmol), 15 mL water, 3.00 g sodium para-toluenesulfinate (15.4 mmol), 1.80 mL 
phenylacetaldehyde (15.4 mmol), and 3.40 mL formic acid (90.1 mmol). The reaction was 
stirred for 72 h to afford the product as a white precipitate. The precipitate was filtered off, 
dissolved in ether, and washed nine times with water to remove excess aldehyde. The organics were dried 
with magnesium sulfate, concentrated, and dried under vacuum to afford the product as a pale yellow oil 
(2.15 g, 5.49 mmol, 42% yield). This compound exists as a series of conformers in slow exchange on the 
NMR time scale; NMR spectra are attached in Appendix D. HRMS m/z calculated for C20H25NO3S2K 
[M+K]+ 430.0913; found 430.0925. 
 
Standard Procedure H:101 To a stirred solution of sulfone (1 equiv) in anhydrous dichloromethane (0.1 
M) under nitrogen was added TMS-quinine or TMS-quinidine (0.4 or 0.7 equiv). The solution was cooled 
to −78 °C and DIEA (3.5 equiv) was added followed by addition of a solution of lithium iodide (0.7 
equiv) in ether (0.2 M). A solution of propionyl chloride (0.5 equiv) in anhydrous dichloromethane (1.8 
M) was added dropwise over 20 minutes after which the solution was allowed to stir 1 h. Addition of 
lithium iodide and propionyl chloride solutions followed by reaction time of 1 h was repeated an 
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additional four times after which the reaction was allowed to stir at −78 °C for 16 h. The solution was 
then quenched with acetic acid in ether (10% v/v) and washed three times with saturated ammonium 
chloride solution. The aqueous washes were combined and extracted with ether. The ether and organic 
layers were combined, washed three times with brine, run through a silica plug, eluting with ether, and 
concentrated. The concentrate was purified using column chromatography and dried under vacuum.  
 
(4S,5R) Isopropyl Thiazinone (47a): Standard Procedure H was employed using 1.02 g 
compound 44 (2.96 mmol), 470 mg TMS-quinine (1.18 mmol, 0.4 equiv), 26 mL anhydrous 
dichloromethane, 188 mL DIEA (10.8 mmol), 1.25 g lithium iodide (9.35 mmol), 18 mL 
ether, and 650 μL propionyl chloride (7.5 mmol). The crude reaction mixture was purified using column 
chromatography (0.5% ethyl ether in pentane) to afford a mixture of the product and ketene dimer. The 
impure mixture was dried under vacuum to eliminate any residual ketene dimer, affording the product as 
a yellow oil (67 mg, 0.28 mmol) that was used directly. 1H NMR (300 MHz, CDCl3) δ 4.29 (t, J = 6.8 Hz, 
2 H), 3.03 (dd, J = 3.02, 9.63 Hz, 1 H), 2.77 (qd, J = 2.83, 7.18 Hz, 1H), 1.92 (m, 1 H), 1.70 (m, 2 H), 
1.43 (m, 2 H), 1.11 (d, J = 6.61 Hz, 3 H), 1.02 (d, J = 7.18 Hz), 0.96 (t, J = 7.18 Hz, 3 3 H), 0.95 (d, J = 
6.61 Hz, 3 H). 
 
(4R,5S) Isopropyl Thiazinone (47b): Standard Procedure H was employed using 1.13 g 
compound 44 (3.28 mmol), 520 mg TMS-quinidine (1.31 mmol), 28 mL anhydrous 
dichloromethane, 2.08 mL DIEA (11.9 mmol), 1.25 g lithium iodide (9.35 mmol), 18 mL 
ether, and 720 μL propionyl chloride (8.3 mmol).  The crude reaction mixture was purified using column 
chromatography (0.5% ethyl ether in pentane) to afford a mixture of the product and ketene dimer. The 
impure mixture was dried under vacuum to eliminate any residual ketene dimer, affording the product as 
a yellow oil (160 mg, 0.66 mmol) that was used directly. 1H NMR (300 MHz, CDCl3) δ 4.29 (t, J = 6.61 
Hz, 2 H), 3.03 (dd, J = 3.02, 9.63 Hz, 1 H), 2.77 (qd, J = 2.83, 7.18 Hz, 1H), 1.92 (m, 1 H), 1.70 (m, 2 H), 
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1.43 (m, 2 H), 1.11 (d, J = 6.61 Hz, 3 H), 1.02 (d, J = 7.18 Hz), 0.96 (t, J = 7.18 Hz, 3 3 H), 0.95 (d, J = 
6.61 Hz, 3 H). 
 
(4S,5R) Isopropyl Thiazinone (48a): Standard Procedure H was employed using 867 mg 
compound 45 (2.75 mmol), 500 mg TMS-quinine (1.26 mmol, 0.4 equiv), 100 mL 
dichloromethane, 1.70 mL DIEA (9.76 mmol), 1.25 g lithium iodide (9.33 mmol), and 600 µL 
propionyl chloride (6.88 mmol). Column chromatography (1% diethyl ether in hexanes) afforded the 
product as a colorless oil (149 mg, 0.692 mmol, 25% yield). 1H NMR (400 MHz, CDCl3) δ 4.20 (m, 2 H), 
3.88 (m, 1 H), 2.62 (m, 1 H), 1.66 (m, 2 H), 1.39 (m, 2 H), 1.15 (d, J = 7.0 Hz, 3 H), 1.10 (d, J = 7.0 Hz, 3 
H), 0.93 (t, J = 7.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 199.7, 154.4, 68.4, 55.0, 46.0, 30.7, 19.2, 
13.9, 10.5). [α]D = −31.3 (c = 1.00, CHCl3). HRMS m/z calculated for [C13H24NO2S] 258.1528; found 
258.1538. 
 
(4S,5R) Benzyl Thiazinone (49a): Standard Procedure H employed using 1.07 g compound 
46 (2.73 mmol), 750 mg TMS-quinine (1.89 mmol, 0.7 equiv), 100 mL dichloromethane, 
1.70 mL DIEA (9.76 mmol), 1.25 g lithium iodide (9.33 mmol), and 600 µL propionyl 
chloride (6.88 mmol). Column chromatography (1% diethyl ether in hexanes) afforded a mixture of the 
product (~260 mg, 0.892 mmol) and a coeluting contaminant as a colorless oil which was used directly. 
 
General Procedure I:102 To a stirred solution of thiazinone (1 equiv) in THF (0.04 M) was added a 
solution of lithium hydroxide (3 equiv) in water.  The reaction vessel was stirred overnight and then 
acidified to pH 2 with 1 M hydrochloric acid and extracted three times with dichloromethane. The 
organics were combined and washed twice with brine, dried over magnesium sulfate, and concentrated. 
The concentrate was purified using column chromatography (20% ethyl acetate in hexanes → 50% ethyl 
acetate in hexanes) to afford the product.   
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(4S,5R) Isopropyl Thiocarbamate (50a):  Standard Procedure I was employed using 
67 mg compound 47a (0.28 mmol), 6.4 mL THF, 19 mg lithium hydroxide (0.82 
mmol) and 3.2 mL water to afford the product as yellow crystals (58 mg, 0.22 mmol, 7.5% over two 
steps). [α]D = +20 (c = 1.0, CHCl3). This compound exists as a series of conformers in slow exchange on 
the NMR timescale; NMR spectra are attached in Appendix D. HRMS m/z calculated for [C12H22NO3S] 
260.1320; found 260.1340. 
 
(4R,5S) Isopropyl Thiocarbamate (50b):  Standard Procedure I was employed using 
160 mg compound 47b (0.66 mmol), 15.6 mL THF, 46 mg lithium hydroxide (2.0 
mmol) and 7.66 mL water to afford the product as yellow crystals (144 mg, 0.55 mmol, 17% over two 
steps).  [α]D = −17 (c = 1.0, CHCl3). This compound exists as a series of conformers in slow exchange on 
the NMR timescale; NMR spectra are attached in Appendix D. HRMS m/z calculated for [C12H22NO3S] 
260.1320; found 260.1328. 
 
Standard Procedure J:101 To a stirred solution of thiazinone (1 equiv) in methanol (0.1 M) under 
nitrogen was added DIEA (1.5 equiv). The reaction was stirred overnight then concentrated. The 
concentrate was purified using column chromatography and dried under vacuum to afford the product. 
 
(4S,5R) Methyl Thiocarbamate (51): Standard Procedure J was employed using 149 
mg compound 48a (0.692 mmol), 7 mL methanol, and 182 µL DIEA (1.04 mmol). 
Column chromatography (5% ethyl acetate in hexanes) afforded the product as a colorless oil. This 
compound exists as a series of conformers in slow exchange on the NMR time scale; NMR spectra are 
attached in Appendix D. [α]D = −37.1 (c = 1.00, CHCl3). HRMS m/z calculated for [C11H21NO3S] 
270.1140; found 270.1162. 
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(4S,5R) Benzyl Thiocarbamate (52): Standard Procedure J was employed using 
~260 mg compound 49a (0.804 mmol), 9 mL methanol, and 230 µL DIEA (1.35 
mmol). Column chromatograpy (5% ethyl acetate in hexanes) afforded the product as a colorless oil (76 
mg, 0.25 mmol, 9.1% yield over 2 steps). This compound exists as a series of conformers in slow 
exchange on the NMR time scale; NMR spectra are attached in Appendix D. [α]D = −27.8 (c = 1.00, 
CHCl3). HRMS m/z calculated for C17H26NO3S [M+H]+ 324.1656; found 324.1633. 
 
Standard Procedure K:101 To a stirred solution of thiocarbamate (1 equiv) in 2:1:1 acetone/water/THF 
(0.25 M) under nitrogen at 0 °C was added Oxone (1.5 equiv). The reaction was stirred for 30 minutes at 
0 °C, stirred at room temperature for 2.5 h, and then quenched by adjusting the pH to 11 using saturated 
aqueous sodium carbonate solution. The organics were removed under reduced pressure and the resulting 
aqueous solution was saturated using sodium chloride and extracted 6 times with chloroform. The 
organics were combined, dried with magnesium sulfate, and concentrated to afford the crude amino ester 
which was used directly. To a stirred solution of amino ester (1 equiv) in 1:1 THF/water (0.1 M) under 
nitrogen at 0 °C was added lithium hydroxide (2 equiv). The reaction was allowed to stir overnight at 
room temperature, and then acidified to pH 4 with 1 M hydrochloric acid. The organics were removed 
under reduced pressure to afford the crude amino acid salt in aqueous solution which was used directly. 
To a stirred solution of amino acid salt in 1:1 acetone/water (0.1 M) under nitrogen was added potassium 
bicarbonate (1 or 2 equiv), and Fmoc-OSu (1 equiv). The solution was stirred 48 h, acidified with 1 M 
hydrochloric acid, and extracted with three times ethyl acetate. The organics were combined, dried with 
magnesium sulfate, and concentrated. The concentrate was purified using column chromatography and 
dried under vacuum to afford the product. 
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Fmoc-(2R,3S)-3-amino-2-methylbutanoic acid (53): Standard Protocol K was 
employed using 210 mg compound 51 (0.849 mmol), 6.4 mL 2:1:1 acetone/water/THF, 
791 mg Oxone (1.28 mmol), 10 mL 1:1 THF/water, 40 mg lithium hydroxide (1.7 mmol), 14 mL 1:1 
acetone/water, 83 mg potassium bicarbonate (0.85 mmol), and 287 mg Fmoc-OSu (0.851 mmol). Column 
chromatography (10% → 50% → 67% ethyl acetate in hexanes) afforded the product as a white solid 
(192 mg, 0.566 mmol, 67% yield over 3 steps). 1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1 H), 7.89 (d, 
J = 7.4 Hz, 2 H), 7.69 (d, J = 7.2 Hz, 2 H), 7.41 (t, J = 7.4 Hz, 2 H), 7.33 (t, J = 7.5 Hz, 2 H), 7.19 (d, J = 
9.2 Hz, 1 H), 4.34 (m, 1 H), 4.25 (m, 2 H), 3.65 (m, 1 H), 2.32 (m, 1 H), 1.04 (d, J = 6.4 Hz, 3 H), 0.99 (d 
J = 6.9 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 176.0, 156.7, 143.9, 140.7, 138.8, 127.6, 127.0, 
125.2, 125.1, 120.1, 65.1, 48.6, 46.8, 45.0, 19.2, 14.2. [α]D = +2.3 (c = 0.50, acetone). HRMS m/z 
calculated for C20H22NO4 [M+H]+ 340.1549; found 340.1555. 
 
Fmoc-(2R,3S)-3-amino-2-methyl-4-phenylbutanoic acid (54): Standard Procedure K 
was employed using 221 mg compound 52 (0.683 mmol), 2.8 mL 2:1:1 
acetone/water/THF, 655 mg Oxone (1.07 mmol), 8 mL 1:1 THF/water, 33 mg lithium hydroxide (1.4 
mmol), 8 mL 1:1 acetone/water, 140 mg potassium bicarbonate (1.40 mmol), and 264 mg Fmoc-OSu 
(0.783 mmol). Column chromatography (20% → 50% ethyl acetate in hexanes) afforded a mixture of the 
product (178 mg, 0.41 mmol, 59% yield over 3 steps) and 9-fluorenemethanol (5 mol% by NMR) as a 
white solid. An analytically pure sample was obtained by dissolving the entire sample in 40 mL tert-butyl 
methyl ether. This solution was extracted four times with saturated aqueous sodium carbonate solution. 
The aqueous layers were combined and acidified using concentrated hydrochloric acid. The aqueous 
solution was then extracted 3 times with ethyl acetate. The organics were combined, dried with 
magnesium sulfate, and concentrated to yield the pure product as a white solid. 1H NMR (400 MHz, 
DMSO-d6) δ 12.32 (s, 1 H), 7.88 (d, J = 7.5 Hz, 2 H), 7.61 (d, J = 7.4 Hz, 2 H), 7.40 (t, J = 7.40 Hz, 2 H), 
7.30 (q, J = 7.7 Hz, 2 H), 7.18 (m, 5 H), 4.17 (m, 2 H), 4.10 (m, 1 H), 3.88 (m, 1 H), 2.67 (m, 2 H), 2.42 
(m, 1 H), 1.04 (d, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 176.1, 155.8, 143.8, 140.7, 138.8, 
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129.0, 128.1, 127.6, 127.0, 126.0, 125.2, 120.1, 65.1, 54.4, 46.7, 43.9, 38.5, 13.6. [α]D = −39.7 (c = 1.00, 
acetone). HRMS m/z calculated for C26H25NO4Na [M+Na]+ 438.1681; found 438.1678. 
 
Benzyl 3-(4-(tert-butoxy)phenyl)propanoate (55): To a stirred solution of 4.966 
g compound 37 (22.35 mmol), 1 equiv) in 50 mL dichloromethane under nitrogen 
was added 6.885 g hydroxybenzatriazole monohydrate (45.00 mmol, 2 equiv), 4.66 mL benzyl alcohol 
(45.0 mmol, 2 equiv), and 2.771 g 4-dimethylaminopyridine (22.68 mmol, 1 equiv). The solution was 
cooled to 0 °C and 5.787 g N,Nʹ-dicyclohexylcarbodiimide (28.05 mmol, 1.2 equiv) was added. The 
reaction was stirred for 3 h and run through a silica plug, eluting with ethyl acetate to remove 
dicyclohexylurea, and concentrated. The concentrate was purified using column chromatography (10% 
ethyl acetate in hexanes) and dried under vacuum to afford the product as a colorless oil (6.584 g, 21.07 
mmol, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.33 (m, 5 H), 7.07 (d, J = 8.3 Hz, 2 H), 6.90 (d, J = 8.3 
Hz, 2 H), 5.12 (s, 2 H), 2.94 (t, J = 7.9 Hz, 2 H), 2.67 (t, J = 7.5 Hz, 2 H), 1.33 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 172.9, 153.8, 136.1, 135.4, 128.7, 128.7, 128.3, 124.3, 77.8, 66.4, 36.1, 30.4, 29.0. 
HRMS m/z calculated for C20H24O3 [M]+ 312.1725; found 312.1766. 
 
 
(E)-benzyl 2-4-(tert-butoxy)benzyl)but-2-enoate (56):103 To a solution of 73 mL 
anhydrous THF under nitrogen was added 23.4 mL LDA (1.8 M in 
heptane/THF/ethylbenzene, 42 mmol, 2 equiv). The solution was cooled to −78 °C and 6.584 g compound 
55 (21.07 mmol, 1 equiv) in 16 mL anhydrous THF was added to the LDA solution dropwise over 20 
minutes then stirred for 1 h. After this time, 3.54 mL acetaldehyde (63.3 mmol, 3 equiv) in 22 mL 
anhydrous THF was added dropwise over 20 minutes then stirred 2 h. The reaction was quenched with 
saturated aqueous ammonium chloride, diluted with water, and extracted three times with ethyl acetate. 
The organics were combined, dried with magnesium sulfate, and concentrated. The concentrate was run 
through a silica plug, eluting with 50% ethyl acetate in hexanes, and then concentrated to afford the crude 
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aldol product which was used directly. To a stirred solution of the aldol product (21.07 mmol, 1 equiv) in 
34 mL 1:1 triethylamine/dichloromethane at 0 °C was added 2.45 mL methanesulfonyl chloride (31.2 
mmol, 1.5 equiv) in 6 mL dichloromethane. The reaction was stirred 2 h at room temperature, then run 
through a silica plug, eluting with ethyl acetate and concentrated to afford the crude mesylate which was 
used directly. To a stirred solution of mesylate (21.07 mmol, 1 equiv) in 70 mL anhydrous THF at 0 °C 
was added 4.720 g potassium tert-butoxide. The reaction was stirred at room temperature overnight, 
quenched with 1 M hydrochloric acid, diluted with water, and extracted three times with ethyl acetate. 
The organics were combined, dried with magnesium sulfate, and concentrated to yield a crude mixture of 
product (83:17 E/Z). The concentrate was purified using column chromatography (5% → 10% diethyl 
ether in hexanes) to afford the product in a 94:6 E/Z ratio as a yellow oil (2.467 g, 7.289 mmol, 35% yield 
over 3 steps). 1H NMR (400 MHz, CDCl3) δ 7.28 (m, 5 H), 7.08 (q, J = 7.2 Hz, 1 H), 7.04 (d, J = 8.3 Hz, 
2 H), 6.86 (d, J = 8.4 Hz, 2 H), 5.13, (s, 2 H), 3.66 (s, 2 H), 1.89 (d, J = 7.2 Hz, 3 H), 1.31 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 167.5, 153.5, 139.1, 136.3, 134.5, 132.3, 128.7, 128.5, 128.1, 128.0, 124.2, 
78.2, 66.4, 31.5, 28.9, 14.8. HRMS m/z calculated for C22H26O3Na [M+Na]+ 312.1780; found 312.1775. 
 
(2R,3S)-benzyl-3-benzyl((S)-1-phenylethyl)amino-2-(4-tert-
butoxy)benzyl)butanoate (57):103 To a stirred solution of 2.44 mL (S)-(-)-N-
benzyl-α-methylbenzylamine (11.7 mmol, 1.6 equiv) in 14.6 mL anhydrous 
toluene under nitrogen at 0 °C was added 6.9 mL n-BuLi (1.6 M in hexanes, 11.0 mmol, 1.5 equiv). The 
reaction was cooled to −78 °C and stirred 15 minutes. To the reaction was added 2.467 g compound 56 
(7.290 mmol, 1 equiv) in 7.3 mL anhydrous toluene dropwise and the reaction was stirred 1 h at −78 °C 
and 2 h at −30 °C. The reaction was cooled to −78 °C and diluted with 80 mL anhydrous THF. To the 
reaction was added 4.98 g 2,6-di-tert-butylphenol (24.1 mmol, 3 equiv) in 7 mL anhydrous THF 
dropwise. The reaction was stirred at room temperature for 2 h. The organic solvent was removed under 
reduced pressure, the concentrated solution was diluted with ethyl acetate, washed once with brine, dried 
with magnesium sulfate, and concentrated. The concentrate was run through a silica plug, eluting with 
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hexanes to remove excess 2,6-di-tert-butylphenol, then eluting with ethyl acetate to remove the product. 
The ethyl acetate fraction was concentrated, purified using column chromatography (2% → 5% → 10% 
diethyl ether in hexanes), and dried under vacuum to afford the product in a 94:6 (2R,3S: 2S,3R) 
diastereomeric ratio as a yellow oil (1.812 g, 3.296 mmol, 45% yield). [α]D = −30.9 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 7.45-7.05 (m, 15 H), 6.79 (s, 4 H), 4.87 (q, J = 12.4 Hz, 2 H), 4.02 (q, J = 6.8 
Hz, 1 H), 3.88 (d, J = 13.9 Hz, 1 H), 3.75 (d, J = 13.9 Hz, 1 H), 3.13 (m, 1 Hz), 3.05 (d, J = 13.8, 3.6, Hz, 
1 H), 2.65 (m, 1 H), 2.08 (m, 1 H), 1.43 (d, J = 6.9 Hz, 3 H), 1.31 (s, 9 H), 1.13 (d, J = 6.7 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 175.1, 153.5, 144.2, 141.1, 135.9, 135.1, 129.1, 129.1, 128.5, 128.3, 128.2, 
128.1, 128.1, 127.1, 127.0, 124.1, 78.2, 66.0, 57.2, 54.1, 54.0, 50.4, 36.3, 29.0, 15.4, 15.0. HRMS m/z 
calculated for C37H44NO3 [M+H]+ 550.3321; found 550.3358. 
 
 
(2R, 3S)-3-amino-2-(4-(tert-butoxy)benzyl)butanoic acid (58):92 To a stirred 
solution of 1.702 g compound 57 (3.096 mmol, 1 equiv) in 32 mL methanol was 
added 177.5 µL glacial acetic acid (3.101 mmol, 1 equiv), 3.899 g ammonium 
formate (61.83 mmol, 20 equiv), and 341 mg 20 wt % Pd(OH)2/C (20% w/w). This solution was refluxed 
overnight under nitrogen, filtered through Celite, eluting with methanol, and concentrated to afford the 
crude amino acid which was used directly. To a stirred solution of amino acid (3.096 mmol, 1 equiv) in 
31 mL anhydrous dichloromethane was added 2.16 mL DIEA (12.4 mmol, 4 equiv) and 786 µL TMS-Cl 
(6.20 mmol, 2 equiv). After evolution of gas ceased, 1.150 g Fmoc-OSu (3.409 mmol, 1.1 equiv) was 
added and the reaction stirred overnight. The reaction mixture was washed with brine, dried with 
magnesium sulfate, and concentrated. The concentrate was purified using column chromatography (10% 
→ 20% → 50% → 100% ethyl acetate in hexanes) and dried under vacuum to afford a mixture of the 
product (276 mg by NMR, 0.566 mmol, 18% yield over 2 steps) and 9-fluorenemethanol (~50% by 
NMR) which was used directly in peptide synthesis. [α]D = −3.5 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
DMSO-d6) δ 12.2 (s, 1 H), 7.88 (m, 2 H), 7.70 (d, J = 7.2 Hz, 2 H), 7.39 (m, 3 H), 7.31 (m, 2 H), 7.03 (d, 
J = 8.3 Hz, 2 H), 6.85 (d, J = 8.3 Hz, 2 H), 4.40 (m, 1 H), 4.31 (m, 1 H), 4.23 (m, 1 H), 3.68 (q, J = 8.2 
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Hz, 1 H), 2.75-2.56 (m, 3 H), 1.26 (s, 9 H), 1.07 (d, J = 6.7 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
178.3, 155.8, 154.0, 144.0, 144.2, 133.5, 129.3, 127.8, 127.2, 125.2, 124.4, 120.1, 78.5, 66.8, 52.3, 48.2, 
47.4, 34.2, 28.9, 17.6. HRMS m/z calculated for C30H34NO5 [M+H]+ 488.2437; found 488.2440. 
2.3.1.5 Synthesis of cis Fmoc-ACPC Monomers 
 
 
 
Scheme 2.4. Synthesis of cis Fmoc-ACPC monomers. 
 
 
 
N,O-acetal 61, lactam 63,  amino acid hydrochloride 64 were synthesized using published 
procedures.104,105 
 
Racemic cis-azabicyclo[3.2.0]heptan-7-one (59):99 To a stirred solution of 4.5 mL 
cyclopentene (51 mmol, 1 equiv) in 23 mL anhydrous dichloromethane at 0 °C under nitrogen 
was added a solution of 4.3 mL chlorosulfonyl isocyanate (49 mmol, 1 equiv) in 7 mL anhydrous 
dichloromethane dropwise over 30 minutes. The reaction was then heated to 40 °C and stirred for 20 h. 
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The resulting solution was cooled to 0 °C, quenched with dropwise addition of water until bubbling 
ceased, and diluted with 120 mL chloroform. To this solution was added a solution of 15.8 g sodium 
sulfite (125 mmol, 2.5 equiv) and 35.1 g sodium biphosphate heptahydrate (125 mmol, 2.5 equiv) in 240 
mL water and the combined solution stirred 36 h. After this time, the organic layer was collected and the 
aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried with magnesium 
sulfate, and concentrated. The resulting solid was dissolved in ethyl acetate and recrystallized from 
pentane to afford the product as white crystals (3.232 g, 29.1 mmol, 58% yield). NMR spectra of the 
product matched previously published results.99 
 
(1R,2S)-2-aminocyclopentanecarboxylic acid (60):106 To a stirred solution of 1.006 g 
compound 59 (9.05 mmol, 1 equiv) in 180 mL diisopropyl ether was added 9.005 g Lipase 
B from Candida antarctica immobilized on Immobead 150 (50 mg/mL) and 162 μL water (8.99 mmol, 1 
equiv). The reaction was stirred under nitrogen at 60 °C for 10 days, then filtered and rinsed with 
diisopropyl ether. The enzyme solid was washed with water and the water layer was concentrated under 
vacuum. The resulting solid was dissolved in water and recrystallized using acetone to afford the product 
as a white solid (243 mg, 1.88 mmol, 21% yield). NMR spectra of the product matched previously 
published results.106 
Standard Procedure L:104  To a stirred suspension of 2.0 g Amano Lipase PS from Burkholderia 
cepacia and 1.2 g sucrose in 200 mL 20 mM Tris, pH 7.8 was added 6.8 g Celite. The suspension was 
concentrated to dryness to afford 20% w/w lipase on Celite. To a stirred solution of N,O-acetal (1 equiv) 
in anhydrous acetone was added vinyl butyrate (2 equiv) and 20% w/w Lipase PS (60% w/w). The 
solution was allowed to stir until the desired enzymatic resolution was obtained. The enzyme was filtered 
from the solution and washed with acetone. The organics were concentrated and purified using column 
chromatography to afford the desired product. 
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(1S,5R)-6-(hydroxymethyl)-6-azabicyclo[3.2.0]heptan-7-one (62): Standard Procedure L was 
employed using 533 mg compound 61 (3.78 mmol), 38.3 mL acetone, 960 μL vinyl butyrate (7.6 
mmol), and 1.89 g Lipase PS. The reaction was stirred for 36 h until NMR spectroscopy 
indicated 60% conversion.  Column chromatography (50% → 75% ethyl acetate in hexanes) afforded the 
unreacted starting material as a colorless oil (143 mg, 1.01 mmol, 27% yield). NMR spectra for the 
product matched previously published results.104 [α]D = −35 (c = 1.0, CHCl3); [α]D, lit = −32.4 (c = 1, 
CHCl3).104 
 
(1R,2S)-2-Fmoc-aminocyclopentanecarboxylic acid (65a): Standard Procedure F was 
employed using 94 mg compound 60 (0.73 mmol), 485 μL water, 148 mg potassium 
bicarbonate (1.46 mmol) and 245 mg Fmoc-OSu (0.727 mmol).  Column chromatography (20% ethyl 
acetate in hexanes → 50% ethyl acetate in hexanes) afforded the product as a white foam (139 mg, 0.396 
mmol, 54% yield). [α]D = −29 (c = 0.50, CHCl3). NMR spectra for this product matched previously 
published results.99 HRMS m/z calculated for C21H21NO4Na [M+Na]+ 374.1368; found 374.1366. 
 
(1S,2R)-2-Fmoc-aminocyclopentanecarboxylic acid (65b): Standard Procedure F was 
employed using 150 mg acid hydrochloride compound 64 (0.906 mmol), 1.10 mL water, 
182 mg potassium bicarbonate (1.82 mmol) and 308 mg Fmoc-OSu (0.913 mmol).  Column 
chromatography (20% → 50% ethyl acetate in hexanes) afforded the product as a white foam (243 mg, 
0.692 mmol, 76% yield). [α]D = +29 (c = 0.50, CHCl3). NMR spectra for this product matched previously 
published results.99 HRMS m/z calculated for C21H21NO4Na [M+Na]+ 374.1368; found 374.1352. 
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2.3.1.6 Synthesis of cis Fmoc-ACHC Monomers 
 
 
 
Scheme 2.5. Synthesis of cis Fmoc-ACHC monomers. 
 
 
N,O-acetal 67, amino acid hydrochloride 71a, and amino acid hydrochloride 71b were synthesized using 
published procedures.105 
 
Racemic cis-7-azabicyclo[4.2.0]octan-8-one (66):99 To a stirred solution of 10.1 mL 
cyclohexene (100 mmol, 1 equiv) in 45 mL anhydrous dichloromethane at 0 °C under nitrogen 
was added a solution of 8.6 mL chlorosulfonyl isocyanate (100 mmol, 1 equiv) in 15 mL 
anhydrous dichloromethane dropwise over 30 minutes. The reaction was allowed to warm to room 
temperature and stirred for 96 h, then cooled to 0 °C, quenched with dropwise addition of water until 
bubbling ceased, and diluted with 100 mL chloroform. To this solution was added a solution of 31.6 g 
sodium sulfite (250 mmol, 2.5 equiv) and 70.3 g sodium biphosphate heptahydrate (250 mmol, 2.5 equiv) 
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in 500 mL water. The solution was stirred 36 h, then the organic layer was collected and the aqueous 
layer was extracted with ethyl acetate. The organic layers were combined, dried with magnesium sulfate, 
and concentrated. The resulting yellow solid was re-dissolved in ethyl acetate and recrystallized using 
pentane to afford the product as white crystals (4.81 g, 38.4 mmol, 38% yield). NMR spectra matched for 
this product previously published results.105 
 
((1R,6S)-8-oxo-7-azabicyclo[4.2.0]octan-7-yl)methyl butyrate (68): Standard Procedure L was 
employed using 518 mg compound 67 (3.34 mmol), 34 mL acetone, 850 μL vinyl butyrate (6.7 
mmol), and 1.68 g Lipase PS.  The reaction was stirred for 16 h when NMR spectroscopy 
indicated 40% conversion.  Column chromatography (0% → 50% ethyl acetate in dichloromethane → 
75% ethyl acetate in hexanes) afforded the product as a yellow oil (242 mg, 1.08 mmol, 32% yield). NMR 
spectra for this product matched previously published results.105 [α]D −18 (c = 1.0, MeOH); [α]D, lit = 
−15.5 (c = 1, MeOH).105 
 
(1S,6R)-7-(hydroxymethyl-7-azabicyclo[4.2.0]octan-8-one (69): Standard Procedure L was 
employed using 518 mg compound 67 (3.34 mmol), 34 mL acetone, 0.85 mL vinyl butyrate (6.7 
mmol), and 1.68 g Lipase PS.  The reaction was stirred for 16 h when NMR spectroscopy 
indicated 40% conversion.  Column chromatography (75% ethyl acetate in hexanes) afforded the 
unreacted starting material.  Standard Procedure L was then employed again using 142 mg recovered 
starting material (0.915 mmol), 9.3 mL acetone, 230 μL vinyl butyrate (1.8 mmol), and 463 mg Lipase 
PS.  The reaction was stirred for 36 h when NMR spectroscopy indicated 60% conversion.  Column 
chromatography (0% → 50% → 75% ethyl acetate in hexanes) afforded the unreacted starting material as 
a colorless oil (83 mg, 0.54 mmol, 16% yield). NMR spectra for this material matched previously 
published results.105 [α]D = −33 (c = 1.0, MeOH); [α]D, lit = −31.7 (c = 1, MeOH).105 
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Standard Procedure M: Acetal Hydrolysis:105 To a solution of N,O-acetal (1 equiv) in methanol was 
added concentrated aqueous ammonium hydroxide.  The reaction mixture was stirred until TLC indicated 
full conversion to product.  The solution was concentrated under vacuum to afford the product. 
 
(1R,6S)-7-azabicyclo[4.2.0]octan-8-one (70a): Standard Procedure M was employed using 242 
mg compound 68 (1.08 mmol), 15.8 mL methanol, and 1.6 mL concentrated aqueous ammonium 
hydroxide. The reaction was stirred for 3 days then concentrated to afford the product as white 
crystals (99 mg, 0.79 mmol, 73% yield). NMR spectra for this product matched previously published 
results.105 
 
(1S,6R)-7-azabicyclo[4.2.0]octan-8-one (70b): Standard Procedure M was employed using 83 
mg compound 69 (0.54 mmol), 8.3 mL methanol, and 0.8 mL concentrated aqueous ammonium 
hydroxide.  The reaction was stirred 3 days then concentrated to afford the product as white 
crystals (62 mg, 0.50 mmol, 93% yield). NMR spectra matched previously published results.105 
 
(1R,2S)-2-Fmoc-amino-cyclohexanecarboxylic acid (72a): Standard Procedure F was 
employed using 123 mg compound 71a (0.684 mmol), 800 μL water, 137 mg potassium 
bicarbonate (1.36 mmol), and 230 mg Fmoc-OSu (0.682 mmol).  Column chromatography (20% → 50% 
ethyl acetate in hexanes  ethyl acetate in hexanes) afforded the product as a white foam (115 mg, 0.315 
mmol, 46% yield). [α]D = −12 (c = 0.50, CHCl3). NMR spectra for this product matched previously 
published results.99 HRMS m/z calculated for C22H23NO4Na [M+Na]+ 388.1525; found 388.1508. 
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(1S,2R)-2-Fmoc-amino-cyclohexanecarboxylic acid (72b): Standard Procedure F was 
employed using 76 mg compound 71b (0.42 mmol), 510 μL water, 84 mg potassium 
bicarbonate (0.84 mmol), and 142 mg Fmoc-OSu (0.421 mmol). Column chromatography (20% → 50% 
ethyl acetate in hexanes) afforded the product as a white foam (97 mg, 0.27 mmol, 50% yield). [α]D = +13 
(c = 0.50, CHCl3). NMR spectra matched previously published results.99 HRMS m/z calculated for 
C22H23NO4Na [M+Na]+ 388.1525; found 388.1521. 
2.3.2 Peptide Synthesis 
Peptides were synthesized using standard microwave-assisted Fmoc solid-phase synthesis techniques on a 
MARS microwarve reactor (CEM). NovaPEG Rink Amide resin NovaPEG Rink Amide resin or H-
Glu(tBu) HMPB NovaPEG resin was used as the solid support. Couplings were carried out in NMP with 
a 2 min ramp to 70 °C and a 4 min hold at that temperature, using Fmoc-protected amino acid (4 equiv), 
HCTU (4 equiv), and DIEA (4 equiv). Deprotections were performed with a 2 min ramp to 80 °C 
followed by a 2 min hold at that temperature, using an excess of 20% 4-methylpiperidine in DMF. After 
each coupling or deprotection cycle, the resin was washed three times with DMF. Double coupling was 
performed at sequence positions following proline residues. N-terminal acetylation, when present, was 
carried out on resin by treatment with 8:2:1 v/v/v DMF:DIEA:Ac2O.  
 Peptides 8a, 8b, 9a, and 9b were synthesized using thiocarbamate-protected monomers. These 
monomers were coupled using standard microwave-assisted coupling procedures. For deprotection, the 
resin was first suspended in 1 mL dioxane. 1 mL of 0.04 M solution of Oxone in water was added to the 
suspension and stirred for 90 minutes. After this time, the solution was drained and the resin washed five 
times with 1:1 dioxane/water and washed three times with DMF.  
Prior to cleavage from resin, peptides were washed three times each with DMF, dichloromethane, and 
methanol, and then dried. Peptide cleavage was performed using 95% trifluoroacetic acid (TFA), 2.5% 
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triisopropylsilane, and 2.5% water. Cysteine-containing peptides were purified, lyophilized, dissolved in 
10 mM phosphate buffer (pH 8.9, 5% v/v DMSO), stirred until analytical HPLC and MS showed 
complete conversion to the cyclic disulfide (1-2 d), and then re-purified. 
Peptides were purified by HPLC on a C18 preparative column using gradients between 0.1% TFA 
in water and 0.1% TFA in acetonitrile. All peptides were >95% pure by analytical HPLC on a C18 
column. Identities of peptides were confirmed using a Voyager DE Pro MALDI-TOF instrument (Table 3 
and Table 4).  
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Table 3. MALDI-TOF data for peptides 1a-17a and 1b-17b. 
Peptide [M+H]
+ m/z 
Calculated Observed 
1a 1507.8 1508.3 
2a 1504.9 1505.1 
3a 1504.9 1505.0 
4a 1504.9 1504.7 
5a 1504.9 1504.4 
6a 1532.9 1532.9 
7a 1532.9 1532.9 
8a 1532.9 1533.0 
9a 1532.9 1533.0 
10a 1500.8 1501.0 
11a 1500.8 1501.0 
12a 1500.8 1500.6 
13a 1500.8 1500.6 
14a 1528.9 1528.8 
15a 1528.9 1528.8 
16a 1528.9 1528.6 
17a 1528.9 1528.5 
1b 1507.8 1507.7 
2b 1504.9 1504.6 
3b 1504.9 1505.0 
4b 1504.9 1504.7 
5b 1504.9 1504.4 
6b 1532.9 1532.9 
7b 1532.9 1532.7 
8b 1532.9 1533.0 
9b 1532.9 1533.0 
10b 1500.8 1500.5 
11b 1500.8 1500.6 
12b 1500.8 1500.6 
13b 1500.8 1500.4 
14b 1528.9 1528.5 
15b 1528.9 1528.9 
16b 1528.9 1528.5 
17b 1528.9 1528.6 
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Table 4. MALDI-TOF data for peptides 18-26 and their derivatives. 
Peptide [M+H]
+ m/z 
Calculated Observed 
18 1862.8 1862.7 
19a 1897.0 1897.8 
19b 2143.0 2143.8 
19c 1006.5 1006.2 
19d 951.5 951.1 
20a 1837.0 1837.6 
20b 2084.4 2084.8 
20c 976.5 976.3 
20d 921.5 921.2 
 21a 1798.9 1799.9 
22a 1739.8 1739.2 
 22b
* 2007.8 2008.3 
22c* 928.4 928.2 
22d* 915.5 916.0 
23a 1625.8 1626.6 
23b 1871.8 1871.3 
23c 871.4 871.8 
23d 836.5 837.1 
24a 1653.8 1654.1 
24b 1899.9 
 
1900.2 
24c* 863.4 855.2 
24d 850.5 850.6 
25a 1795.9 1796.1 
25b 2041.9 2042.1 
25c 934.4 934.6 
25d 921.5 921.6 
26a 1852.0 1852.1 
26b 2098.0 2098.2 
26c 984.5 984.6 
26d 949.5 949.7 
*[M+Na]+ Peak 
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2.3.3 NMR Sample Preparation and Data Collection 
NMR samples were prepared by dissolving 2-3 mg peptide in 750-850 µL de-gassed buffer solution to 
make 0.2−2 mM solutions. For peptides 1a-17a and 1b-17b, 0.1 M NaOAc-d3, 90% H2O/D2O, pH 3.8 
(uncorrected for the presence of D2O) was used as the buffer system. For peptides 18-26 and their 
derivatives, 50 mM phosphate, 9:1 H2O/D2O, pH 6.3, uncorrected, was used. 3-(Trimethylsilyl)-1-
propanesulfonic acid sodium salt (DSS, 50 mM in water) was added to a final concentration of 0.2 mM 
DSS in the sample. Each solution was passed through a 0.2 µm syringe filter, transferred to an NMR tube, 
and stored until analysis. The NMR tube headspace was purged with a stream of nitrogen prior to 
capping. 
NMR spectra of peptides were recorded on a Bruker-Avance-600 or Bruker Avance-700 
spectrometer. Chemical shifts are reported relative to DSS (0 ppm). TOCSY, NOESY, and COSY pulse 
programs used excitation-sculpted gradient-pulse solvent suppression. All experiments were obtained 
using 2048 data points in the direction dimension and 512 data points in the indirect dimension. TOCSY 
were acquired with a mixing time of 60 or 80 ms and NOESY were acquired with a mixing time of 200 
ms. 
 For peptides 1a-17a and 1b-17b, NMR measurements were performed at 277 K. Other NMR 
measurements were performed at a temperature of 293 K unless otherwise noted. Linear hairpin peptides 
with unnatural backbones (23a-26a) were measured at 278 K to maximize folded population and facilitate 
comparison of folded stability. Natural backbone peptide 22a was measured at both 278 K and 293 K. 
NMR data at 293 K were used for comparison among the α-peptide series (18, 19a-22a), while data at 
278 K were used for comparison with the unnatural backbone series (23a-26a). 
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2.3.4 NMR Data Analysis and Structure Determination 
The Sparky software package (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, 
San Francisco) was used to analyze 2D NMR data. Backbone chemical shift assignments were generated 
(Appendix A) and each peptide was analyzed for qualitative NOE’s indicative of folding. Peptides that 
showed a high degree of folding were fully assigned and inter-residue NOE’s were tabulated. NOE 
integration values were converted to distance restraints using equation 1:  
(1) 𝐼 = 𝑐𝑟−6 
where I is intensity, c is a constant (determined using resolved diastereotopic CH2 groups), r is 
distance.117 The distances were then classified as strong (≤2.7 Å), medium (≤3.5 Å), weak (≤4.5 Å), or 
very weak (≤5.5 Å) to generate distance restraints (Appendix B). 
The Crystallography and NMR system (CNS) software package was used to generate 3D 
resolution structures.118,119  Patches were written to accommodate β-residues. Distance restraints 
calculated above were used in 100 simulated annealing runs using default suggested parameters for 
protein NMR. Structures including any NOE distance-restraint violations (>0.5 Å) were discarded and the 
20 lowest energy structures were obtained. The minimum energy average of these 10 or 20 structures was 
inspected to identify H-bonding contacts. These contacts were then included in an additional restraint file 
and the annealing process repeated to generate an ensemble of 10 or 20 lowest energy structures and a 
minimized average structure for each peptide.  
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2.3.5 Calculation of Folding Equilbria by NMR 
Fraction folded from chemical shift deviation (fHα) was calculated using experimentally determine Hα 
chemical shifts (δHα) using equation 2:111 
  (2) 𝑓𝐻𝛼 = 𝛿𝐻𝛼,𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑−𝛿𝐻𝛼,𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑𝛿𝐻𝛼,𝑓𝑜𝑙𝑑𝑒𝑑−𝛿𝐻𝛼,𝑢𝑛𝑓𝑜𝑙𝑑𝑒𝑑   
where δHα,observed is the chemical shift of a particular Hα in the unknown peptide, δHα,unfolded its chemical 
shift in an N- or C-terminal fragment, and δHα,folded its chemical shift in a disulfide-bridged cyclic analog. 
Values of f reported are averages calculated using chemical shift data for residues 4, 11, and 13. 
Fraction folded from separation of diasterotopic Gly Hα’s (fGly) was calculated using equation 3:  
(3) 𝑓𝐺𝑙𝑦 = Δ𝛿𝐻𝛼/𝐻𝑎′,𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑Δ𝛿𝐻𝛼/𝐻𝑎′,𝑓𝑜𝑙𝑑𝑒𝑑  
where ∆δHα/Hα’,observed is the chemical shift difference between Gly Hα’s in an unknown peptide and 
∆δHα/Hα’,folded the corresponding difference in a disulfide-bridged cyclic analogue. 
The equilibrium constant for the folding equilibrium (Kfold) and corresponding free energy of 
folding (∆G°fold) were calculated from fraction folded using eq. 4 and eq. 5: 
(4) 𝐾𝑓𝑜𝑙𝑑 = 𝑓1−𝑓   
(5) Δ𝐺𝑓𝑜𝑙𝑑 = −𝑅𝑅𝑅𝑅(𝐾𝑓𝑜𝑙𝑑) 
Experimental uncertainty for folded population determined by Hα chemical shift deviation (fHα) 
was estimated using the standard deviation of the mean for populations based on residues 4, 11, and 13. 
Error for folded population determined by Gly Hα separation (fGly) was estimated by assuming 0.01 ppm 
error in NMR peak assignment. The above values were used in standard error propagation based on eqs. 
3, 4, and 5 to give uncertainties for fGly, Kfold, and ∆Gfold.  A lower bound for the folded population of 
peptide 25a was calculated using equation 3, an estimated minimum measurable glycine separation value 
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of 0.03 ppm, and an estimated value for the fully folded state of 0.322 ppm (average observed for 
peptides 22b, 23b, 24b, and 26b). 
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3.0  GAMMA RESIDUES AND N-METHYL-ALPHA-RESIDUES IN HETEROGENEOUS 
BACKBONE HAIRPINS 
Some of the results detailed in this chapter have been published in: 
1. Lengyel, G.A.; Eddinger, G.A.; Horne, W.S., “Introduction of Cyclically Constrained γ-Residues 
Stabilizes an α-Peptide Hairpin in Aqueous Solution,” Organic Letters, 2013, 944-947. 
 
Chapter 2 highlights the advantages and consequences of applying β-residue substitutions in hairpin-
forming peptides. A 1:1 α- to β-residue substitution strategy inverts the display of side chains and 
hydrogen bonding pattern beyond the insertion site of the unnatural amino acids, but even with this 
inversion, hybrid α/β-peptides can still fold into hairpin conformations in water. Utilizing 2:1 or 2:2 α- to 
β-residue substitution strategies prevents this inversion and allows native-like folding from the hybrid 
backbones, but significantly destabilizes the folded state. Because of this destabilization, we sought to 
investigate alternative monomer types which would both prevent side chain inversion and would have 
either a neutral or beneficial impact on folded stability. 
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3.1 1:1 ALPHA- TO GAMMA-RESIDUE SUBSTITUTION 
3.1.1 Design of Alpha- to Gamma-Residue Substitution Strategies 
Direct substitution of a single α-amino acid in a strand with a β-amino acid causes side chain inversion 
due to the incorporation of an additional carbon unit in the backbone of the amino acid. Previous work 
has shown that incorporation of γ-amino acids, which increase the length of the amino acid backbone by 
two carbon atoms, can prevent inversion in extended strands (Figure 35).69 
 
 
 
Figure 35. 1:1 α- to γ-residue substitution resulting in backbone expansion. 
 
 
Additional work has shown that while γ-residues can prevent inversion of side chains without 
rigidifying the backbone of the γ-residue, the hairpin itself may become too flexible to form a discrete 
folded structure.70,120 With these factors in mind, we selected three γ-residues with varying degrees of 
backbone constraint for use in a 1:1 α- to γ-residue substitution strategy (Figure 36). 
 
 
 
Figure 36. Backbone-constrained γ-residues. 
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 Of the three γ-amino acids chosen, two have backbones incorporated into six-membered rings. 
meta-Aminobenzoic acid (mABA) has been successfully inserted into a hairpin peptide that folds in 
organic solvent71 while substituted derivatives of this amino acid have been used in sheets to discourage 
sheet stacking and aggregation.53,59 (1R,3S)-Aminocyclohexanecarboxylic acid (Acc) also has a ring-
constrained backbone and can be used in place of L-α-amino acids72 to form cyclic β-sheets in a 
nanotubular system.73,74   
 While both mABA and Acc have been shown as effective α-amino acid replacements in sheets, 
use of these monomers eliminates any side chain functionality which may be essential to protein folding 
in larger proteins. To maintain side chain functionality while keeping a constrained backbone, we also 
examined vinylogous γ4-amino acids in our studies. These α,β-unsaturated acids, which have a backbone 
rigidified with one double bond paired with a side chain functionalized γ-carbon, have been used in both a 
small tetrapeptide sheet system69 and a larger hairpin peptide.70 In all of the studies mentioned above, only 
the structural impacts have been examined in organic solvent; there have been no examinations of the 
thermodynamic implications of γ-residue substitution or of structural impacts in aqueous media. 
3.1.2 Thermodynamic Analysis of 1:1 Alpha- to Gamma-Residue Substitution 
Using the same model hairpin peptide described in Section 2.2, we synthesized peptides 73, 74, and 75, 
incorporating mABA, Acc, and vinylogous γ4-alanine, respectively, in place of residues Ala4 and Ala13 of 
hairpin 22a (Figure 37). 
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Figure 37. Model hairpin sequence 22a and α/γ-hybrid peptide sequences 73-75. 
 
 
Peptides 73, 74, and 75 were synthesized and analyzed at 278 K in aqueous phosphate buffer pH 
6.3 using multidimensional NMR. The backbone Hα and NH resonances of each peptide were fully 
assigned and glycine separation was measured (Table 5) using the same methodology described in 
Section 2.1.2. Using a value of 0.310 ppm (determined from cyclized parent peptide 22b) as the 
maximum value of glycine Hα separation for a fully-folded state, we determined the folded population of 
each peptide and the associated ∆Gfold. 
 
 
 
Table 5. Folded populations and ∆Gfold for parent peptide 22a and α/γ-hybrid peptides 73-75. 
Peptide Glycine Separation (ppm) 
Folded Population  
(%) 
∆Gfold  
(kcal/mol) 
∆∆Gfold
a  
(kcal/mol) 
22a 0.21 ± 0.01 66 ± 5 −0.35 ± 0.14 --- 
73 0.25 ± 0.01 79 ± 6 −0.74 ± 0.20 −0.4 ± 0.2 
74 0.26 ± 0.01 83 ± 6 −0.88 ± 0.23 −0.5 ± 0.2 
75 0.12 ± 0.01 39 ± 5 0.24 ± 0.11 +0.6 ± 0.2 
a. Values calculated versus ∆Gfold of peptide 22a. 
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The folded populations of the hybrid peptides containing cyclic γ-residues (73 and 74) were both 
higher than the folded population of parent peptide 22a. The corresponding ∆∆Gfold for 73 and 74 relative 
to 22a shows a stabilization of approximately 0.5 kcal/mol. Both mABA and Acc are significantly more 
stabilizing than the β-residue substitutions discussed in Section 2.2.5, where the most favorable case was 
a 1 kcal/mol penalty to folding from modifying two strands of the hairpin. Vinylogous γ4-amino acid 
containing peptide 75, with a ∆∆Gfold of +0.6 kcal/mol, is not stabilized like peptides 73 and 74, but is 
more stable than the peptides utilizing β-residue substitutions The decreased stability of this system 
compared to the cyclic γ-residues most likely results from increased backbone flexibility. 
3.1.3 Structural Analysis of 1:1 Alpha- to Gamma-Residue Substitution 
Having accomplished the goal of finding amino acids that are more thermodynamically favored as α-
amino acid replacements than β-amino acids, we next sought to investigate the structural impacts of γ-
residue substitution to the hairpin fold. As peptide 75 had a folded population less than 50%, we 
synthesized a cyclic variant, 76 (Figure 38), for structural analysis using a terminal disulfide bridge as 
discussed in Section 2.2.4. 
 
 
 
Figure 38. Sequence of cyclized α/γ-hybrid peptide 76. 
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The proton resonances of peptides 73, 74, and 76 were fully assigned, and the solution fold of 
these peptides investigated using NOE analysis (see Section 2.1.3 for details). In each case, as expected 
from our design principles, substitution of an α-amino acid with a γ-amino acid prevented side chain 
inversion and NOE’s were visible across the entire length of the backbone, suggesting hairpin-like 
structures (Figure 39). 
 
 
 
Figure 39. Cross-strand NOE’s displayed by peptides 73, 74, and 76. 
Ambiguous assignments are shown as dotted lines. Cylic γ-residues are highlighted green while vinylogous γ4-
residues are highlighted orange. 
 
 
 With evidence of hairpin formation in hand, we generated NOE distance restraints and NMR 
structures of peptides 73, 74, and 76 as described in Section 3.3.4. We calculated the average structure for 
each compound using the 10 lowest energy structures for each (Figure 40). In the case of 74, we saw a 
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minor conformer of a horseshoe shape in 2 of the 10 structures and calculated the average structure 
excluding the minor conformation. 
 
 
 
Figure 40. NMR solution structures of α/γ-hybrid peptides 73, 74, and 76. 
Structures calculated from the average of 10 lowest energy conformations determined using NOE distance restraints 
from NMR. Samples consisted of ~1 mM solution of peptide and 50 mM phosphate in 90% H2O/D2O, pH 6.3.  
Hydrophobic side chains displayed as spheres. mABA and Acc residues are colored green while vinylogous γ4-
residues are colored orange. 
 
 
Analysis of the 3D structures shows that each peptide forms a hairpin structure in aqueous 
solution. Peptide 74 experiences some twisting near the terminus, but the termini of hairpins are the least 
constrained section of the folded structure and are often subject to fraying. When viewed from the side, 
the four hydrophobic core residues of each hairpin are displayed on the same face, demonstrating no 
evidence of the inversion seen with 1:1 α- to β-residue substitution. 
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Closer examination of the two cyclic γ-residues used in peptides 73 and 74 shows a minor 
difference in the display of the amides on either end of the residues (Figure 41). The mABA in peptide 73, 
due to the planarity enforced by the conjugated ring, forces the adjacent amide NH and carbonyl groups 
closer together while the Acc monomer in 74 allows an extended backbone conformation that more 
closely mimics that of a natural sheet.  However, in both cases, the amides are oriented in such a way as 
to allow for inter-sheet stacking without steric disruption from the backbones of the unnatural residues. 
 As a final point of comparison, peptides 73, 74, and 76 were overlaid with parent peptide 22a. 
(Figure 42). In each case, measuring the RMSD values for the C, Cα, Cβ, N, and O atoms of residues Trp3, 
Tyr5, Phe12, and Val14 between peptides 73, 74, and 76 versus 22a gave values of 1.5 Å, 1.9 Å, and 1.5 Å, 
respectively. These values suggest that while 1:1 α- to γ-residue substitution changes the hairpin structure 
to a small degree, this substitution strategy using mABA, Acc, and vinylogous γ4-amino acids can be 
applied while still maintaining a native-like hairpin structure.  
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Figure 41. Close-up view of the cyclic γ-residues from the NMR solution structures of peptides 73 and 74. 
 
 
 
Figure 42. Overlays of the NMR solution structures of peptides 73, 74, and 76 (yellow) with parent peptide 22a 
(white). 
mABA and Acc residues are colored green while vinylogous γ4-residues are colored orange. 
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3.1.4 Conclusions 
Unlike a 1:1 α- to β-residue substitution strategy which causes inversion of side chain display or 2:1 and 
2:2 α- to β-residue substitution strategies which significantly destabilize the folded structure of small 
hairpin peptides, 1:1 α- to γ-residue substitution in each strand of a hairpin maintains native side chain 
display. Because γ-residues have an additional carbon atom in their backbones relative to β-residues, they 
can prevent the side chain inversion seen in β-residues.  
Use of cyclic γ-amino acids mABA and Acc increases the stability of the folded structure by ~0.5 
kcal/mol. The enhanced stability of the hairpin arises from the ring constraint and backbone 
preorganization of cyclic γ-residues (Figure 43).  
 
 
 
Figure 43. An α-residue and cyclic γ-residues mABA and Acc. 
 
 
The aromaticity of mABA residues enforces an extended chain geometry similar to that seen with 
an α-residue. Acc residues, while not aromatic, also promote an extended chain in a similar fashion, 
enforced by a chair conformation equatorial substituents. Use of vinylogous γ4-residues, on the other 
hand, slightly destabilizes the hairpin (∆∆Gfold = +0.6 kcal/mol for two substitutions). Unlike the cyclic γ-
residue variants, the backbones of vinylogous γ4-residues are not as strongly constrained by aromaticity or 
a cyclohexane chair structure; instead, the α,β-unsaturation is the sole source of backbone 
preorganization. While this double bond constrains rotation of the Cα-Cβ bond, the N-Cγ and Cγ-Cβ bonds 
are still relatively unconstrained and can freely rotate. The increased flexibility of the γ4-residues relative 
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to cyclic γ-residues is likely the cause of the minor destabilization seen in the hairpin peptide. Unlike the 
cyclic residues, however, vinylogous γ4-residues allow for retention of side chain functionality. 
Overall, these data imply that 1:1 α- to γ-residue substitution could be applied to a sheet in a 
larger protein with a well-defined tertiary fold. Cyclic γ-residues can be used in place of α-residues to 
when the side chain functionality is not critical. Vinylogous γ4-residues can be used when a side chain 
functional group must be maintained, although with a slight penalty to overall stability. 
3.2 N-METHYLATION OF SELECTED ALPHA-RESIDUES 
While use of γ-residues in hairpin substitution strategies prevents inversion and can stabilize the folded 
structure, they also result in backbone lengthening which could impact the folded structure of larger 
proteins in unexpected ways. We chose to focus our next experiments on N-methylated α-residues as 
these residues do not increase the length of the amino acid backbone and have been shown to impart 
enhanced proteolytic resistance121 and increase bioavailability.122 As with γ-residue substitution, the 
thermodynamic impact of N-methylation in peptide or protein β-sheets has not previously been examined. 
3.2.1 N-Methylation Strategies Applied to a Model Hairpin Peptide 
We first chose to individually substitute non-hydrogen bonding residues Trp3, Tyr5, Phe11, and Val13 of 
peptide 22a to generate peptides 77-80, respectively (Figure 44). These four residues were individually 
substituted to determine the thermodynamic impact of N-methylation placement relative to the hairpin 
turn. Non-hydrogen-bonded positions were chosen as N-methylation has been shown to disrupt sheet 
stacking;74,123 substitution at hydrogen-bonded positions would eliminate the possibility of the N-methyl 
residues disrupting inter-strand hydrogen-bonding. 
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Figure 44. Sequences of model hairpin peptide 22a and N-methylated peptides 77-80. 
 
3.2.2 NMR Analysis of N-Methylated Hairpin Peptides 
Peptides 77-80 were synthesized by Fmoc solid-phase peptide synthesis methods and analyzed using 
multidimensional NMR as described in Section 3.3.4. Each N-methylated peptide showed evidence of 
two distinct conformations which we attributed to cis / trans isomerization about the tertiary amide at the 
site of N-methylation. We calculated the percentage of each conformation (Figure 45) by integration of 
the Asn6 NH-Hα and NH-Hβ TOCSY signals for each conformer. In this sequence, the protons of Asn6 
demonstrate clear dispersion from the resonances of other protons (Figure 46).  
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Figure 45. Populations of cis and trans conformations of N-methylated peptides 77-80. 
 
 
 
 
Figure 46. Close-up views of TOCSY spectra of peptide 80. 
NH-Hα and NH-Hβ regions are displayed on the left and right, respectively. Asn6 cross-peaks are colored green. 
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Immediately apparent is the larger population of one conformation relative to the other. We 
assigned the predominant population as trans as this amide conformation has been shown to be the major 
conformer in peptide backbones. For all of the N-methyl peptides, NOE evidence verified this assignment 
as the N-Me protons had NOE contacts with both the side chain and Hα protons of the preceding residue; 
these NOE’s are consistent with the trans rather than the cis conformation (Figure 47). The trans amide 
population was roughly equal for peptides 77 and 79 while peptide 80 had a much higher population of 
trans conformer relative to the other peptides. The larger trans population of peptide 80 is consistent with 
published work showing that amino acids with β-branched side chains (such as valine) have a more 
destabilized cis conformation.124 The cis amide conformation of an N-methyl amide forces the side chains 
of the N-Me and preceding residues closer together than in the trans conformation (Figure 48); 
introducing β-branching in the side chain of an N-Me residue creates additional steric clash, thereby 
destabilizing the cis conformation.  
 
 
 
Figure 47. Predicted NOE signals with trans and cis N-Me amide configurations. 
Green arrows represent positive NOE contacts while red arrows represent NOE contacts not seen for the populations 
of N-Me peptides 77-80 assigned as trans. 
 
 
 
Peptide 78 also has a larger population of trans conformer despite its lack of β-branching. In this 
peptide, the hydrophobic core side chains of Tyr5, Phe12, and Val14 are found together in both cis and 
trans amide conformations (Figure 49); we hypothesized the increased trans population serves to draw 
Trp3 into the hydrophobic core as well.  
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Figure 48. Comparison of side chain steric clash (red) seen in a trans vs cis N-Me amide conformation. 
 
 
 
 
Figure 49. trans and cis conformers of peptide 80. 
Hydrophobic contacts between core residues Trp3, Tyr5, Phe12, and Val14 are shown as arrows. In the cis 
conformation, several of these contacts are lost. 
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Using glycine separation analysis as in Section 2.1.2, we calculated the folded populations for 
both the cis and trans conformations of peptides 77-80 (Figure 50).  
 
 
 
Figure 50. Folded populations of peptides 77-80. 
Populations of cis and trans conformations were calculated using glycine separation analysis. 
 
 
 
Peptides 77-80 each demonstrate a dramatic decrease in folded stability of the cis conformers 
relative to their respective trans conformers. This change is reasonable as the cis amide conformation 
redirects the peptide backbone, thereby disrupting the positioning of hydrophobic core residues necessary 
for maintaining the folded state. The magnitude of destabilization varies but is most significant when the 
N-methylation is found near the turn as in peptides 78 and 79. As shown in peptides 77 and 80, increasing 
the distance between the site of N-methylation and the turn of the hairpin decreases the degree of 
destabilization found with the cis conformer.  
Analyzing the folded population of the trans conformers, we saw a decrease in folded stability 
when the site of N-methylation occurs near the turn. Computational studies have shown that N-
methylation of α-residues limits their energetically accessible conformations.125 The region of the 
Ramachandran plot corresponding to dihedrals for extended conformations126 becomes energetically 
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unfavorable for N-methyl residues, potentially leading to a change in backbone conformation and 
subsequent destabilization of folded structure. 
To determine overall folded populations for peptides 77-80, we multiplied the fraction of trans 
population by the folded population of the trans conformers (Table 6).  
 
 
Table 6. Folded populations and ∆Gfold for peptide 22a and N-methyl peptides 77-80. 
Peptide Folded Population (%) ∆Gfold (kcal/mol) ∆∆Gfold (kcal/mol) 
22a 66 ± 5 −0.3 ± 0.1 --- 
77 37 ± 4 +0.3 ± 0.1 +0.6 
78 19 ± 4 +0.8 ± 0.2 +1.1 
79 29 ± 3 +0.5 ± 0.2 +0.8 
80 55 ± 5 −0.1 ± 0.1 +0.2 
 
 
 
N-methylation destabilizes the fold of a hairpin peptide by 0.2 – 0.6 kcal/mol when applied near 
the termini (peptides 77 and 80) and ~1 kcal/mol when applied near the turn (peptides 78 and 79). N-
methylation of β-branched amino acids such as the valine used in peptide 80 can provide an increase in 
the trans population of the N-methyl amide and can increase folded stability.  
3.2.3 Conclusions 
Relative to the other monomer types discussed, N-methylation is less destabilizing than β-residue 
substitution but more destabilizing than γ-residue substitution. Unlike β-residue or vinylogous γ4-residue 
substitution which can incorporate side chains required for folding or cyclic γ-residue substitution which 
can be applied at sites where side chain functionality is not required, choice of the location of N-
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methylation is much more limited. Optimally, N-methylation would be restricted to sites with β-branched 
side chains. This decreases the population of the cis amide conformer, stabilizing the fold. Another 
important limitation is the need to restrict N-methylation to non-hydrogen bonded sites so as not to 
disrupt inter-strand contacts with the newly introduced backbone carbon. Additionally, N-methyl residues 
cannot be incorporated in the central strands of large sheet systems without disrupting hydrogen bonding. 
Overall, N-methylation can be used as a substitution strategy for α-residues, but with some degree of 
destabilization and perhaps a limited selection of substitution sites. 
3.3 EXPERIMENTAL 
3.3.1 Monomer Synthesis 
3.3.1.1 General Information 
Optical rotations were measured on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at 
ambient temperature. NMR spectra of synthetic small molecules were recorded on a Bruker Avance-400 
spectrometer. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
(HCTU), NovaPEG Rink Amide Resin, 9-fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu), and 
Fmoc-protected α-amino acids were purchased from Novabiochem. Solvents and all other reagents were 
purchased from Aldrich, Baker, Fisher, or TCI and used as received without further purification. Flash 
chromatography was performed using SorbTech silica gel (60 Å, 40-63 µm). Boc-(1R,3S)-3-
aminocyclohexanecarboxylic acid (82) was synthesized from racemic cis-3-aminocyclohexanecarboxylic 
acid using a published protocol.127 The Weinreb amide of Fmoc-Ala-OH (84) was synthesized using a 
published protocol.128 
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3.3.1.2 Synthesis of Fmoc-mABA-OH 
 
 
 
Scheme 3.1. Synthesis of Fmoc-mABA-OH (81). 
 
 
Fmoc-m-aminobenzoic acid (81): To a solution of 501 mg m-aminobenzoic acid 
(3.65 mmol, 1 equiv) in 13 mL p-dioxane was added a solution of 1.53 g sodium 
bicarbonate (18.2 mmol, 5 equiv) in 5 mL of water followed by 1.04 g Fmoc chloride (4.02 mmol, 1.1 
equiv). The reaction was allowed to stir overnight, then neutralized with 1 M hydrochloric acid and 
extracted three times with ethyl acetate. The organic layers were combined, dried with magnesium 
sulfate, and concentrated. The concentrate was purified using column chromatography (10% → 33% 
ethyl acetate in hexanes) and dried under vacuum to afford the product as a white solid (799 mg, 2.22 
mmol, 61% yield). 1H NMR matched previously reported spectral data.129  
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3.3.1.3 Synthesis of Fmoc-Acc-OH 
 
 
 
Scheme 3.2. Synthesis of Fmoc-Acc-OH (83). 
 
 
Fmoc-(1R, 3S)-3-aminocyclohexanecarboxylic acid (83): To a stirred solution of 
1.116 g compound 82 (4.59 mmol, 1 equiv) in 4.6 mL dichloromethane was added 
4.6 mL trifluoroacetic acid. The solution was stirred 2 h after which time it was concentrated and the 
solvent co-evaporated three times with chloroform to afford the amino acid TFA salt which was used 
directly. The concentrate (4.59 mmol, 1 equiv) was dissolved in 20 mL water and titrated to pH 7 with 
saturated aqueous sodium bicarbonate. To this solution was added 766 mg sodium bicarbonate (9.18 
mmol, 2 equiv), 20 mL dioxane, and 1.548 g Fmoc-OSu (4.59 mmol, 1 equiv). The reaction was stirred 
overnight and then the organic solvent was removed under reduced pressure. The remaining aqueous 
solution was acidified with 1 M hydrochloric acid solution and extracted three times with ethyl acetate. 
The organics were dried with magnesium sulfate, concentrated, and purified using column 
chromatography (50% ethyl acetate in hexanes with 1% triethylamine → ethyl acetate → ethyl acetate 
with 1% acetic acid) to afford the product along with residual acetic acid. The acetic acid was removed 
via co-evaporation with heptane and the resulting residue was dried under vacuum to afford the product as 
a white solid (990 mg, 2.71 mmol, 59% yield). [α]D = −29 (c = 0.50, MeOH); 1H NMR (400 MHz, 
DMSO-d6) δ 12.10 (s, 1 H), 7.88 (d, J = 7.4 Hz, 2 H), 7.69 (d, J = 7.2 Hz, 2 H), 7.41 (t, J = 7.3 Hz, 2 H), 
7.32 Hz (t, J = 7.4 Hz, 2 H), 7.27 (d, J = 7.8 Hz, 1 H), 4.30 (m, 2 H), 4.22 (d, J = 6.4 Hz, 1 H), 3.31 (m, 1 
H), 2.27 (t, J = 11.5 Hz, 1 H), 2.00 (d, J = 11.7 Hz, 1 H), 1.76 (m, 3 H), 1.26 (m, 2 H), 1.11 (m, 2 H); 13C 
NMR (100 MHz, DMSO-d6) δ 176.0, 155.3, 143.9, 140.7, 127.6, 1270, 125.2, 120.1, 65.1, 49.0, 46.8, 
41.7, 35.1, 32.0, 27.9, 23.8; HRMS m/z calculated for C22H23NO4Na [M+Na]+ 388.1525; found 388.1502. 
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3.3.1.4 Synthesis of Fmoc-γ4-Ala-OH 
 
 
 
Scheme 3.3. Synthesis of Fmoc-γ4-Ala-OH (86). 
 
Fmoc-γ4-Ala-OtBu (85).130 To a stirred solution of 673 mg compound 84 (1.90 
mmol, 1 equiv) in 15 mL tetrahydrofuran at −25 °C was added 79 mg lithium 
aluminum hydride (2.1 mmol, 1.1 equiv). The reaction was allowed to stir for 30 minutes, then quenched 
with 1 M hydrochloric acid, diluted with water, and extracted three times with ethyl acetate. The 
combined organics were washed with brine, dried with magnesium sulfate, and concentrated to afford the 
desired Fmoc-aldehyde which was used directly without purification. To a stirred solution of aldehyde 
(1.90 mmol, 1 equiv) in 10mL tetrahydrofuran was added 717 mg (tert-butoxycarbonylmethylene) 
triphenylphosphorane (1.90 mmol, 1 equiv). The reaction was stirred overnight, concentrated, and 
purified using column chromatography (20% ethyl acetate in hexanes) to afford the product as a white 
foam (426 mg, 1.08 mmol, 57% yield over 2 steps). [α]D = −13.2 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 7.77 (d, J = 7.5 Hz, 2 H), 7.59 (d, J = 7.3 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.32 (t, J = 7.3 Hz, 
2 H), 6.77 (dd, J = 4.6, 15.7, 1 H), 5.83 (d, J = 15.6 Hz, 1 H), 4.78 (d, J = 6.8 Hz, 1 H), 4.44 (m, 3 H), 
4.22 (t, J = 6.7 Hz, 1 H), 1.50 (s, 9 H), 1.30 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 165.5, 
155.4, 147.4, 143.8, 141.3, 127.7, 127.0, 125.0, 122.3, 120.0, 80.6, 66.7, 47.2, 28.1, 20.3. HRMS m/z 
calculated for C24H28NO4 [M+H]+ 394.2018; found 394.2014. 
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Fmoc-γ4-Ala-OH (86). To a stirred solution of 351 mg compound 85 (0.892 mmol, 
1 equiv) in 5 mL dichloromethane was added 5 mL trifluoroacetic acid. The reaction 
was stirred 4 h, concentrated, solvent-exchanged with chloroform three times, and purified using column 
chromatography (50% ethyl acetate in hexanes) to afford the product as a white solid (240 mg, 0.711 
mmol, 80% yield).  [α]D = −13 (c = 0.50, DMSO-d6).  1H NMR (400 MHz, CDCl3) δ 12.33 (s, 1 H), 7.89 
(d, J = 7.4 Hz, 2 H), 7.71 (d, J = 7.3 Hz, 2 H), 7.60 (d, J = 7.9 Hz, 1 H), 7.41 (t, J = 7.4 Hz, 2 H), 7.33 (t, 
J = 7.2 Hz, 2 H), 6.67 (dd, J = 15.7 Hz, 5.0 Hz, 1 H), 5.77 (d, J = 15.7 Hz, 1 H), 4.32 (m, 2 H), 4.23 (m, 2 
H), 1.19 (d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 167.1, 155.4, 149.7, 143.9, 140.7, 127.6, 
127.0, 125.2, 120.2, 120.1, 79.2, 65.4, 47.1, 46.7, 19.8. HRMS m/z calculated for C20H20NO4 [M+H]+ 
338.1392; found 338.1382. 
3.3.2 Peptide Synthesis 
Peptides were synthesized using standard microwave-assisted (CEM MARS) Fmoc solid-phase synthesis 
techniques on NovaPEG Rink Amide resin. Couplings were carried out with a two minute ramp to 70 °C 
and a four minute hold at that temperature using 4 equiv Fmoc-protected amino acid, 4 equiv HCTU, and 
6 equiv DIEA using N-methyl-2-pyrrolidone as the solvent. Deprotections were performed with a two 
minute ramp to 80 °C with a two minute hold at that temperature using an excess of 20% 4-
methylpiperidine in DMF. After each coupling or deprotection cycle, the resin was washed three times 
with DMF. Residue Asn6 and residues following N-methyl residues were double coupled and residues 
immediately following mABA residues were triple coupled to prevent deletion products.  
Prior to cleavage, the resin was washed three times with DMF, washed three times with 
dichloromethane, washed three times with methanol and dried under vacuum. Peptides were cleaved from 
resin by agitating in solution of 95% trifluoroacetic acid, 2.5% triisopropyl silane, and 2.5% water for 3 h. 
104 
Crude peptide was precipitated from the cleavage mixture by dilution with ether and purified by 
HPLC on a C18 preparative column using gradients between 0.1% TFA in water and 0.1% TFA in 
acetonitrile 
 Cysteine-containing peptide 76 was purified, lyophilized, dissolved in 10 mM phosphate buffer 
(pH 8.9, 5% v/v DMSO), stirred until analytical HPLC and MS showed complete conversion to the cyclic 
disulfide (2 d), and then re-purified. 
All peptides were >95% pure by analytical HPLC on a C18 column. Identities were confirmed 
using a Voyager DE Pro MALDI-TOF instrument (Table 7). 
 
 
Table 7. MALDI-TOF masses of peptides 73-80. 
Peptide [M+H]
+ m/z 
Calculated Observed 
73 1857.8 1857.9 
74 1847.9 1847.8 
75 1791.9 1791.4 
76 2037.9 2037.5 
77 1753.9 1753.8 
78 1753.9  1753.8 
79 1753.9 1753.7 
80 1753.9 1752.8 
 
3.3.3 NMR Sample Preparation and Data Collection 
NMR samples were prepared by dissolving 2-3 mg peptide in 750-850 µL de-gassed buffer solution (50 
mM phosphate, 9:1 H2O/D2O, uncorrected pH 6.3) to make ~2 mM solutions. 3-(Trimethylsilyl)-1-
propanesulfonic acid sodium salt (DSS, 50 mM in water) was added to a final concentration of ~0.2 mM 
DSS in the sample. Each solution was passed through a 0.2 µm syringe filter, transferred to an NMR tube, 
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and stored until analysis. The NMR tube headspace was purged with a stream of nitrogen prior to 
capping. 
NMR spectra of peptides were recorded on a Bruker Avance-700 spectrometer. Chemical shifts 
are reported relative to DSS (0 ppm). NMR spectra were measured at 278 K. TOCSY, NOESY, and 
COSY pulse programs used excitation-sculpted gradient-pulse solvent suppression. All experiments were 
obtained using 2048 data points in the direction dimension and 512 data points in the indirect dimension. 
TOCSY were acquired with a mixing time of 80 ms and NOESY were acquired with a mixing time of 
200 ms.  
3.3.4 NMR Data Analysis and Structure Determination 
NMR data was obtained and analyzed as detailed in Section 2.3.4. The ten lowest energy structures were 
used for calculating average structures of each peptide. 
3.3.5 Calculation of Folding Equilibria by NMR 
Population analysis was performed as detailed in Section 2.3.5. 
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4.0  UNNATURAL SHEET MODIFICATION APPLIED TO PROTEIN GB1 
Part of the results detailed in this chapter has been published in: 
1. Reinert, Z.E.; Lengyel, G.A.; Horne, W.S., “Protein-like Tertiary Folding Behavior from 
Heterogeneous Backbones,” Journal of the American Chemical Society, 2013, 12528-12531. 
 
Previous chapters have detailed the structural and thermodynamic consequences of various unnatural 
residue substitution strategies in model β-hairpins. Application of a 1:1 α- to β-residue substitution 
disrupted the side chain and hydrogen bond display of the hairpin peptide model system (Section 2.1). All 
other strategies, 2:1 or 2:2 α- to β-residue substitution (Section 2.2), 1:1 α- to γ-residue substitution 
(Section 3.1), and N-methylation (Section 3.2), prevented this inversion while having varying impacts on 
the thermodynamics of folding. 
To provide an overall comparison of the thermodynamic impact of each residue substitution 
strategy, the ∆∆Gfold values for each substitution strategy tested were normalized to the number of α-
residues replaced (Table 8). 
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Table 8. Normalized thermodynamic impacts of examined unnatural residue substitution strategies. 
Substitution Strategy ∆∆Gfold per replacement (kcal/mol) 
1:1 α to β --- 
2:1 α to β2/β3 +0.5 
2:1 α to β2,3 +0.7 
2:2 α to β2/β3 >0.9 
2:2 α to β2,3 +0.5 
1:1 α to γ (mABA) −0.2 
1:1 α to γ (Acc) −0.3 
1:1 α to γ (vinylogous γ4) +0.3 
N-methylation (turn) +1.1 
N-methylation (terminal) +0.6 
N-methylation (terminal, β-branched) +0.2 
 
 
Overall, unnatural residue substitution had an accompanying ∆∆Gfold ranging from +0.9 to −0.3 
kcal/mol per α-residue replaced. Because this data set is limited to a short hairpin peptide, conclusions 
that can be made for a larger protein with a more complex folded structure are limited. To gauge the 
utility of the successful unnatural residue substitutions examined in the hairpin peptide, we applied these 
strategies to a protein with a well-defined tertiary fold. 
4.1 UNNATURAL RESIDUE SUBSTITUTIONS IN PROTEIN GB1 
As a model system, we chose protein GB1, from which the hairpin peptide used for our previous 
thermodynamic analysis is derived.41 Protein GB1 is the 56 residue B1 domain of protein G, an 
immunoglobin binding protein from Streptoccoccus bacteria.81 GB1 has a compact tertiary fold with four 
β-strands packed against an α-helix (Figure 51).82-84 
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Figure 51. X-ray crystal structure and sequence of protein GB1. 
 
 
GB1’s relatively small size for a well-folded protein, 56 residues, makes it synthetically 
accessible using solid-phase peptide synthesis. Additionally, GB1 has a cooperative two-state folding 
transition with a melting temperature (Tm) of 82 °C in aqueous solution as measured by circular dichroism 
spectroscopy (CD),131,132 providing a handle for determining the thermodynamics of its folding. Due to 
these factors, GB1 has been a useful model system for our group for examination of the structural and 
thermodynamic impact of modification of loops, turns, and helices.132,133 
4.1.1 N-Methyl Residue Substitution in Protein GB1 
N-Methyl residues maintain the same backbone length as typical α-residues, and we theorized that the 
structural impact of their introduction into GB1 should be minimal. We synthesized protein 82 (Figure 
52) derived from protein GB1 (81) with N-methyl residue substitution at two sites found on the exterior 
strands of the four-strand β-sheet, sites chosen so as not to disrupt inter-strand hydrogen bonding (Figure 
53). These two sites were selected to be approximately at the same location in the strands. 
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Figure 52. Sequences of parent protein 81 and N-methylated protein 82. 
 
 
 
 
Figure 53. Model of GB1 variant 82 with positions of N-methyl residues highlighted pink. 
N-methylated amides are shown as spheres. Coordinates based on PDB: 2QMT. 
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 Proteins 81 and 82 were synthesized using solid-phase peptide synthesis techniques and analyzed 
using CD in aqueous phosphate buffer, pH 7 (Figure 54). CD measures the differential absorbance of 
circularly polarized light by chiral molecules.134 As peptides have chiral centers, they will demonstrate 
characteristic signatures depending on their secondary structure content. 
 
 
 
Figure 54. CD scans of proteins 81 and 82. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
The CD scan of GB1, protein 81, shows clear minima at 209 and 220 nm that are typical of a 
protein with combined α-helical and β-sheet structures.135 The scan of N-methyl variant 82 shows a 
similar shape, although the minima are less intense. The intensity of the minima at 209 and 220 nm are 
indicative of folded structure, suggesting protein 82 is not as well-folded as protein 81. To quantify the 
degree of destabilization caused by N-methylation, we performed thermal denaturation experiments on 
proteins 81 and 82 (Figure 55). 
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Figure 55. Thermal denaturation melts of proteins 81 and 82. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
 
Thermal denaturation can be used as an assessment of folded structure stability; we monitored the 
CD signature of proteins 81 and 82 at 220 nm as a function of temperature. Both proteins 81 and 82 show 
a sigmoidal unfolding transition with a well-defined fully-folded baseline. A sigmoidal transition allows 
for measurement of a melting temperature (Tm) and is indicative of cooperativity of folding; as one part of 
the protein begins to unfold, the entire protein unfolds. Using a two-state thermal denaturation model,136 
we calculated the midpoint of the melting transition for 81 and 82 (Table 9). From these Tm values and a 
∆Hfold value of −58.4 kcal/mol for wild-type protein 81 found using differential scanning calorimetry,137 
we used equation 6 to estimate the ∆∆Gfold for mutant protein 82.138 
 
(6) ∆∆𝐺𝑓𝑜𝑙𝑑 = ∆𝐻𝑓𝑜𝑙𝑑 ∆𝑇𝑚𝑇𝑚  
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Table 9. Folding thermodynamics of proteins 81 and 82. 
Protein Tm (°C) ∆Tm (°C) 
∆∆Gfold 
(kcal/mol) 
81 82.1 ± 0.3 --- --- 
82 75.6 ± 0.2 −6.5 +1.1 ± 0.1 
 
 
Protein 82 has a Tm decrease of 6.5 °C relative to parent protein 81. This value corresponds to an 
overall destabilization of roughly 1 kcal/mol or ~0.5 kcal/mol per α- to N-Me-α-residue substitution.  This 
value is similar to the hairpin peptide value of ~0.4 kcal/mol per substitution for a non β-branched N-
methyl residue found distant from the turn. 
Overall, incorporation of N-methyl amino acids in the sheet of a protein is tolerated with a small 
amount of destabilization and folding similar to the parent protein. One significant limitation of this 
system, however, is the requirement of substitution of residues where the N-methyl group is facing away 
from the other strands found in a sheet so as not to disrupt inter-strand hydrogen bonding.  
4.1.2 Beta-Residue Substitution in Protein GB1 
To move away from N-methyl amino acids, where substitution sites are limited by hydrogen bonding, we 
applied 2:1 (83) and 2:2 (84) α- to β-residue substitution strategies to a stripe of residues found in the 
central positions of each strand, similar to the positions selected in our work with β-hairpin peptides 
(Figure 56). As use of a combination of β2- and β3-amino acids or β2,3-amino acids had similar 
thermodynamic impacts in our hairpin studies, we chose to utilize β2- and β3-amino acids in this study for 
ease of monomer synthesis.  
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Figure 56. Sequences parent protein 81 and α/β-hybrids proteins 83 and 84. 
 
 
 A 2:1 α- to β-residue substitution strategy was applied with protein 83. Use of a 2:1 substitution 
shortens the backbone by two atoms, essentially acting as an amide deletion while maintaining the 
backbone carbon atoms of the two α-residues replaced. Residues Ile6, Glu15, Thr44, and Thr53, shown to 
have side chains oriented opposite the helix in the crystal structure of 81, were removed. Hydrophobic 
packing residues Leu5, Val16, Tyr45, and Phe52 were modified to either β2- or β3-residues, depending on the 
side chain display required to mimic the natural protein. Thr16 was mutated to valine for ease of synthesis 
of the unnatural monomer. Valine is an isostere of threonine but lacks the alcohol functionality that 
requires an additional protecting group when used in SPPS.  
 A 2:2 α- to β-residue substitution strategy was applied to generate protein 84, keeping the same 
four core side chains retained in protein 83. Unlike 2:1 substitution which shortens the backbone by two 
atoms, 2:2 substitution extends the length of the backbone by two atoms. Ile6, Glu15, Thr44, and Thr53 were 
also retained with mutations of the two threonine side chains to valine. Again, β2- or β3-amino acids were 
selected depending on the side chain display of parent protein 81. 
CD scans and thermal denaturation melts were obtained for proteins 81, 83, and 84 (Figure 57). 
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Figure 57. CD scans and melts of proteins 81, 83, and 84. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
In contrast to wild-type protein 81 which has a well-defined minima at 209 and 220 nm, the scans 
of 83 and 84 show a marked loss of minima at these two wavelengths and a new minimum near 200 nm, 
suggestive of random-coil structure. Counter to our work in the β-hairpin peptide which shows 2:2 α- to 
β2/β3-residue substitutions are the most destabilized, protein 84 demonstrates slightly more pronounced 
minima than protein 83 incorporating a 2:1 substitution. We hypothesize the added flexibility of two β-
residues allows for accommodation of the lengthened backbone and formation of a more native-like fold, 
but the CD scan data suggest neither β-substituted proteins are stable enough to maintain an ordered 
folded tertiary structure.  
Analysis of the melt data shows hybrid protein 83 undergoes no thermal transition while protein 
84 undergoes a very minor transition near 35 °C. Based on these data combined with the results from the 
CD scans, it can be concluded that introducing β-amino acids into GB1 significantly destabilizes the 
folded structure or abolishes it completely. 
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4.1.3 Gamma-Residue Substitution in Protein GB1 
Consistent with data from the hairpin peptide, introduction of β-amino acids in protein GB1 destabilized 
its folded structure considerably. Use of γ-amino acids, however, was either stabilizing or less 
destabilizing than use of β-amino acids in the hairpin peptide, so we designed our next GB1 mutants with 
a 1:1 α- to γ-residue substitution in each strand of the sheet. Because only one α-residue site was 
necessary for replacement, we chose to substitute residues Ile6, Glu15, Thr44, and Thr53, four residues 
which do not pack against the helix and which are the same residues substituted or eliminated in the β-
residue substitution patterns. Hybrid protein 85 was synthesized using vinylogous γ4-amino acids (Figure 
58). Because of the similarity in the stability of Acc and mABA residue substitutions in our hairpin and 
the difficulty of couplings following mABA, Acc was chosen for incorporation into hybrid protein 86. 
Proteins 85 and 86 were analyzed using CD spectroscopy (Figure 59). 
 
 
 
Figure 58. Sequences of parent protein 81 and α/γ-hybrid proteins 85 and 86. 
 
 
116 
 
Figure 59. CD scans and melts for proteins 81, 85, and 86. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
 Analysis of the CD scans shows that, unlike the proteins with β-residue substitutions, Acc-
substituted protein 86 has a similar shape to that of wild-type protein 81 with minima near 209 and 220 
nm. Protein 85, while having a distinct minimum around 218 nm, does not have the signature minimum at 
209 nm. NMR structures showed that insertion of vinylogous γ4-amino acids in our hairpin peptide did 
not significantly alter the shape of the β-sheet, so we theorized the change in CD signature results from 
the spectral character of the vinylogous γ4-residue rather than a structural change of the protein. If this 
hypothesis is correct, CD scans of the hairpin peptide containing vinylogous γ4-residues will also have a 
minimum shifted to 218 nm. We analyzed model hairpin peptide 22a and hybrid hairpins 74 and 75 
containing Acc and vinylogous γ4-residues, respectively by CD (Figure 60). 
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Figure 60. CD scans of model hairpin peptide 22a and α/γ-hybrid peptides 74 and 75. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
CD scans of model peptide 22a and Acc hybrid peptide 74 have similar shapes, suggesting Acc 
residues do not significantly alter the CD signature of a peptide. Vinylogous γ4-hybrid peptide 75, 
however, has a decreased signature near 218 nm relative to peptide 22a. Also of note is a gradual tailing 
to a mean molar absorptivity of 0 in the range of 230 to 260 nm. Peptides 22a and 74 have a signature 
near 0 along the same range. This data supports the hypothesis that the shift in CD signature of protein 85 
relative to parent protein 81 may be a result of the change in signature from vinylogous γ4-residues and 
not of a change in the folded structure of the protein. 
We next compared the thermal denaturation melts for proteins 85 and 86 to protein 81. Unlike β-
residue containing proteins 83 and 84, both proteins 85 and 86 have sigmoidal unfolding transitions, 
suggesting an ordered folded structure. Analysis of the melts gave Tm values of 43.5 °C and 46.7 °C for 
proteins 85 and 86, respectively (Table 10). These two Tm values are significantly lower than the wild-
type Tm of 82.1 °C, suggesting the inclusion of γ-amino acids in GB1 is significantly destabilizing. 
Calculating ∆∆Gfold gave values near 6 kcal/mol or ~1.5 kcal/mol per residue. Compared to the expected 
change of −0.3 kcal/mol for Acc and +0.3 kcal/mol for the vinylogous γ4-residues in our hairpin model 
system, introduction of these amino acids in GB1 is significantly more destabilizing. 
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Table 10. Folding thermodynamics for proteins 81, 85, and 86. 
Protein Tm (°C) ∆Tm (°C) 
∆∆Gfold 
(kcal/mol) 
81 82.1 ± 0.3 --- --- 
85 43.5 ± 0.9 −38.6 +6.3 ± 0.2 
 86 46.5 ± 0.5 −35.6 +5.9 ± 0.1 
 
 
  
As γ-residue substitution was unpredictably destabilizing, we sought to further investigate the 
cause of this destabilization. Substitutions with Acc stabilized the hairpin peptide model system more 
than use of vinylogous γ4-amino acids, so we focused on Acc substitution. Originally, positions for Acc 
substitution in protein 86 were chosen so as not to replace any of the hydrophobic residues that pack 
against the helix of GB1, but we did not take other stabilizing factors, such as salt-bridges or charge-
charge interactions, into consideration. Looking at the crystal structure of wild-type GB1, we identified 
two sites where a stabilizing side chain interactions could be disrupted with Acc substitution (Figure 61). 
 
 
Figure 61. Side chain interactions of Acc-substituted positions (green) in protein 86. 
Polar contacts are shown as black dotted lines. Coordinates based on PDB: 2QMT. 
 
 Acc-substituted position Glu15 forms an inter-strand salt-bridge with Lys4. Additionally, the side 
chains of Thr44 and Thr53 have a hydrogen-bond interaction which would be lost with Acc substitution. To 
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determine the exact thermodynamic effects of losing these stabilizing interactions, we designed GB1 
mutant 87 with an alanine mutation of Glu15 and valine mutations of Thr44 and Thr53 (Figure 62). These 
mutations were chosen to eliminate any side-chain polar interactions while providing similar β-sheet 
propensities. We analyzed protein 87 using CD spectroscopy (Figure 63). 
 
 
 
Figure 62. Sequences of wild-type protein 81 and side chain mutant 87. 
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Figure 63. CD scans and melts of proteins 81, 86, and 87. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
 The scan of protein 87 has a very similar shape to wild-type protein 81, suggesting a folded 
structure similar to the parent protein. The thermal denaturation melt also has a similar cooperativity and 
only a 4 °C shift in Tm. We calculated the ∆∆Gfold for comparison purposes (Table 11). 
 
 
Table 11. Folding thermodynamics for proteins 81, 86, and 87. 
Protein Tm (°C) ∆Tm (°C) 
∆∆Gfold 
(kcal/mol) 
81 82.1 ± 0.3 --- --- 
86 46.5 ± 0.5 −35.6 +5.9 ± 0.1 
87 78.0 ± 0.4 −4.1 +0.7 ± 0.1 
 
 
 
 Removal of the stabilizing salt-bridge and hydrogen bond by mutation of residues results in only 
a 0.7 kcal/mol destabilization, accounting for only a small portion of the 5.9 kcal/mol destabilization seen 
in protein 86 and suggesting the large destabilization resulted from a different source. We theorized the 
destabilization seen in γ-residue mutants of GB1 might result from increased backbone length as γ-
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residues contain two additional carbon atoms in their backbones. To analyze how a change in strand 
length could impact folded stability, we once again examined the crystal structure of GB1 (Figure 64).  
 
 
Figure 64. Crystal structure of GB1 highlighting helix packing residues (white) and Acc substitution sites (green). 
Coordinates based on PDB: 2QMT. 
 
 
γ-Residue substitution would extend the backbone length of the residues found between the helix 
packing residues, potentially forcing the hydrophobic side chains apart. While this increased length did 
not impact the stability of the small hairpin peptide, full length GB1 has a helix that packs against these 
residues in the tertiary fold. We hypothesized that shifting the position of the packing residues in the sheet 
may be the cause of the large destabilizing effect of γ-residue substitution in 81. To test this hypothesis, 
we chose to shift the stripe of Acc substitution to residues Asn8, Lys13, Glu42, and Thr55, away from the 
center of the β-strands (Figure 65) to generate protein 88 (Figure 66).  
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Figure 65. Crystal structure of GB1 highlighting helix packing residues (white) and new Acc substitution sites 
(green). 
Coordinates based on PDB: 2QMT. 
 
 
 
 
Figure 66. Sequences of parent protein 81 and Acc variants 86 and 88. 
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We synthesized protein 88 and analyzed by CD (Figure 67). 
 
 
 
Figure 67. CD scans and melts of proteins 81, 86, and 88. 
Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. 
 
 
 Gratifyingly, shifting the stripe of Acc away from the center of the strands in GB1 resulted in a 
dramatic shift in both the scan and melt of protein 88 relative to protein 86. The CD scan shows stronger 
minima than those experienced by wild-type protein 81, suggesting native-like folding behavior. More 
importantly, however, was the dramatic increase in the Tm from 46.5 °C to 74.4 °C. From these Tm data, 
we calculated ∆∆Gfold (Table 12).  
 
 
Table 12. Folding thermodynamics for proteins 81, 86, and 88. 
Protein Tm (°C) ∆Tm (°C) 
∆∆Gfold 
(kcal/mol) 
81 82.1 ± 0.3 --- --- 
86 46.5 ± 0.5 −35.6 +5.9 ± 0.1 
88 74.4 ± 0.2 −7.7 +1.3 ± 0.1 
Protein 88 shows a decrease in Tm of ~8 °C relative to wild-type protein 81, corresponding to a 
loss of stability of 1.3 kcal/mol. This destabilization, while not predicted by our hairpin data, is 
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significantly minimized compared to protein 86; there is a 4.6 kcal/mol increase in stability between the 
two Acc-hybrid proteins. Substitution of Acc in protein 88 is very well-tolerated with a ∆∆Gfold of 0.3 
kcal/mol per residue. 
 
4.2 CONCLUSIONS 
To compare the thermodynamic impact of unnatural residue substitution between our hairpin peptide and 
full-length protein GB1, we calculated the ∆∆Gfold on a per residue basis (Table 13). We estimated a 4.6 
kcal/mol destabilization for placement of γ-residues in the center of GB1’s β-strands and used this to 
estimate a ∆∆Gfold for vinylogous γ4-residue substitution away from this location. 
Some general conclusions can be drawn from comparison of the hairpin peptide and full-length 
protein. The hairpin seems to be an appropriate system to determine general trends in the stability of 
unnatural residue substitutions. Substitutions involving β-amino acids, for example, were significantly 
more destabilizing than the other substitution strategies in both systems. Ranking amino acid stability in 
the hairpin peptide shows Acc > vinylogous γ4-amino acids  ≥ N-methylated amino acid. Assuming ideal 
positioning of substitutions, this same trend is observed, although less pronounced, in full-length GB1. 
Although the hairpin could determine the relative sheet propensity of each monomer type, it 
could not predict the overall effect of backbone lengthening in the full-length protein. Larger proteins 
have much more complicated folded structures than those seen in short hairpin sequences and are 
therefore subject to more variables in predicting monomer suitability. Notably, positioning of the 
backbone-lengthened γ-residues had a significant effect on the stability of the overall fold evidenced by a 
dramatic increase in folded stability with just a minor shift in substitution position. 
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Table 13. Thermodynamic impacts of unnatural residue substitutions in β-sheets. 
Substitution Strategy Hairpin ∆∆Gfold per replacement (kcal/mol) 
Protein ∆∆Gfold per  
replacement (kcal/mol) 
1:1 α to β --- --- 
2:1 α to β2/β3 +0.5 Significantly Destabilized 
2:1 α to β2,3 +0.7 --- 
2:2 α to β2/β3 >0.9 Significantly Destabilized 
2:2 α to β2,3 +0.5 --- 
1:1 α to γ (mABA) −0.2 --- 
1:1 α to γ (Acc) −0.3 +1.5, +0.3a 
1:1 α to γ (vinylogous γ4) +0.3 +1.6, +0.5b 
N-methylation (turn) +1.1 --- 
N-methylation (terminal) +0.6 +0.6 
N-methylation (terminal, β-branched) +0.2 --- 
a. Calculated from a shift in position of residues. 
b. Estimated from 4.6 kcal/mol shift in stability as seen with Acc substitution. 
 
 
 Either vinylogous γ4-residues or Acc can be directly substitution on a 1:1 basis for α-residues 
with a minor change in the stability of the folded structure. However, substitution with γ-residues, while 
potentially effective in large proteins, requires careful positioning of the backbone-lengthened γ-residues. 
In the case where γ-residues will not be tolerated, N-methylation might be utilized as an appropriate 
substitute. However, positioning of the N-methyl functionality also has to be considered so as not to 
disrupt inter-strand hydrogen bonding. Folding in large proteins is too complex to define general rules for 
unnatural residue substitution in β-sheets, but with appropriate care in positioning of substitutions, we 
have found three unnatural residues which can be used as effective α-residue substitutes in hybrid 
proteins. Future work applying the preferred substitution strategies discussed above will show whether or 
not the guidelines demonstrated in this work can be applicable to other protein systems.  
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4.3 EXPERIMENTAL 
4.3.1 Monomer Synthesis 
4.3.1.1 General Information 
Optical rotations were measured on a Perkin-Elmer 241 digital polarimeter with a sodium lamp at 
ambient temperature. NMR spectra of synthetic small molecules were recorded on a Bruker Avance-400 
spectrometer. 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
(HCTU), NovaPEG Rink Amide Resin, 9-fluorenylmethyl N-succinimidyl carbonate (Fmoc-OSu), and 
Fmoc-protected α-amino acids were purchased from Novabiochem. Solvents and all other reagents were 
purchased from Aldrich, Baker, Fisher, or TCI and used as received without further purification. Flash 
chromatography was performed using SorbTech silica gel (60 Å, 40-63 µm). The Weinreb amides of 
Fmoc-Ile-OH, Fmoc-Glu(tBu)-OH, and Fmoc-Thr(tBu)-OH were synthesized using a published 
protocol.128 
4.3.1.2 Synthesis of Fmoc-β2-Monomers 
Fmoc-β2-monomers were synthesized as detailed in Section 2.3.1.2. 
4.3.1.3 Synthesis of Fmoc-Acc-OH 
Fmoc-Acc-OH was synthesized as detailed in Section 3.3.1.3. 
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4.3.1.4 Synthesis of Vinylogous Fmoc-γ4-Monomers 
 
Scheme 4.1. Synthesis of vinylogous Fmoc-γ4-monomers. 
 
 
Standard Procedure N: To a stirred solution of Fmoc-Weinreb amide (1 equiv) in tetrahydrofuran (0.1 
M) at −25 °C was added lithium aluminum hydride (1.1 equiv). The reaction was allowed to stir for 30 
minutes and then quenched with 1 M hydrochloric acid, diluted with water, and extracted three times with 
ethyl acetate.  The combined organics were washed with brine, dried with magnesium sulfate, and 
concentrated to afford the desired Fmoc-aldehyde which was used directly without purification.  
 
Standard Procedure O:130 To a stirred solution of aldehyde (1 equiv) in tetrahydrofuran (0.2 M) was 
added (tert-butoxycarbonylmethylene) triphenylphosphorane (1 equiv). The reaction was stirred 
overnight, concentrated, and purified using column chromatography.   
 
Standard Procedure P:139 To a stirred solution of aldehyde (1 equiv) in toluene (0.1 M) at 80 °C was 
added (allyloxycarbonylmethyl)triphenylphosphonium iodide (1.6 equiv) and DIEA (1.4 equiv). The 
reaction was stirred 3 h. After this time, the reaction was washed with 0.1 M aqueous hydrochloric acid, 
saturated aqueous sodium bicarbonate solution, and brine. The organics were dried with magnesium 
sulfate, concentrated, and purified using column chromatography.  
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Fmoc-γ4-Ile-OtBu (89): Standard Procedure N was followed using 1.149 mg 
Fmoc-Ile Weinreb amide (2.89 mmol), 23 mL tetrahydrofuran, and 124 mg lithium 
aluminum hydride (3.27 mmol). The resulting aldehyde was subjected to Standard Procedure O using 15 
mL tetrahydrofuran and 1.092 g (tert-butoxycarbonylmethylene) triphenylphosphorane (2.90 mmol).  The 
crude mixture was purified using column chromatography (20% ethyl acetate in hexanes) to afford the 
product as a white solid (815 mg, 1.87 mmol, 64% yield over 2 steps). [α]D = −3.4 (c = 1.00, CHCl3). 1H 
NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2 H), 7.60 (d, J = 7.3 Hz, 2 H), 7.41 (t, J = 7.4 Hz, 2 H), 
7.32 (J = 7.3 Hz, 2 H), 6.76 (dd, J = 5.5, 15.6 Hz, 1 H), 5.84 (d, J = 15.6 Hz, 1 H), 4.82 (d, J = 9.0 Hz, 1 
H), 4.45 (m, 2 H), 4.30 (m, 1 H), 4.23 (t, J = 6.5 Hz, 1 H), 1.63 (m, 1 H), 1.50 (s, 9 H), 1.46 (m, 1 H), 1.13 
(m, 1 H), 0.91 (m, 6 H);  13C NMR (100 MHz, CDCl3) δ 165.1, 155.4, 144.8, 143.5, 141.0, 127.4, 126.7, 
124.6, 123.3, 119.6, 80.2, 66.3, 55.9, 47.0, 38.6, 27.8, 24.9, 14.9, 11.2. HRMS m/z calculated for 
C27H34NO4 [M+H]+ 436.2488; found 436.2488. 
 
Fmoc-γ4-Glu(tBu)-OAllyl (90): Standard Procedure N was followed using 1.835 g 
Fmoc-Glu(tBu) Weinreb amide (3.92 mmol), 30 mL tetrahydrofuran, and 162 mg 
lithium aluminum hydride (4.27 mmol). Standard Procedure P was followed using 
3.06 g phosphonium (6.27 mmol), 960 μL DIEA (5.51 mmol), and 39 mL toluene. The crude mixture was 
purified using column chromatography (20% ethyl acetate in hexanes) to afford the product as a white 
solid (1.272 g, 2.59 mmol, 66% yield over 2 steps). [α]D = −6.7 (c = 1.00, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2 H), 7.59 (d, J = 7.3 Hz, 2 H), 7.40 (t, J = 7.4 Hz, 2 H), 7.31 (t, J = 7.3 Hz, 
2 H), 6.86 (dd, J = 5.3, 15.6 Hz, 1 H), 5.94 (m, 2 H), 5.34 (dd, J = 1.4, 17.2 Hz, 1 H), 5.26 (dd, J = 1.1, 
10.4 Hz, 1 H), 5.12 (d, J = 8.3 Hz, 1 H), 4.64 (d, J = 5.7 Hz, 2 H), 4.43 (m, 2 H), 4.36 (m, 1 H), 4.20 (t, J 
= 6.7 Hz, 1 H), 2.32 (m, 2 H), 1.93 (m, 1 H), 1.83 (m, 1 H), 1.44 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 
172.3, 165.7, 155.7, 147.5, 143.8, 141.3, 132.0, 127.7, 127.1, 125.0, 121.1, 120.0, 118.4, 81.0, 66.7, 65.2, 
51.8, 47.2, 31.7, 28.9, 28.0. HRMS m/z calculated for C27H34NO6 [M+H]+ 492.2386; found 492.2362.   
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Fmoc-γ4-Thr(tBu)-OAllyl (91): Standard Procedure N was followed using 2.385 g 
Fmoc-Glu(tBu) Weinreb amide (5.41 mmol), 43 mL tetrahydrofuran, and 228 mg 
lithium aluminum hydride (6.00 mmol). Standard Procedure P was followed using 4.22 g phosphonium 
(8.64 mmol), 1.35 mL DIEA (7.75 mmol), and 54 mL toluene. The crude mixture was purified using 
column chromatography (20% ethyl acetate in hexanes) to afford the product as a colorless oil (1.652 g, 
3.56 mmol, 66% yield over 2 steps). [α]D = +9.4 (c = 1.00, CHCl3). 1H NMR, Major Conformer (400 
MHz, CDCl3) δ 7.78 (d, J = 7.4 Hz, 2 H), 7.62 (d, J = 7.2 Hz, 2 H), 7.41 (t, J = 7.3 Hz, 2 H), 7.33 (t, J = 
6.8 Hz, 2 H), 6.98 (dd, J = 4.9, 15.7 Hz, 1 H), 5.96 (m, 2 H), 5.34 (dd, J = 1.3, 17.2 Hz, 1 H), 5.24 (m, 2 
H), 4.66 (d, J = 5.7 Hz, 2 H), 4.45 (m, 2 H), 4.26 (m, 2 H), 3.82 (m, 1 H), 1.17 (m, 12 H); 13C NMR (100 
MHz, CDCl3) δ 165.7, 156.1, 147.7, 143.8, 141.3, 132.1, 127.7, 127.0, 125.0, 121.1, 119.9, 118.1, 74.11, 
68.0, 66.8, 65.0, 57.4, 47.3, 28.5, 20.3. HRMS m/z calculated for C28H33NO5Na [M+Na]+ 486.2256; 
found 486.2242.   
 
Standard Procedure Q: To a stirred solution of ester in 5 mL dichloromethane was added 5 mL 
trifluoroacetic acid. The reaction was stirred 4 h, concentrated, solvent-exchanged with chloroform three 
times, and purified using column chromatography. 
 
Fmoc-γ4-Ile-OH (92): Standard procedure Q was followed using 815 mg compound 
89 (1.87 mmol). Column chromatography (50% ethyl acetate in hexanes) afforded 
the product as a white solid (659 mg, 1.74 mmol, 93% yield).  [α]D = −7.6 (c = 1.0, CHCl3).  1H NMR, 
Major Conformer (400 MHz, CDCl3) δ 10.04 (s, 1 H), 7.77 (d, J = 7.3 Hz, 2 H), 7.60 (d, J = 7.3 Hz, 2 H), 
7.41 (t, J = 7.2 Hz, 2 H), 7.33 (t, J = 6.7 Hz, 2 H), 6.96 (dd, J = 15.6, 5.2 Hz, 1 H), 5.91 (d, J = 15.6 Hz, 1 
H), 4.88 (d, J = 9.0 Hz, 1 H), 4.48 (d, J = 6.4 Hz, 2 H), 4.35 (m, 1 H), 4.22 (t, J = 6.3 Hz, 1 H), 1.28-1.71 
(m, 2 H), 1.13 (m, 1 H), 0.91 (m, 6 H); 13C NMR (100 MHz, CDCl3) δ 170.9, 155.9, 149.0, 143.7, 141.3, 
127.7, 127.1, 124.9, 121.2, 120.0, 66.6, 56.3, 47.3, 38.8, 25.2, 15.3, 11.5. HRMS m/z calculated for 
C23H26NO4 [M+H]+ 380.1862; found 380.1864. 
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Standard Procedure R: To a stirred solution of allyl ester (1 equiv) in dichloromethane (0.1 M) was 
added tetrakis(triphenylphosphine)palladium (0.1 equiv) and triethylsilane (5 equiv). The reaction was 
stirred 3 h, then diluted with ethyl acetate and washed once with 1 M HCl and twice with brine. The 
organics were dried with magnesium sulfate, concentrated, and purified using column chromatography. 
 
Fmoc-γ4-Glu(tBu)-OH (93): Standard Procedure R was followed using 71 mg 
compound 90 (0.14 mmol), 18 mg tetrakis (0.016 mmol), 115 μL triethylsilane (0.72 
mmol), and 1.4 mL dichloromethane. Column chromatography (50% ethyl acetate in 
hexanes) afforded the product as a pale yellow solid (15 mg, 0.033 mmol, 23% yield). [α]D = −9.1 (c = 
1.0, CHCl3). 1H NMR, Major Conformer (400 MHz, CDCl3) δ 7.75 (d, J = 7.4 Hz, 2 H), 7.59 (d, J = 7.0 
Hz, 2 H), 7.39 (t, J = 7.3 Hz, 2 H), 7.31 (t, J = 7.2 Hz, 2 H), 6.93 (dd, J = 15.7, 5.0 Hz, 1 H), 5.92 (d, J = 
15.6 Hz, 1 H), 5.24 (d, J = 8.2 Hz, 1 H), 4.43 (m, 3 H), 4.20 (t, J = 6.3 Hz, 1 H), 2.31 (m, 2 H), 1.92 (m, 1 
H), 1.83 (m, 1 H), 1.44 (s, 9 H), 13C NMR (100 MHz, CDCl3) δ 172.2, 170.5, 155.8, 149.4, 143.7, 141.3, 
127.7, 127.0, 124.9, 120.8, 119.9, 81.1, 66.7, 51.8, 47.2, 31.7, 28.9, 28.0. HRMS m/z calculated for 
C26H30NO6 [M+H]+ 452.2073; found 452.2070. 
 
Fmoc-γ4-Thr(tBu)-OH (94): Standard Procedure R was followed using 1.517 g 
compound 91 (3.27 mmol), 378 mg tetrakis (0.327 mmol), 2.6 mL triethylsilane (16 
mmol), and 32 mL dichloromethane. Following a silica plug eluting with ethyl acetate, column 
chromatography (20% → 50% ethyl acetate in hexanes) afforded the product as a pale yellow solid (905 
mg, 2.14 mmol, 65% yield). [α]D = +3.8 (c = 1.0, CHCl3). 1H NMR, Major Conformer (400 MHz, CDCl3) 
δ 7.78 (d, J = 7.4 Hz, 2 H), 7.62 (d, J = 7.0 Hz, 2 H), 7.41 (t, J = 7.3 Hz, 2 H), 7.33 (t, J = 7.0 Hz, 2 H), 
7.06 (dd, J = 15.7, 4.6 Hz, 1 H), 5.92 (d, J = 15.7 Hz, 1 H), 5.25 (d, J = 9.0 Hz, 1 H), 4.47 (d, J = 6.8 Hz, 2 
H), 4.31 (m, 1 H), 4.25 (t, J = 6.7 Hz, 1 H), 3.83 (m, 1 H), 1.17 (m, 12 H); 13C NMR (100 MHz, CDCl3) δ 
171.0, 156.2, 149.9, 143.8, 141.3, 127.7, 127.1, 125.0, 120.8, 120.0, 74.2, 68.0, 66.9, 57.4, 47.3, 28.5, 
20.3. HRMS m/z calculated for C25H28NO5 [M+H]+ 422.1962; found 422.1976.  
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4.3.2 Peptide Synthesis 
Modified GB1 proteins were synthesized with automated methods on a PTI Tribute synthesizer using 
NovaPEG Rink Amide resin (70 μmol scale). Coupling reactions were performed by combining 3 mL of 
0.4 M N-methylmorpholine in DMF with 7 equiv Fmoc-amino acid and 7 equiv HCTU. Following a two 
minute preactivation, the activated amino acid was added to the resin and vortexed for 45 min. 
Deprotection reactions were carried out twice with 3 mL of a 20% v/v solution of 4-methylpiperidine in 
DMF for 4 min. The resin was washed three times with 3 mL of DMF for 40 s between each cycle. After 
the final deprotection step, the resin was washed with 3 mL of dichloromethane followed by 3 mL of 
methanol. Resin was dried and subjected to cleavage by treatment with a solution of 94% TFA, 1% TIS, 
2.5% water, and 2.5% ethanedithiol. Crude protein was precipitated by addition of cold diethyl ether. The 
solid was pelleted by centrifugation and dissolved in 6 M guanidinium chloride, 25 mM sodium 
phosphate, pH 6. This solution was subjected to purification by preparative C18 reverse-phase HPLC 
using gradients between 0.1% TFA in water and 0.1% TFA in acetonitrile. Each protein was subjected to 
a second purification by anion-exchange chromatography on a monoQ 5/50GL column (GE Healthcare) 
using 0.02 M Tris buffer at pH 8 and eluting with increasing concentrations of KCl. 
All proteins were >95% pure as determined by analytical HPLC on a C18 column. Identities were 
confirmed by mass spectrometry using a Voyager DE Pro MALDI-TOF instrument (Table 14).  
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Table 14. MALDI-TOF data for proteins 81-88. 
Peptide [M+H]
+ m/z 
Calculated Observed 
81 6179.6 6178.6 
82 6207.7 6207.5 
83 5789.3 5791.5 
84 6271.9 6274.6 
85 6280.9 6281.8 
86 6232.1 6231.1 
87 6114.1 6113.6 
88 6204.1 6204.5 
 
4.3.3 CD Measurements 
CD measurements were performed on an Olis DSM17 Circular Dichroism Spectrometer in 2 mm quartz 
cells. Samples consisted of 40 μM protein in 20 mM sodium phosphate buffer, pH 7.0. Scans were carried 
out at 25 °C over the range of 200-260 nm with 1 nm increments and a 2 nm bandwidth. Scan data were 
smoothed by the Savitzky-Golay method. Melts were monitored at 220 nm over the range of 4 ºC to 98 ºC 
with 2 ºC increments, a dead band of 0.5 ºC, and a 2 min equilibration time at each temperature. All 
measurements were baseline corrected for blank buffer. Temperature-dependent CD data were fit to a 
two-state unfolding model to obtain melting temperature (Tm). The change in free energy of folding for 
each mutant relative to wild-type (ΔΔGfold) was estimated from the change in Tm  (ΔTm) using the enthalpy 
of folding determined for GB1 by differential scanning calorimetry. 
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APPENDIX A 
HAIRPIN PEPTIDE BACKBONE CHEMICAL SHIFTS 
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Table 15. Backbone 1H chemical shift assignments (in ppm) for oligomers 1a-17a and 1b-17b. 
 R1 W2 X3 Y4 V5 P6 G7 K8 F9 X10 V11 Q12 
# Hα H Hα H Hα Hα' Hβ Hβ' H Hα H Hα Hα H Hα Hα ' H Hα H Hα H Hα Hα' Hβ Hβ' H Hα H Hα 
1a 4.04 8.88 4.88 8.75 4.44 − − − 8.63 4.87 8.70 4.52 4.37 8.39 3.75 3.99 7.90 4.59 8.90 4.63 8.55 4.49 − − − 8.32 3.86 8.42 4.25 
1b 4.05 8.94 4.62 8.04 4.15 − − − 8.22 4.20 8.01 4.21 4.22 8.50 3.89 3.92 8.20 4.27 8.48 4.74 8.20 4.34 − − − 8.42 4.07 8.63 4.24 
2a 3.95 8.78 4.66 7.96 1.65 2.02 3.89 − 8.05 4.85 8.77 4.07 4.36 8.31 3.81 3.88 7.97 4.37 8.39 4.27 8.02 1.98 2.43 3.99 − 8.39 4.16 8.67 3.99 
2b 3.91 8.72 4.66 8.15 1.83 2.11 3.88 − 8.14 4.59 8.21 3.74 4.21 8.45 3.82 3.85 8.06 4.19 8.21 4.56 8.13 2.31 2.54 4.03 − 8.28 4.15 8.60 3.88 
3a 4.01 8.89 4.71 7.86 2.17 2.22 3.74 − 8.31 4.70 8.63 4.45 4.40 8.47 3.87 3.94 8.04 4.39 8.41 4.36 8.02 2.31 2.45 3.98 − 8.32 4.04 8.61 4.26 
 3b 4.01 8.90 4.70 7.95 2.22 2.30 3.78 − 8.34 4.52 8.13 4.26 4.23 8.53 3.90 3.94 8.17 4.25 8.28 4.62 8.14 2.39 2.52 4.06 − 8.30 4.06 8.63 4.29 
4a 3.98 8.83 4.58 7.73 1.87 − 3.00 3.32 7.84 4.69 8.58 4.37 4.38 8.40 3.82 3.92 8.01 4.31 8.36 4.44 8.03 2.29 − 3.16 3.41 8.23 4.00 8.64 4.27 
4b 3.98 8.89 4.63 8.11 1.93 − 3.07 3.48 7.99 4.44 8.02 4.18 4.16 8.46 3.87 3.90 8.12 4.22 8.30 4.60 8.16 2.32 − 3.31 3.44 8.34 4.01 8.66 4.28 
5a 3.88 8.61 4.74 8.34 2.15 − 3.10 3.57 8.21 4.75 8.68 3.78 4.30 8.12 3.84 3.87 7.97 4.24 8.11 4.28 7.92 2.34 − 3.23 3.36 8.35 4.12 8.59 4.03 
5b 3.89 8.60 4.74 8.33 2.18 − 3.16 3.54 8.28 4.67 8.29 3.72 4.19 8.44 3.82 3.86 8.11 4.22 8.16 4.49 8.06 2.38 − 3.33 3.37 8.35 4.13 8.55 4.04 
6a 3.82 8.58 4.86 8.32 2.53 − 3.84 − 8.18 4.76 8.73 3.38 4.31 7.94 3.80 3.84 7.86 4.20 8.15 4.47 8.03 2.75 − 3.80 − 8.26 4.24 8.58 3.76 
6b 3.82 8.59 4.84 8.32 2.53 − 3.82 − 8.19 4.69 8.32 3.38 4.18 8.42 3.78 3.82 7.96 4.15 8.19 4.62 8.15 2.75 − 3.87 − 8.27 4.23 8.60 3.68 
7a 4.00 8.91 4.81 7.58 2.61 − 3.33 − 8.39 4.66 8.58 4.47 4.45 8.40 3.88 3.91 7.98 4.27 8.29 4.52 7.83 2.78 − 3.70 − 8.34 4.04 8.57 4.24 
7b 3.98 8.89 4.80 7.69 2.62 − 3.47 − 8.32 4.56 8.18 4.32 4.29 8.55 3.91 3.94 8.13 4.26 8.30 4.66 7.94 2.75 − 3.80 − 8.33 4.00 8.60 4.29 
8a 4.08 8.98 4.80 7.74 2.21 − 3.77 − 8.16 5.08 8.96 4.57 4.37 8.57 3.69 4.05 7.97 4.58 8.70 4.45 8.11 2.62 − 3.83 − 8.80 4.14 8.82 4.20 
8b 4.00 8.96 4.75 7.88 2.18 − 3.61 − 8.43 4.64 8.24 4.31 4.30 8.56 3.90 3.93 8.14 4.23 8.50 4.66 7.95 2.55 − 3.82 − 8.52 3.98 8.69 4.28 
9a 4.08 9.01 4.90 7.82 2.50 − 3.72 − 8.46 5.07 8.93 4.54 4.39 8.69 3.79 4.08 8.03 4.66 8.77 4.22 7.84 2.48 − 3.69 − 8.06 4.04 8.71 4.22 
9b 4.05 8.98 4.86 7.79 2.39 − 3.64 − 8.57 4.51 8.09 4.23 4.20 8.50 3.88 3.93 8.17 4.25 8.53 4.70 7.96 2.59 − 3.82 − 8.53 4.06 8.67 4.28 
10a 4.00 8.79 4.53 8.10 1.76 − 3.97 − 7.84 4.77 8.77 4.29 4.40 8.47 3.85 8.94 8.09 4.44 8.50 4.06 8.01 2.32 − 4.18 − 8.12 4.17 8.64 4.19 
10b 4.00 8.75 4.55 8.22 1.85 − 4.07 − 8.04 4.59 8.28 3.99 4.23 8.48 3.87 3.92 8.21 4.22 8.25 4.51 8.04 2.50 − 4.19 − 8.29 4.17 8.62 4.16 
11a 4.04 8.99 4.60 7.89 2.46 − 3.92 − 8.27 4.79 8.63 4.48 4.41 8.58 3.90 3.97 8.08 4.52 8.53 4.10 7.90 2.51 − 3.98 − 8.13 4.00 8.59 4.26 
11b 4.02 8.94 4.55 7.87 2.43 − 3.90 − 8.30 4.55 8.17 4.24 4.23 8.52 3.90 3.94 8.18 4.29 8.35 4.50 8.14 2.58 − 4.14 − 8.33 4.05 8.67 4.28 
12a 3.88 8.61 4.68 8.11 2.86 − 4.34 − 7.90 4.55 8.44 4.06 4.40 8.22 3.73 3.85 8.01 4.21 8.17 4.50 7.68 3.05 − 4.32 − 8.15 3.86 8.55 4.25 
12b 3.91 8.70 4.70 8.14 2.87 − 4.35 − 8.12 4.30 7.88 4.11 4.18 8.44 3.84 3.87 8.06 4.19 8.24 4.60 7.76 3.06 − 4.39 − 8.16 3.88 8.59 4.25 
13a 4.02 8.85 4.59 7.62 2.73 − 4.04 − 8.16 4.49 8.54 4.15 4.40 8.25 3.87 3.90 8.09 4.32 8.40 4.36 7.63 2.99 − 4.22 − 8.16 4.18 8.52 4.19 
13b 4.10 8.85 4.66 7.70 2.78 − 4.11 − 8.25 4.43 8.13 4.14 4.27 8.45 3.90 3.95 8.21 4.24 8.39 4.47 7.60 3.02 − 4.23 − 8.12 4.17 8.53 4.18 
14a 3.82 8.47 4.72 8.66 2.34 − 3.87 − 8.22 4.74 8.70 3.32 4.28 7.91. 3.79 3.85 7.95 4.18 7.85 4.40 8.26 2.47 − 3.89 − 8.24 4.27 8.58 3.60 
14b 3.82 8.44 4.71 8.64 2.35 − 3.86 − 8.21 4.68 8.29 3.30 4.14 8.38 3.80 3.84 8.03 4.15 7.99 4.53 8.34 2.46 − 3.88 − 8.28 4.24 8.60 3.62 
15a 3.94 8.70 4.54 7.65 2.10 − 3.70 − 8.15 4.68 8.41 4.39 4.40 8.34 3.85 3.90 8.14 4.29 8.13 4.50 8.20 2.28 − 3.81 − 8.20 3.99 8.59 4.28 
15b 3.97 8.78 4.60 7.75 2.11 − 3.68 − 8.17 4.54 8.13 4.25 4.24 8.52 3.91 3.95 8.22 4.28 8.17 4.50 8.20 2.26 − 3.82 − 8.22 3.99 8.59 4.29 
16a 3.86 8.62 4.83 8.09 2.50 − 4.23 − 7.60 4.62 8.52 3.91 4.39 8.16 3.65 3.88 7.95 4.24 8.19 4.57 7.78 2.72 − 4.16 − 8.05 3.90 8.51 4.20 
16b 3.95 8.72 4.76 7.97 2.37 − 4.12 − 7.80 4.33 7.96 4.01 4.21 8.46 3.85 3.88 8.09 4.22 8.25 4.67 7.90 2.70 − 4.28 − 8.05 3.94 8.57 4.18 
17a 4.01 8.84 4.69 7.48 2.42 − 3.88 − 7.93 4.49 8.50 4.30 4.42 8.27 3.85 3.90 8.05 4.34 8.41 4.42 7.59 2.72 − 4.12 − 8.01 4.16 8.53 4.23 
17b 4.09 8.85 4.70 7.55 2.47 − 3.99 − 7.95 4.44 8.23 4.23 4.29 8.48 3.93 3.96 8.22 4.29 8.39 4.52 7.65 2.74 − 4.13 − 8.00 4.13 8.54 4.24 
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Table 16. Backbone chemical shift data for peptide 
18. 
 
Residue Atom δ (ppm) 
G H --- 
G Hα 3.710 
G Hαʹ 3.827 
E H 8.655 
E Hα 4.395 
W H 8.623 
W Hα 4.927 
T H 8.459 
T Hα 4.331 
Y H 8.582 
Y Hα 4.311 
D H 8.159 
D Hα 4.58 
D H 8.445 
D Hα 4.293 
A H 8.389 
A Hα 4.242 
T H 7.768 
T Hα 4.246 
K H 8.098 
K Hα 4.055 
T H 7.653 
T Hα 4.478 
F H 8.607 
F Hα 4.965 
T H 8.634 
T Hα 4.498 
V H 8.467 
V Hα 4.173 
T H 8.450 
T Hα 4.356 
E H 8.611 
E Hα 4.255 
 
Table 17. Backbone chemical shift data for peptide 
19 its derivatives. 
 
Residue Atom 
Chemical Shift (ppm) 
19a 
(293 K) 
19b 
(293 K) 
19c 
(293 K) 
19d 
(293 K) 
C H --- 8.454 --- --- 
C Hα --- 4.513 --- --- 
K H --- a --- --- 
K Hα 4.057 a a --- 
K H 8.708 8.566 8.076 --- 
K Hα 4.625 4.594 4.348 --- 
W H 8.755 8.695 8.52 --- 
W Hα 5.181 5.233 4.66 --- 
T H 9.195 9.175 7.902 --- 
T Hα 4.761 4.749 4.192 --- 
Y H 8.949 9.028 8.122 --- 
Y Hα 4.174 4.085 4.358 --- 
N H 7.636 7.598 8.320 --- 
N Hα 5.013 5.01 4.854 --- 
P Hα 3.986 3.961 4.249 --- 
A H 7.888 7.861 8.079 --- 
A Hα 4.226 4.208 4.254 --- 
T H 7.07 7.005 --- 8.292 
T Hα 4.409 4.398 --- 4.304 
G H 8.358 8.349 --- 8.553 
G Hα 3.745 3.729 --- 3.920 
G Hαʹ 4.054 4.059 --- --- 
K H 7.314 7.264 --- 8.088 
K Hα 4.692 4.714 --- 4.261 
F H 8.866 8.894 --- 8.322 
F Hα 5.271 5.269 --- 4.723 
T H 9.041 9.071 --- 8.121 
T Hα 4.743 4.711 --- 4.321 
V H 8.467 8.423 --- 8.264 
V Hα 4.175 4.338 --- 4.095 
Q H 8.541 8.569 --- 8.521 
Q Hα 4.491 4.621 --- 4.363 
E H 8.306 8.654 --- 8.176 
E Hα 4.053 4.443 --- 4.128 
C H --- 8.41 --- --- 
C Hα --- 4.351 --- --- 
a. Indicates an ambiguous assignment.  
136 
Table 18. Backbone chemical shift data for peptide 
20 its derivatives. 
 
Residue Atom 
δ (ppm) 
20a 
(293 K) 
20b 
(293 K) 
20c 
(293 K) 
20d 
(293 K) 
C H --- a --- --- 
C Hα --- a --- --- 
K H --- a --- --- 
K Hα a a a --- 
K H a a 8.066 --- 
K Hα a a 4.338 --- 
W H 8.537 8.46 8.438 --- 
W Hα 4.818 5.06 4.593 --- 
A H 8.602 8.737 8.094 --- 
A Hα 4.540 4.691 4.223 --- 
Y H 8.473 a 7.983 --- 
Y Hα 4.088 a 4.377 --- 
N H 7.997 7.744 8.301 --- 
N Hα 4.940 4.975 4.857 --- 
P Hα 4.114 3.997 4.251 --- 
A H 8.002 7.848 8.066 --- 
A Hα 4.260 4.218 4.254 --- 
T H 7.382 7.064 --- 8.292 
T Hα 4.377 4.408 --- 4.321 
G H 8.339 8.317 --- 8.572 
G Hα 3.805 3.732 --- 3.922 
G Hαʹ 4.023 4.051 --- --- 
K H 7.672 7.376 --- 8.132 
K Hα 4.525 4.718 --- 4.225 
F H 8.544 8.546 --- 8.222 
F Hα 4.772 5.025 --- 4.639 
A H 8.473 8.581 --- 8.142 
A Hα 4.502 4.578 --- 4.320 
V H 8.215 8.344 --- 8.139 
V Hα 3.958 4.225 --- 4.089 
Q H 8.542 8.787 --- 8.512 
Q Hα 4.386 4.616 --- 4.381 
E H 8.548 8.637 --- 8.177 
E Hα 4.222 4.435 --- 4.136 
C H --- 8.453 --- --- 
C Hα --- 4.398 --- --- 
a. Indicates an ambiguous assignment. 
 
Table 19.  Backbone chemical shift data for peptide 
22 its derivatives. 
 
Residue Atom 
δ (ppm) 
21a 
(278 K) 
21b 
(293 K) 
21c 
(293 K) 
21d 
(293 K) 
C H --- 8.475 --- --- 
C Hα --- 4.411 --- --- 
G H --- 8.771 --- --- 
G Hα 3.715 3.692 a --- 
G Hαʹ 3.829 4.11 --- --- 
E H 8.648 7.853 8.612 --- 
E Hα 4.471 4.554 4.285 --- 
W H 8.718 8.77 8.364 --- 
W Hα 4.790 4.646 4.636 --- 
A H 8.633 8.733 8.066 --- 
A Hα 4.556 4.716 4.219 --- 
Y H 8.592 8.732 7.976 --- 
Y Hα 3.896 3.726 4.367 --- 
N H 7.966 7.784 8.260 --- 
N Hα 4.919 4.967 4.857 --- 
P Hα 4.078 4.001 4.251 --- 
A H 8.016 7.891 8.060 --- 
A Hα 4.244 4.221 4.255 --- 
T H 7.334 7.087 --- 8.291 
T Hα 4.379 4.398 --- 4.320 
G H 8.383 8.347 --- 8.573 
G Hα 3.802 3.741 --- 3.920 
G Hαʹ 4.004 4.047 --- --- 
K H 7.637 7.380 --- 8.140 
K Hα 4.576 4.723 --- 4.215 
F H 8.670 8.705 --- 8.208 
F Hα 4.743 4.826 --- 4.639 
A H 8.016 8.586 --- 8.151 
A Hα 4.244 4.519 --- 4.327 
V H 8.312 8.186 --- 8.211 
V Hα 4.087 3.955 --- 4.159 
T H 8.446 8.454 --- 8.273 
T Hα 4.377 4.272 --- 4.359 
E H 8.617 8.796 --- 8.430 
E Hα 4.257 4.351 --- 4.279 
C H --- 8.817 --- --- 
C Hα --- 4.589 --- --- 
a. Indicates an ambiguous assignment. 
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Table 20. Backbone chemical shift data for peptide 
23 its derivatives. 
 
Residue Atom 
δ (ppm) 
23a 
(278 K) 
23b 
(293 K) 
23c 
(293 K) 
23d 
(293 
K) 
C H --- 8.506 --- --- 
C Hα --- 4.585 --- --- 
G H --- 8.755 --- --- 
G Hα 3.745 3.825 3.742 --- 
G Hαʹ 3.833 4.035 3.825 --- 
E H 8.718 8.009 8.645 --- 
E Hα 4.324 4.459 4.305 --- 
W H 8.617 8.521 8.454 --- 
W Hα 4.582 4.465 4.601 --- 
β2Y H 8.129 8.141 7.998 --- 
β2Y Hα 2.399 2.404 2.465 --- 
β2Y Hβ 3.103 3.003 3.165 --- 
β2Y Hβʹ 3.356 3.502 3.316 --- 
N H 7.702 7.900 7.614 --- 
N Hα 4.781 4.782 4.790 --- 
P Hα 4.123 3.992 4.153 --- 
A H 8.185 7.989 7.986 --- 
A Hα 4.280 4.220 4.240 --- 
T H 7.819 7.413 --- 8.295 
T Hα 4.314 4.382 --- 4.310 
G H 8.294 7.929 --- 8.547 
G Hα 3.843 3.632 --- 3.916 
G Hαʹ 3.914 3.934 --- --- 
K H 7.844 7.352 --- 7.927 
K Hα 4.119 4.104 --- 4.142 
β3F H 8.140 7.916 --- 8.059 
β3F Hα 2.454 2.126 --- 2.495 
β3F Hαʹ 2.576 2.345 --- 2.676 
β3F Hβ 4.397 4.204 --- 4.455 
V H 8.336 8.085 --- 8.265 
V Hα 4.132 4.221 --- 4.104 
T H 8.398 8.336 --- 8.266 
T Hα 4.327 4.206 --- 4.356 
E H 8.536 8.628 --- 8.433 
E Hα 4.240 4.319 --- 4.268 
C H --- 8.702 --- --- 
C Hα --- 4.587 --- --- 
 
Table 21. Backbone chemical shift data for peptide 
24 its derivatives. 
 
Residue Atom 
δ (ppm) 
24a 
(278 
K) 
24b 
(293 K) 
24c 
(293 K) 
24d 
(293 K) 
C H --- 8.515 --- --- 
C Hα --- 4.63 --- --- 
G H --- 8.644 --- --- 
G Hα --- 3.884 a --- 
G Hαʹ 3.868 3.973 --- --- 
E H 8.782 8.198 8.711 --- 
E Hα 4.385 4.360 4.377 --- 
W H 8.768 8.427 8.620 --- 
W Hα 4.612 4.644 4.614 --- 
β2,3AY H 8.047 7.949 7.933 --- 
β2,3AY Hα 2.176 2.410 2.187 --- 
β2,3AY Hβ 3.732 3.917 3.728 --- 
N H 8.157 8.117 8.062 --- 
N Hα 4.843 4.848 4.84 --- 
P Hα 4.052 3.963 4.066 --- 
A H 8.193 7.961 7.970 --- 
A Hα 4.283 4.240 4.226 --- 
T H 7.872 7.436 --- 8.304 
T Hα 4.290 4.352 --- 4.305 
G H 8.326 8.129 --- 8.549 
G Hα 3.870 3.729 --- 3.903 
G Hαʹ 3.921 4.037 --- --- 
K H 7.974 7.619 --- 7.924 
K Hα 4.084 4.164 --- 4.090 
β2,3FA H 8.018 7.891 --- 7.942 
β2,3FA Hα 2.664 2.622 --- 2.663 
β2,3FA Hβ 4.233 4.274 --- 4.228 
V H 8.600 8.338 --- 8.488 
V Hα 4.217 4.419 --- 4.185 
T H 8.477 8.376 --- 8.338 
T Hα 4.376 4.321 --- 4.374 
E H 8.564 8.576 --- 8.450 
E Hα 4.277 4.376 --- 4.294 
C H --- 8.607 --- --- 
C Hα --- 4.601 --- --- 
a. Indicates an ambiguous assignment. 
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Table 22. Backbone chemical shift data for peptide 
25 its derivatives. 
 
Residue Atom 
δ (ppm) 
25a 
(278 K) 
25b 
 (293 K) 
25c 
(293 K) 
25d 
(293 K) 
C H --- 8.493 --- --- 
C Hα --- 4.627 --- --- 
G H --- 8.585 --- --- 
G Hα 3.713 3.852 a --- 
G Hαʹ 3.824 3.877 --- --- 
E H 8.704 8.254 8.614 --- 
E Hα 4.289 4.198 4.292 --- 
W H 8.496 8.081 8.352 --- 
W Hα 4.513 4.511 4.528 --- 
β3A H 7.954 7.588 7.834 --- 
β3A Hα 1.901 2.103 1.948 --- 
β3A Hβ 4.045 4.120 4.047 --- 
β2Y H 7.989 7.988 7.887 --- 
β2Y Hα 2.786 2.820 2.807 --- 
β2Y Hβ 3.284 3.266 3.283 --- 
β2Y Hβʹ --- 3.403 --- --- 
N H 8.284 8.165 8.209 --- 
N Hα 4.825 4.832 4.854 --- 
P Hα 4.131 4.068 4.149 --- 
A H 8.190 8.03 7.988 --- 
A Hα 4.292 4.266 4.239 --- 
T H 7.850 7.572 --- 8.299 
T Hα 4.290 4.307 --- 4.299 
G H 8.353 8.198 --- 8.56 
G Hα 3.870 3.798 --- 3.913 
G Hαʹ 3.928 3.975 --- --- 
K H 7.941 7.680 --- 7.951 
K Hα 4.138 4.184 --- 4.135 
β3F H 8.098 7.972 --- 8.01 
β3F Hα 2.395 2.400 --- 2.41 
β3F Hαʹ 2.508 2.491 --- 2.521 
β3F Hβ 4.406 4.383 --- 4.422 
β2A H 8.204 8.048 --- 8.085 
β2A Hα 2.731 2.698 --- 2.742 
β2A Hβ 3.099 3.084 --- 3.126 
β2A Hβʹ 3.361 3.232 --- 3.379 
V H 8.368 8.199 --- 8.254 
V Hα 4.100 4.110 --- 4.121 
T H 8.366 8.183 --- 8.249 
T Hα 4.340 4.299 --- 4.355 
E H 8.533 8.462 --- 8.419 
E Hα 4.261 4.339 --- 4.282 
C H --- 8.501 --- --- 
C Hα --- 4.617 --- --- 
a. Indicates an ambiguous assignment. 
Table 23. Backbone chemical shift data for peptide 
26 its derivatives. 
 
Residue Atom 
δ (ppm) 
26a 
(278 K) 
26b 
(293 K) 
26c 
(293 K) 
26d 
(293 K) 
C H --- 8.478 --- --- 
C Hα --- 4.595 --- --- 
G H --- 8.655 --- --- 
G Hα 3.743 3.819 a --- 
G Hαʹ 3.834 3.963 --- --- 
E H 8.731 8.172 a --- 
E Hα 4.319 4.339 4.310 --- 
W H 8.572 8.372 8.405 --- 
W Hα 4.601 4.525 4.611 --- 
β2,3AA H 7.949 7.407 7.846 --- 
β2,3AA Hα 2.122 2.298 2.128 --- 
β2,3AA Hβ 3.792 3.960 3.801 --- 
β2,3AY H 8.293 8.251 8.155 --- 
β2,3AY Hα 2.664 2.992 2.668 --- 
β2,3AY Hβ 4.075 4.142 4.062 --- 
N H 8.395 8.169 8.312 --- 
N Hα 4.923 4.944 4.932 --- 
P Hα 4.094 3.968 4.135 --- 
A H 8.229 7.968 8.017 --- 
A Hα 4.285 4.242 4.238 --- 
T H 7.873 7.369 --- 8.302 
T Hα 4.292 4.385 --- 4.299 
G H 8.355 8.261 --- 8.548 
G Hα 3.869 3.747 --- 3.896 
G Hαʹ 3.944 4.086 --- --- 
K H 7.970 7.581 --- 7.930 
K Hα 4.108 4.271 --- 4.088 
β2,3FA H 8.043 8.113 --- 7.916 
β2,3FA Hα 2.507 2.451 --- 2.538 
β2,3FA Hβ 4.204 4.208 --- 4.210 
β2,3AA H 8.403 8.285 --- 8.251 
β2,3AA Hα 2.564 2.439 --- 2.583 
β2,3AA Hβ 4.109 4.132 --- 4.098 
V H 8.512 8.260 --- 8.378 
V Hα 4.148 4.266 --- 4.146 
T H 8.456 8.444 --- 8.319 
T Hα 4.361 4.318 --- 4.370 
E H 8.568 8.638 --- 8.442 
E Hα 4.265 4.353 --- 4.283 
C H --- 8.686 --- --- 
C Hα --- 4.603 --- --- 
a. Indicates an ambiguous assignment. 
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Table 24. Backbone chemical shift data for peptide 
73. 
 
Residue Atom δ (ppm) 
G1 Hα 3.762 
G1 Hα′ 3.850 
E2 H 8.723 
E2 Hα 4.471 
W3 H 8.776 
W3 Hα 4.671 
X4 H 9.815 
Y5 H 8.903 
Y5 Hα 4.353 
N6 H 8.082 
N6 Hα 4.934 
P7 Hα 4.154 
A8 H 7.990 
A8 Hα 4.258 
T9 H 7.287 
T9 Hα 4.406 
G10 H 8.487 
G10 Hα 3.810 
G10 Hα′ 4.062 
K11 H 7.703 
K11 Hα 4.642 
F12 H 9.031 
F12 Hα 4.525 
X13 H 9.756 
V14 H 8.421 
V14 Hα 4.252 
T15 H 8.513 
T15 Hα 4.364 
E16 H 8.523 
E16 Hα 4.213 
 
 
 
 
 
 
Table 25. Backbone chemical shift data for peptide 
74. 
 
 Residue Atom δ (ppm) 
G1 Hα 3.772 
G1 Hα′ 3.852 
E2 H 8.612 
E2 Hα 4.639 
W3 H 8.994 
W3 Hα 4.229 
X4 H 7.478 
X4 Hα 2.379 
X4 Hγ 3.587 
Y5 H 8.661 
Y5 Hα 3.722 
N6 H 7.906 
N6 Hα 4.935 
P7 Hα 4.033 
A8 H 7.951 
A8 Hα 4.220 
T9 H 7.132 
T9 Hα 4.399 
G10 H 8.399 
G10 Hα 3.778 
G10 Hα′ 4.036 
K11 H 7.420 
K11 Hα 4.739 
F12 H 8.956 
F12 Hα 4.338 
X13 H 7.442 
X13 Hα 2.064 
X13 Hγ 3.463 
V14 H 8.303 
V14 Hα 4.040 
T15 H 8.454 
T15 Hα 4.351 
E16 H 8.660 
E16 Hα 4.277 
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Table 26. Backbone chemical shift data for peptide 
75. 
 
Residue Atom δ (ppm) 
G1 Hα 3.798 
G1 Hα′ 3.857 
E2 H 8.767 
E2 Hα 4.363 
W3 H 8.669 
W3 Hα 4.521 
X4 H 8.114 
X4 Hα 5.300 
X4 Hβ 6.137 
X4 Hγ 4.333 
Y5 H 8.216 
Y5 Hα 4.487 
N6 H 8.395 
N6 Hα 4.990 
P7 Hα 4.264 
A8 H 8.221 
A8 Hα 4.308 
T9 H 7.697 
T9 Hα 4.378 
G10 H 8.474 
G10 Hα 3.869 
G10 Hα′ 3.991 
K11 H 7.993 
K11 Hα 4.419 
F12 H 8.698 
F12 Hα 4.424 
X13 H 8.104 
X13 Hα 5.763 
X13 Hβ 6.302 
X13 Hγ 4.421 
V14 H 8.263 
V14 Hα 4.238 
T15 H 8.477 
T15 Hα 4.378 
E16 H 8.548 
E16 Hα 4.251 
 
 
 
 
 
 
Table 27. Backbone chemical shift data for peptide 
76. 
 
Residue Atom δ (ppm) 
C1 H 8.478 
C1 Hα 4.590 
G2 H 8.544 
G2 Hα 3.756 
G2 Hα′ 3.889 
E3 H 8.257 
E3 Hα 4.277 
W4 H 8.184 
W4 Hα 4.514 
X5 H 7.780 
X5 Hα 5.819 
X5 Hβ 6.404 
X5 Hγ 4.460 
Y6 H 8.542 
Y6 Hα 4.271 
N7 H 8.037 
N7 Hα 5.009 
P8 Hα 4.149 
A9 H 7.993 
A9 Hα 4.266 
T10 H 7.284 
T10 Hα 4.416 
G11 H 8.410 
G11 Hα 3.784 
G11 Hα′ 4.073 
K12 H 7.568 
K12 Hα 4.597 
F13 H 8.755 
F13 Hα 4.425 
X14 H 7.955 
X14 Hα 5.834 
X14 Hβ 6.357 
X14 Hγ 4.489 
V15 H 8.049 
V15 Hα 4.192 
T16 H 8.356 
T16 Hα 4.260 
E17 H 8.540 
E17 Hα 4.349 
C18 H 8.546 
C18 Hα 4.620 
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Table 28. Backbone chemical shift data for peptide 
77. 
 
Residue Atom 
δ (ppm)  
trans cis 
G1 Hα 3.599 a 
G1 Hα′ 3.794 a 
E2 H 8.572 8.557 
E2 Hα 4.791 4.807 
W3 Hα 5.330 5.230 
W3 HMe 3.118 2.902 
A4 H 8.403 8.561 
A4 Hα 4.524 4.407 
Y5 H 8.637 8.612 
Y5 Hα 4.117 4.508 
N6 H 8.061 8.375 
N6 Hα 4.948 4.961 
P7 Hα 4.126 4.250 
A8 H 8.061 8.219 
A8 Hα 4.254 4.301 
T9 H 7.409 7.752 
T9 Hα 4.373 4.349 
G10 H 8.400 8.426 
G10 Hα 3.813 3.887 
G10 Hα′ 4.001 3.973 
K11 H 7.697 8.028 
K11 Hα 4.522 4.317 
F12 H 8.618 8.427 
F12 Hα 4.766 4.682 
A13 H 8.480 8.319 
A13 Hα 4.355 4.333 
V14 H 8.204 8.353 
V14 Hα 4.077 4.152 
T15 H 8.362 8.350 
T15 Hα 4.367 4.321 
E16 H 8.572 8.534 
E16 Hα 4.231 4.237 
aIndicates an ambiguous assignment. 
 
 
 
 
 
 
 
 
Table 29. Backbone chemical shift data for peptide 
78. 
 
Residue Atom 
δ (ppm) 
trans cis 
G1 Hα 3.724 3.707 
G1 Hα′ 3.814 3.804 
E2 H 8.648 8.7 
E2 Hα 4.356 4.334 
W3 H 8.59 8.34 
W3 Hα 4.696 4.656 
A4 H 8.397 a 
A4 Hα 4.809 a 
Y5 H 4.769 4.879 
Y5 HMe 2.989 2.930 
N6 H 8.099 8.478 
N6 Hα 4.923 4.594 
P7 Hα 4.222 4.343 
A8 H 8.258 8.287 
A8 Hα 4.289 4.288 
T9 H 7.707 7.992 
T9 Hα 4.345 4.293 
G10 H 8.366 8.394 
G10 Hα 3.864 3.909 
G10 Hα′ 3.956 --- 
K11 H 7.905 8.197 
K11 Hα 4.388 4.194 
F12 H 8.487 8.300 
F12 Hα 4.738 4.614 
A13 H 8.476 8.218 
A13 Hα 4.403 4.291 
V14 H 8.329 8.335 
V14 Hα 4.099 4.145 
T15 H 8.404 a 
T15 Hα 4.356 a 
E16 H 8.576 8.546 
E16 Hα 4.258 4.260 
aIndicates an ambiguous assignment. 
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Table 30. Backbone chemical shift data for peptide 
79. 
 
Residue Atom 
δ (ppm) 
trans cis 
G1 Hα 3.708 3.703 
G1 Hα′ 3.817 3.806 
E2 H 8.666 8.690 
E2 Hα 4.371 4.275 
W3 H 8.594 8.482 
W3 Hα 4.709 4.625 
A4 H 8.331 8.153 
A4 Hα 4.292 4.212 
Y5 H 8.182 8.099 
Y5 Hα 4.072 4.346 
N6 H 8.204 8.286 
N6 Hα 4.878 4.831 
P7 Hα 4.167 4.239 
A8 H 8.125 8.227 
A8 Hα 4.271 4.278 
T9 H 7.645 7.815 
T9 Hα 4.339 4.288 
G10 H 8.387 8.352 
G10 Hα 3.823 3.905 
G10 Hα′ 3.94 --- 
K11 H 7.786 8.138 
K11 Hα 4.765 4.307 
F12 Hα 5.204 5.050 
F12 HMe 3.083 2.902 
A13 H 8.27 8.386 
A13 Hα 4.382 4.345 
V14 H 8.386 8.474 
V14 Hα 4.162 4.23 
T15 H 8.453 8.431 
T15 Hα 4.36 4.366 
E16 H 8.589 8.557 
E16 Hα 4.261 4.257 
 
 
 
 
 
 
 
 
 
Table 31. Backbone chemical shift data for peptide 
80. 
 
Residue Atom 
δ (ppm) 
trans cis 
G1 Hα 3.683 a 
G1 Hα′ 3.831 a 
E2 H 8.637 8.729 
E2 Hα 4.492 4.282 
W3 H 8.717 8.453 
W3 Hα 4.754 4.771 
A4 H 8.662 8.342 
A4 Hα 4.541 4.354 
Y5 H 8.543 8.302 
Y5 Hα 3.888 4.196 
N6 H 7.986 8.08 
N6 Hα 4.912 4.885 
P7 Hα 4.082 4.149 
A8 H 8.01 8.101 
A8 Hα 4.244 4.275 
T9 H 7.364 7.556 
T9 Hα 4.383 4.350 
G10 H 8.37 8.357 
G10 Hα 3.811 3.857 
G10 Hα′ 4.006 3.974 
K11 H 7.663 7.808 
K11 Hα 4.55 4.402 
F12 H 8.61 8.573 
F12 Hα 4.757 4.699 
A13 H 8.625 8.477 
A13 Hα 4.844 4.970 
V14 Hα 4.668 4.675 
V14 HMe 3.029 2.891 
T15 H 8.513 a 
T15 Hα 4.334 a 
E16 H 8.682 a 
E16 Hα 4.287 a 
aIndicates an ambiguous assignment. 
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APPENDIX B 
NOE-DERIVED DISTANCE RESTRAINTS FOR SELECT HAIRPIN PEPTIDES 
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Table 32. NOE distance restraints for peptide 1a. 
Residue Proton Residue Proton Distance 
5 V HA 6 P QD 2.7 
6 P QD 5 V HA 2.7 
4 Y HA 5 V H 2.7 
9 F HA 10 T H 2.7 
2 W HA 3 Q H 2.7 
8 K HA 9 F H 2.7 
10 T HA 11 V H 2.7 
11 V H 10 T HA 2.7 
1 R HA 2 W H 2.7 
11 V HA 12 Q H 2.7 
4 Y H 3 Q HA 2.7 
7 G HA1 7 G H 2.7 
9 F H 8 K HA 2.7 
3 Q HA 4 Y H 2.7 
12 Q H 11 V HA 2.7 
2 W H 1 R HA 2.7 
10 T H 9 F HA 2.7 
7 G H 6 P HA 2.7 
6 P HA 7 G H 2.7 
12 Q HB1 12 Q H 3.5 
7 G H 8 K H 3.5 
4 Y HA 9 F HA 3.5 
2 W HA 11 V HA 3.5 
8 K H 7 G H 3.5 
1 R QB 2 W H 3.5 
1 R HA 2 W HD1 3.5 
7 G HA1 8 K H 3.5 
7 G HA2 8 K H 3.5 
5 V H 8 K H 3.5 
11 V H 10 T HB 3.5 
8 K H 5 V H 3.5 
4 Y H 3 Q HB2 3.5 
2 W HB1 3 Q H 3.5 
4 Y HB2 5 V H 3.5 
3 Q H 2 W HB2 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
8 K H 7 G HA1 3.5 
4 Y HA 10 T H 3.5 
4 Y H 3 Q HB1 3.5 
4 Y H 3 Q HG1 3.5 
10 T H 3 Q H 3.5 
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Residue Proton Residue Proton Distance 
9 F HB2 10 T H 3.5 
2 W HB2 3 Q H 3.5 
5 V H 4 Y HB1 3.5 
9 F HA 5 V H 3.5 
3 Q H 10 T H 3.5 
4 Y HB1 5 V H 3.5 
11 V HB 12 Q H 3.5 
8 K H 7 G HA2 3.5 
10 T H 9 F HB2 3.5 
8 K HB1 9 F H 3.5 
5 V QQXG 6 P QD 4.5 
12 Q H 3 Q H 4.5 
4 Y QE 9 F HB1 4.5 
8 K HA 4 Y QD 4.5 
8 K HA 4 Y QE 4.5 
2 W H 1 R QG 4.5 
8 K QG 9 F H 4.5 
2 W HE3 3 Q HA 4.5 
10 T QXGT 11 V H 4.5 
12 Q H 11 V QQXG 4.5 
7 G HA1 4 Y QD 4.5 
5 V H 4 Y QD 4.5 
4 Y HA 9 F QD 4.5 
9 F QD 10 T H 4.5 
5 V H 6 P QD 4.5 
10 T H 9 F QD 4.5 
9 F H 10 T H 4.5 
9 F HB1 10 T H 4.5 
4 Y QD 5 V H 4.5 
2 W HE3 9 F QD 4.5 
10 T H 11 V H 4.5 
9 F H 8 K H 4.5 
2 W HA 12 Q H 4.5 
10 T H 9 F HB1 4.5 
11 V H 10 T H 4.5 
4 Y HB2 2 W HE3 4.5 
4 Y HB1 9 F QE 4.5 
4 Y HA 3 Q HA 4.5 
9 F H 4 Y QE 4.5 
10 T HA 2 W HE3 4.5 
8 K H 6 P HA 4.5 
9 F HA 4 Y QD 4.5 
3 Q H 2 W HE3 4.5 
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Residue Proton Residue Proton Distance 
8 K H 9 F H 4.5 
9 F H 4 Y QD 4.5 
12 Q HA 11 V HA 4.5 
10 T H 9 F H 4.5 
5 V HA 7 G H 4.5 
6 P HA 8 K H 4.5 
7 G H 5 V H 4.5 
2 W HE3 10 T H 4.5 
2 W HE3 10 T HA 4.5 
6 P QB 7 G H 4.5 
2 W HE3 3 Q H 4.5 
11 V HA 3 Q H 4.5 
7 G HA1 9 F HB2 4.5 
4 Y QD 8 K H 4.5 
5 V H 7 G H 4.5 
11 V HA 2 W HE3 4.5 
2 W HZ2 9 F QD 4.5 
10 T H 2 W HE3 4.5 
3 Q H 11 V HA 4.5 
10 T HA 11 V QQXG 4.5 
7 G H 6 P QB 4.5 
4 Y HA 8 K H 4.5 
10 T H 4 Y QD 4.5 
6 P QD 5 V H 4.5 
4 Y QE 9 F H 4.5 
3 Q H 12 Q H 4.5 
3 Q HA 2 W HE3 4.5 
11 V HA 2 W HD1 4.5 
4 Y H 3 Q HG2 4.5 
7 G HA1 4 Y QE 5.5 
5 V QQXG 4 Y H 5.5 
10 T QXGT 12 Q H 5.5 
11 V QQXG 9 F QE 5.5 
10 T QXGT 5 V H 5.5 
4 Y QE 7 G HA1 5.5 
8 K QD 9 F H 5.5 
9 F H 10 T QXGT 5.5 
5 V HB 10 T QXGT 5.5 
11 V QQXG 2 W HD1 5.5 
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Table 33. NOE distance restraints for peptide 2a. 
Residue Proton Residue Proton Residue 
2 W HA 3 X H 2.7 
4 Y HA 5 V H 2.7 
8 K HA 9 F H 2.7 
5 V HA 6 P HD2 2.7 
1 R HA 2 W H 2.7 
11 V HA 12 Q H 2.7 
5 V HA 6 P HD1 2.7 
3 X HA1 4 Y H 2.7 
6 P HD2 5 V HA 2.7 
2 W H 1 R HA 2.7 
12 Q H 11 V HA 2.7 
6 P HD1 5 V HA 2.7 
3 X H 2 W HA 2.7 
9 F HA 10 X H 2.7 
4 Y H 3 X HA2 2.7 
10 X H 9 F HA 2.7 
6 P HA 7 G H 2.7 
7 G HA2 8 K H 2.7 
3 X HA2 4 Y H 3.5 
7 G HA1 8 K H 3.5 
7 G H 6 P QG 3.5 
6 P QG 7 G H 3.5 
2 W QB 3 X H 3.5 
3 X H 2 W QB 3.5 
4 Y HA 9 F HA 3.5 
8 K H 7 G H 3.5 
8 K H 7 G HA1 3.5 
7 G H 8 K H 3.5 
12 Q H 12 Q HA 3.5 
11 V HB 12 Q H 3.5 
12 Q H 11 V HB 3.5 
6 P HD2 7 G H 3.5 
7 G H 6 P HD2 3.5 
4 Y HB2 5 V H 3.5 
9 F H 8 K H 3.5 
5 V H 4 Y HB2 3.5 
8 K HA 9 F QB 3.5 
3 X HB 10 X HA2 3.5 
5 V QXG2 2 W HD1 3.5 
5 V QXG1 6 P HD1 3.5 
11 V HB 2 W QB 3.5 
9 F QB 10 X H 3.5 
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Residue Proton Residue Proton Residue 
9 F H 10 X H 3.5 
4 Y HA 10 X H 3.5 
12 Q H 11 V QQXG 4.5 
11 V QQXG 12 Q H 4.5 
2 W HA 3 X HB 4.5 
9 F HA 4 Y QD 4.5 
5 V HA 2 W QB 4.5 
5 V QXG1 6 P HD2 4.5 
10 X HA2 3 X HB 4.5 
3 X QQXD 4 Y H 4.5 
1 R QG 2 W H 4.5 
4 Y QD 9 F HA 4.5 
1 R HA 2 W QB 4.5 
4 Y QE 9 F QB 4.5 
5 V QXG2 6 P HD1 4.5 
2 W QB 5 V HA 4.5 
4 Y QD 5 V H 4.5 
7 G HA1 6 P HA 4.5 
7 G H 6 P HD1 4.5 
12 Q H 11 V H 4.5 
7 G HA2 6 P HA 4.5 
11 V H 12 Q H 4.5 
3 X HB 4 Y H 4.5 
6 P HD1 7 G H 4.5 
5 V HA 6 P HA 4.5 
6 P HD2 5 V H 4.5 
4 Y HB1 5 V H 4.5 
4 Y HB2 7 G H 4.5 
6 P QB 7 G H 4.5 
2 W HA 11 V H 4.5 
4 Y HB2 7 G HA2 4.5 
5 V H 4 Y HB1 4.5 
4 Y HB1 7 G H 4.5 
3 X HB 2 W HA 4.5 
5 V H 7 G H 4.5 
4 Y HB1 7 G HA1 4.5 
6 P HD1 5 V H 4.5 
9 F QD 10 X H 4.5 
5 V H 4 Y H 4.5 
7 G H 4 Y HB2 4.5 
4 Y H 5 V H 4.5 
7 G HA1 4 Y HB2 4.5 
10 X HA1 9 F HA 4.5 
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Residue Proton Residue Proton Residue 
3 X HB 10 X H 4.5 
2 W HE3 3 X H 4.5 
11 V H 2 W HA 4.5 
3 X HG 4 Y H 4.5 
11 V H 2 W H 4.5 
9 F HA 5 V H 4.5 
10 X HB 9 F HA 4.5 
11 V HB 2 W H 4.5 
3 X QQXD 9 F QE 4.5 
5 V QXG2 2 W QB 4.5 
5 V QXG2 6 P HD2 4.5 
10 X H 9 F QD 4.5 
5 V HA 7 G H 4.5 
4 Y QD 8 K HA 4.5 
3 X HA2 2 W HD1 4.5 
7 G H 5 V HA 4.5 
2 W HA 1 R HA 4.5 
4 Y HB1 8 K H 4.5 
11 V QQXG 2 W QB 5.5 
3 X QQXD 4 Y QE 5.5 
3 X QQXD 4 Y QD 5.5 
3 X QQXD 2 W HA 5.5 
2 W QB 4 Y H 5.5 
5 V QXG2 2 W HE1 5.5 
1 R QD 2 W HE1 5.5 
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Table 34. NOE distance restraints for peptide 8a. 
Residue Proton Residue Proton Residue 
6 P QD 5 V HA 2.7 
10 X H 9 F HA 2.7 
9 F HA 10 X H 2.7 
12 Q H 11 V HA 2.7 
11 V HA 12 Q H 2.7 
9 F H 8 K HA 2.7 
8 K HA 9 F H 2.7 
11 V H 10 X HA 2.7 
10 X HA 11 V H 2.7 
2 W H 1 R HA 2.7 
1 R HA 2 W H 2.7 
7 G HA1 7 G H 2.7 
4 Y HA 5 V H 2.7 
3 X HB 10 X HA 2.7 
7 G HA2 7 G H 2.7 
4 Y H 3 X QXE 3.5 
3 X QXE 4 Y H 3.5 
7 G H 8 K H 3.5 
8 K H 7 G H 3.5 
11 V H 2 W H 3.5 
11 V H 10 X QXD1 3.5 
10 X QXD1 11 V H 3.5 
5 V H 8 K H 3.5 
8 K H 5 V H 3.5 
4 Y HA 9 F HA 3.5 
7 G HA1 8 K H 3.5 
1 R QG 2 W H 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
9 F HA 4 Y QD 3.5 
5 V H 4 Y HB2 3.5 
4 Y HB2 5 V H 3.5 
3 X HB 10 X H 3.5 
11 V H 10 X HB 3.5 
10 X HB 11 V H 3.5 
3 X HB 4 Y H 3.5 
10 X HG 11 V H 3.5 
3 X HG 4 Y H 3.5 
9 F H 8 K HB1 3.5 
8 K HB1 9 F H 3.5 
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Residue Proton Residue Proton Residue 
11 V H 3 X HB 3.5 
3 X HB 11 V H 3.5 
9 F HB1 8 K HA 3.5 
11 V HA 10 X HG 3.5 
6 P QD 5 V QXG2 4.5 
4 Y QE 9 F HB1 4.5 
9 F HB1 4 Y QE 4.5 
8 K H 7 G HA2 4.5 
7 G HA2 8 K H 4.5 
9 F QD 3 X HG 4.5 
3 X HG 9 F QD 4.5 
10 X QXD1 5 V HB 4.5 
9 F QD 10 X QXE 4.5 
10 X QXE 9 F QD 4.5 
10 X QXE 3 X HB 4.5 
3 X QXE 2 W HE1 4.5 
2 W HA 3 X QXE 4.5 
10 X H 9 F QD 4.5 
9 F QD 10 X H 4.5 
4 Y QE 9 F HB2 4.5 
9 F HB2 4 Y QE 4.5 
10 X QXD1 9 F HA 4.5 
3 X HG 10 X QXE 4.5 
10 X QXE 9 F HA 4.5 
10 X HA 3 X QXE 4.5 
3 X QXE 10 X HA 4.5 
10 X H 9 F HB1 4.5 
9 F HB1 10 X H 4.5 
3 X QXE 2 W HB2 4.5 
5 V QXG2 6 P HA 4.5 
4 Y QD 3 X HG 4.5 
3 X HG 4 Y QD 4.5 
10 X H 9 F HB2 4.5 
9 F HB2 10 X H 4.5 
4 Y QD 5 V H 4.5 
12 Q HA 1 R QG 4.5 
1 R QG 12 Q HA 4.5 
5 V H 4 Y HB1 4.5 
4 Y HB1 5 V H 4.5 
9 F HA 10 X HA 4.5 
10 X HA 9 F HA 4.5 
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Residue Proton Residue Proton Residue 
3 X QXE 2 W HZ2 4.5 
8 K H 6 P HA 4.5 
6 P HA 8 K H 4.5 
3 X HG 9 F HA 4.5 
5 V H 6 P QD 4.5 
6 P QD 5 V H 4.5 
9 F HA 5 V H 4.5 
10 X QXD1 2 W HE3 4.5 
9 F H 10 X H 4.5 
10 X H 9 F H 4.5 
9 F H 8 K HG1 4.5 
8 K HG1 9 F H 4.5 
10 X QXE 9 F HB1 4.5 
9 F H 8 K H 4.5 
8 K H 9 F H 4.5 
5 V H 4 Y H 4.5 
3 X QXE 2 W HB1 4.5 
1 R HE 12 Q HA 4.5 
9 F HB2 8 K HA 4.5 
5 V HB 8 K H 4.5 
3 X QXE 2 W HZ3 4.5 
5 V H 10 X H 4.5 
9 F H 8 K HG2 4.5 
8 K HG2 9 F H 4.5 
4 Y HB2 5 V HA 4.5 
4 Y QE 9 F HA 4.5 
3 X HG 4 Y QE 4.5 
12 Q HA 2 W H 4.5 
3 X HG 10 X H 4.5 
11 V H 10 X H 4.5 
10 X H 11 V H 4.5 
3 X HG 10 X HA 4.5 
11 V H 2 W HB1 4.5 
11 V H 2 W HB2 4.5 
2 W HB2 11 V H 4.5 
2 W HE3 11 V H 4.5 
8 K H 4 Y QD 4.5 
4 Y QD 8 K H 4.5 
1 R HA 2 W HB2 4.5 
2 W HB2 1 R HA 4.5 
8 K H 4 Y HB2 4.5 
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Residue Proton Residue Proton Residue 
9 F HA 4 Y HB2 4.5 
4 Y HB2 9 F HA 4.5 
9 F HA 4 Y HB1 4.5 
1 R HE 2 W H 4.5 
8 K HG2 6 P HA 4.5 
1 R HE 12 Q H 4.5 
5 V QXG1 2 W HZ3 4.5 
12 Q HA 1 R QB 4.5 
1 R QB 12 Q HA 4.5 
10 X QXE 1 R QD 5.5 
3 X QXE 10 X H 5.5 
10 X QXE 11 V HA 5.5 
5 V QXG1 2 W HZ2 5.5 
5 V QXG1 4 Y H 5.5 
3 X QXE 11 V H 5.5 
10 X QXD1 11 V HA 5.5 
5 V QXG1 10 X H 5.5 
3 X QXE 4 Y HB1 5.5 
4 Y QE 9 F H 5.5 
4 Y HB2 6 P QD 5.5 
3 X QXE 2 W H 5.5 
4 Y QD 10 X H 5.5 
7 G HA1 6 P HA 5.5 
3 X QXE 5 V H 5.5 
6 P QD 5 V QXG1 5.5 
5 V QXG1 6 P QD 5.5 
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Table 35. NOE distance restraints for peptide 9a. 
Residue Proton Residue Proton Residue 
6 P QD 5 V HA 2.7 
9 F H 8 K HA 2.7 
8 K HA 9 F H 2.7 
10 X H 9 F HA 2.7 
11 V H 10 X HA 2.7 
12 Q H 11 V HA 2.7 
11 V HA 12 Q H 2.7 
7 G HA1 7 G H 2.7 
2 W H 1 R HA 2.7 
4 Y HA 5 V H 2.7 
7 G HA2 7 G H 2.7 
3 X HB 10 X QXD1 3.5 
7 G H 6 P HA 3.5 
6 P HA 7 G H 3.5 
10 X QXE 5 V HB 3.5 
7 G H 8 K H 3.5 
8 K H 7 G H 3.5 
2 W H 1 R QB 3.5 
5 V H 8 K H 3.5 
8 K H 5 V H 3.5 
3 X H 2 W QB 3.5 
2 W QB 3 X H 3.5 
4 Y HA 9 F HA 3.5 
7 G HA2 8 K H 3.5 
8 K H 7 G HA1 3.5 
4 Y H 3 X HG 3.5 
3 X HG 4 Y H 3.5 
9 F H 8 K HB2 3.5 
8 K HB2 9 F H 3.5 
5 V H 4 Y HB1 3.5 
11 V H 10 X HG 3.5 
10 X HG 11 V H 3.5 
4 Y H 3 X QXD2 4.5 
3 X QXD2 4 Y H 4.5 
3 X QXD1 10 X HA 4.5 
3 X HG 5 V QXG1 4.5 
5 V QXG1 3 X HG 4.5 
11 V H 10 X QXE 4.5 
10 X QXE 11 V H 4.5 
3 X HG 10 X QXE 4.5 
2 W QB 11 V HB 4.5 
11 V HB 2 W QB 4.5 
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Residue Proton Residue Proton Residue 
11 V H 10 X QXD1 4.5 
10 X QXD1 11 V H 4.5 
7 G HA1 8 K H 4.5 
6 P QD 5 V HB 4.5 
7 G H 6 P QD 4.5 
6 P QD 7 G H 4.5 
5 V H 10 X QXE 4.5 
10 X QXE 5 V H 4.5 
3 X QXD1 2 W QB 4.5 
4 Y HB1 5 V H 4.5 
11 V H 3 X QXD1 4.5 
3 X QXD1 11 V H 4.5 
11 V QXG2 12 Q H 4.5 
10 X QXD1 1 R QD 4.5 
10 X QXD1 12 Q HA 4.5 
4 Y H 3 X HB 4.5 
3 X HB 4 Y H 4.5 
2 W HA 3 X HA 4.5 
12 Q H 11 V H 4.5 
11 V H 12 Q H 4.5 
1 R HA 2 W QB 4.5 
2 W HA 3 X QXD2 4.5 
5 V H 6 P QD 4.5 
6 P QD 5 V H 4.5 
2 W HD1 3 X H 4.5 
4 Y HA 10 X H 4.5 
3 X QXD2 2 W HD1 4.5 
10 X QXD1 1 R HG1 4.5 
2 W H 3 X H 4.5 
3 X QXD1 4 Y H 4.5 
9 F H 8 K HB1 4.5 
8 K HB1 9 F H 4.5 
2 W H 1 R HG1 4.5 
1 R HG1 2 W H 4.5 
5 V H 9 F HA 4.5 
9 F HA 5 V H 4.5 
7 G H 4 Y HB1 4.5 
4 Y HB1 7 G H 4.5 
10 X QXD2 12 Q HA 4.5 
3 X HG 5 V H 4.5 
2 W H 1 R HG2 4.5 
1 R HG2 2 W H 4.5 
8 K H 6 P HA 4.5 
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Residue Proton Residue Proton Residue 
6 P HA 8 K H 4.5 
8 K H 4 Y HB1 4.5 
6 P HB2 7 G H 4.5 
8 K HB1 5 V H 4.5 
7 G H 5 V HA 4.5 
5 V HA 7 G H 4.5 
9 F H 4 Y QE 4.5 
4 Y QE 9 F H 4.5 
8 K HG2 9 F H 4.5 
9 F H 8 K H 4.5 
8 K H 9 F H 4.5 
5 V H 4 Y HB2 4.5 
4 Y HB2 5 V H 4.5 
7 G HA2 6 P HA 4.5 
8 K HG1 9 F H 4.5 
8 K HA 4 Y QE 4.5 
5 V H 4 Y H 4.5 
4 Y H 5 V H 4.5 
10 X H 9 F H 4.5 
2 W H 11 V H 4.5 
11 V H 2 W H 4.5 
7 G H 4 Y HB2 4.5 
11 V HB 2 W HE3 4.5 
10 X HG 12 Q H 4.5 
10 X H 5 V H 4.5 
8 K H 4 Y HB2 4.5 
10 X QXE 3 X QXD1 5.5 
10 X QXE 8 K QD 5.5 
4 Y HB1 8 K H 5.5 
11 V QXG2 2 W HE3 5.5 
5 V QXG1 10 X H 5.5 
3 X QXD1 11 V HB 5.5 
10 X QXD2 9 F HB2 5.5 
12 Q H 11 V QXG1 5.5 
11 V QXG1 12 Q H 5.5 
10 X QXD1 1 R HG2 5.5 
11 V QXG1 2 W HE3 5.5 
10 X QXD1 2 W H 5.5 
3 X QXD2 2 W HE3 5.5 
3 X QXD1 2 W HZ2 5.5 
3 X QXD2 2 W HZ2 5.5 
11 V HA 10 X QXD1 5.5 
5 V QXG1 4 Y H 5.5 
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Residue Proton Residue Proton Residue 
10 X QXD2 9 F HB1 5.5 
8 K QD 9 F H 5.5 
3 X QXD1 2 W HE3 5.5 
4 Y HB1 6 P QD 5.5 
10 X QXD1 12 Q H 5.5 
11 V H 10 X QXD2 5.5 
10 X QXD2 11 V H 5.5 
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Table 36. NOE Distance restraints for peptide 22a. 
Residue Proton Residue Proton Distance 
2 E HA 3 W H 2.70 
2 E HB1 3 W H 2.70 
3 W H 2 E HA 2.70 
4 A HA 5 Y H 2.70 
5 Y H 4 A HA 2.70 
5 Y HA 6 N H 2.70 
6 N H 5 Y HA 2.70 
6 N HA 7 P HD1 2.70 
6 N HA 7 P HD2 2.70 
8 A H 9 T H 2.70 
9 T H 8 A H 2.70 
9 T H 10 G H 2.70 
10 G H 9 T H 2.70 
11 K HA 12 F H 2.70 
12 F H 11 K HA 2.70 
13 A HA 14 V H 2.70 
14 V H 13 A HA 2.70 
14 V HA 15 T H 2.70 
15 T H 14 V HA 2.70 
15 T HA 16 E H 2.70 
16 E H 15 T HA 2.70 
1 G HA1 2 E H 3.50 
1 G HA2 2 E H 3.50 
2 E HB2 3 W H 3.50 
3 W H 2 E HB2 3.50 
3 W HA 4 A H 3.50 
3 W HA 14 V HA 3.50 
3 W HA 15 T H 3.50 
4 A H 3 W HA 3.50 
4 A H 3 W HB2 3.50 
4 A QXB 5 Y H 3.50 
5 Y H 6 N H 3.50 
5 Y HA 12 F HA 3.50 
5 Y QD 7 P HB2 3.50 
6 N H 5 Y H 3.50 
6 N H 11 K H 3.50 
6 N H 13 A H 3.50 
6 N HA 8 A H 3.50 
6 N HB2 11 K H 3.50 
7 P HA 5 Y QD 3.50 
7 P HA 8 A H 3.50 
7 P HB2 5 Y QD 3.50 
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Residue Proton Residue Proton Distance 
7 P HB2 8 A H 3.50 
7 P HD1 8 A H 3.50 
7 P HD2 6 N H 3.50 
7 P HD2 8 A H 3.50 
7 P QG 8 A H 3.50 
8 A H 7 P HA 3.50 
8 A H 7 P HD1 3.50 
8 A H 7 P HD2 3.50 
8 A H 7 P QG 3.50 
8 A HA 9 T H 3.50 
8 A HA 10 G H 3.50 
9 T H 8 A HA 3.50 
9 T HA 10 G H 3.50 
10 G H 8 A HA 3.50 
10 G H 9 T HA 3.50 
10 G H 11 K H 3.50 
10 G HA1 11 K H 3.50 
10 G HA2 11 K H 3.50 
11 K H 6 N H 3.50 
11 K H 10 G H 3.50 
11 K H 10 G HA1 3.50 
11 K H 10 G HA2 3.50 
11 K H 12 F H 3.50 
11 K HB2 12 F H 3.50 
11 K HG1 12 F H 3.50 
12 F H 11 K HB2 3.50 
12 F HA 5 Y HA 3.50 
12 F HA 6 N H 3.50 
12 F HA 13 A H 3.50 
12 F HB1 13 A H 3.50 
13 A H 12 F HA 3.50 
13 A H 12 F HB1 3.50 
13 A QXB 14 V H 3.50 
14 V HA 3 W HA 3.50 
14 V HA 4 A H 3.50 
14 V HB 15 T H 3.50 
15 T H 14 V HB 3.50 
15 T HB 16 E H 3.50 
16 E H 15 T HB 3.50 
4 A H 3 W HB1 4.50 
4 A HA 5 Y QB 4.50 
4 A QXB 5 Y QB 4.50 
5 Y HA 13 A H 4.50 
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Residue Proton Residue Proton Distance 
5 Y QB 4 A HA 4.50 
5 Y QB 6 N H 4.50 
5 Y QB 12 F QD 4.50 
5 Y QD 7 P QG 4.50 
5 Y QE 6 N H 4.50 
6 N H 5 Y QB 4.50 
6 N HA 7 P QG 4.50 
6 N HB2 10 G H 4.50 
7 P HA 5 Y QE 4.50 
7 P HB2 5 Y QE 4.50 
7 P QG 5 Y QD 4.50 
7 P QG 5 Y QE 4.50 
8 A H 10 G H 4.50 
8 A QXB 9 T HA 4.50 
10 G H 8 A H 4.50 
12 F HA 5 Y QB 4.50 
12 F HB1 3 W HE1 4.50 
12 F HB2 3 W HE1 4.50 
12 F HB2 13 A H 4.50 
12 F QD 5 Y HA 4.50 
13 A H 5 Y HA 4.50 
13 A H 12 F HB2 4.50 
13 A HA 14 V HA 4.50 
13 A QXB 15 T H 4.50 
14 V QXG2 15 T H 4.50 
15 T H 14 V QXG2 4.50 
3 W HH2 14 V QXG2 5.50 
4 A QXB 6 N HD2 5.50 
8 A QXB 6 N HD2 5.50 
8 A QXB 10 G H 5.50 
14 V QXG1 15 T H 5.50 
15 T H 14 V QXG1 5.50 
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Table 37. NOE Distance restraints for peptide 22b. 
Residue Proton Residue Proton Distance 
6 Y HA 7 N H 2.70 
7 N H 6 Y HA 2.70 
7 N HA 8 P QD 2.70 
9 A H 10 T H 2.70 
10 T H 9 A H 2.70 
10 T H 11 G H 2.70 
11 G H 10 T H 2.70 
12 K HA 13 F H 2.70 
13 F HA 6 Y HA 2.70 
13 F HA 14 A H 2.70 
14 A HA 15 V H 2.70 
15 V H 14 A HA 2.70 
15 V HA 16 T H 2.70 
16 T H 15 V HA 2.70 
16 T HB 17 E H 2.70 
17 E H 16 T HB 2.70 
17 E HA 18 C H 2.70 
17 E HB2 1 C H 2.70 
18 C H 17 E HA 2.70 
2 G HA1 3 E H 3.50 
3 E H 2 G HA1 3.50 
3 E H 2 G HA2 3.50 
3 E H 16 T HA 3.50 
4 W HA 16 T H 3.50 
6 Y QE 8 P HA 3.50 
7 N HB2 12 K H 3.50 
8 P HA 6 Y QE 3.50 
8 P HG1 9 A H 3.50 
8 P HG2 6 Y QE 3.50 
8 P HG2 9 A H 3.50 
8 P QD 7 N HB1 3.50 
8 P QD 9 A H 3.50 
9 A H 8 P QD 3.50 
9 A HA 10 T H 3.50 
10 T HA 11 G H 3.50 
11 G H 8 P HA 3.50 
11 G H 10 T HA 3.50 
11 G H 12 K H 3.50 
12 K H 7 N H 3.50 
12 K H 11 G H 3.50 
12 K H 11 G HA1 3.50 
12 K HB2 13 F H 3.50 
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Residue Proton Residue Proton Distance 
13 F H 12 K HB2 3.50 
13 F HA 7 N H 3.50 
14 A H 13 F HB1 3.50 
14 A QXB 15 V H 3.50 
15 V H 14 A QXB 3.50 
16 T H 3 E H 3.50 
16 T HA 3 E H 3.50 
16 T HA 17 E H 3.50 
17 E H 16 T HA 3.50 
2 G HA1 15 V QXG2 4.50 
2 G HA2 3 E H 4.50 
3 E H 16 T H 4.50 
4 W HA 15 V HA 4.50 
4 W HA 15 V QXG1 4.50 
4 W QB 13 F HB1 4.50 
4 W QB 13 F QD 4.50 
5 A H 15 V HA 4.50 
6 Y QD 7 N H 4.50 
6 Y QD 8 P HA 4.50 
6 Y QD 8 P HG2 4.50 
6 Y QD 8 P QD 4.50 
7 N H 6 Y QD 4.50 
7 N H 6 Y QE 4.50 
7 N H 12 K H 4.50 
7 N HA 9 A H 4.50 
7 N HB2 11 G H 4.50 
8 P HA 6 Y QD 4.50 
8 P HA 9 A H 4.50 
8 P HG2 6 Y QD 4.50 
8 P QD 6 Y QD 4.50 
8 P QD 6 Y QE 4.50 
8 P QD 7 N H 4.50 
9 A H 8 P HA 4.50 
9 A H 11 G H 4.50 
9 A QXB 10 T H 4.50 
10 T HB 12 K H 4.50 
11 G H 9 A H 4.50 
12 K HA 13 F QD 4.50 
12 K HB1 13 F H 4.50 
13 F HA 6 Y QD 4.50 
13 F HB1 4 W QB 4.50 
13 F HB1 14 A H 4.50 
13 F HB2 14 A H 4.50 
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Residue Proton Residue Proton Distance 
13 F QD 4 W QB 4.50 
14 A HA 15 V QXG1 4.50 
15 V HA 4 W HA 4.50 
15 V HA 5 A H 4.50 
15 V HB 16 T H 4.50 
15 V QXG1 16 T H 4.50 
15 V QXG2 2 G HA1 4.50 
16 T H 15 V QXG1 4.50 
16 T H 15 V QXG2 4.50 
16 T QXGT 17 E H 4.50 
17 E H 16 T QXGT 4.50 
6 Y QD 13 F QD 5.50 
9 A QXB 10 T HA 5.50 
13 F QD 6 Y QD 5.50 
15 V QXG1 4 W QB 5.50 
15 V QXG2 16 T H 5.50 
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Table 38. NOE Distance restraints for peptide 23b. 
Residue Proton Residue Proton Distance 
4 W HA 5 BY H 2.70 
4 W HA 13 V HA 2.70 
5 BY H 4 W HA 2.70 
5 BY HA 6 N H 2.70 
6 N H 5 BY HA 2.70 
11 K HA 12 BF H 2.70 
12 BF H 11 K HA 2.70 
12 BF HA2 13 V H 2.70 
13 V H 12 BF HA2 2.70 
13 V HA 14 T H 2.70 
14 T H 13 V HA 2.70 
14 T HA 15 E H 2.70 
15 E HA 16 C H 2.70 
16 C H 15 E HA 2.70 
1 C HA 2 G H 3.50 
2 G H 1 C HA 3.50 
2 G H 1 C HB1 3.50 
2 G HA1 3 E H 3.50 
3 E H 2 G H 3.50 
3 E H 2 G HA1 3.50 
3 E H 2 G HA2 3.50 
4 W H 5 BY H 3.50 
5 BY H 13 V HA 3.50 
5 BY HG1 4 W QB 3.50 
6 N HA 7 P QD 3.50 
6 N HB2 11 K H 3.50 
8 A H 7 P HA 3.50 
8 A H 9 T H 3.50 
8 A HA 9 T H 3.50 
9 T H 7 P HA 3.50 
9 T H 8 A H 3.50 
9 T H 8 A HA 3.50 
9 T H 10 G H 3.50 
9 T HA 10 G H 3.50 
9 T QXGT 11 K HA 3.50 
10 G H 9 T H 3.50 
10 G H 9 T HA 3.50 
10 G H 11 K H 3.50 
10 G HA2 11 K H 3.50 
11 K H 10 G H 3.50 
11 K H 10 G HA1 3.50 
12 BF HA1 5 BY H 3.50 
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Residue Proton Residue Proton Distance 
12 BF HA1 13 V H 3.50 
13 V HA 5 BY H 3.50 
13 V HB 14 T H 3.50 
14 T H 13 V HB 3.50 
15 E HB2 16 C H 3.50 
1 C H 2 G H 4.50 
2 G H 1 C H 4.50 
2 G H 1 C HB2 4.50 
2 G HA2 3 E H 4.50 
3 E H 4 W H 4.50 
3 E H 14 T H 4.50 
3 E HB1 4 W H 4.50 
4 W H 3 E H 4.50 
4 W HA 13 V QXG1 4.50 
4 W HA 13 V QXG2 4.50 
4 W HE3 14 T H 4.50 
4 W HE3 5 BY H 4.50 
4 W HE3 12 BF QE 4.50 
4 W QB 13 V QXG2 4.50 
5 BY H 5 BY H 4.50 
5 BY H 4 W HE3 4.50 
5 BY HA 4 W QB 4.50 
5 BY HB1 12 BF QE 4.50 
6 N H 6 N H 4.50 
6 N H 5 BY HB1 4.50 
6 N HA 5 BY HB2 4.50 
6 N HB2 8 A H 4.50 
6 N HB2 9 T H 4.50 
7 P QD 12 BF QE 4.50 
8 A QXB 8 A H 4.50 
9 T H 9 T H 4.50 
9 T QXGT 8 A QXB 4.50 
9 T QXGT 10 G H 4.50 
10 G HA1 11 K H 4.50 
11 K HA 11 K H 4.50 
12 BF HA1 12 BF QE 4.50 
12 BF HA1 4 W HE3 4.50 
12 BF HA1 4 W HE3 4.50 
12 BF HA2 4 W HZ3 4.50 
12 BF HB 4 W HE3 4.50 
12 BF HG1 5 BY HA 4.50 
12 BF HG2 13 V H 4.50 
13 V H 4 W HZ3 4.50 
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Residue Proton Residue Proton Distance 
13 V H 12 BF HG2 4.50 
13 V HA 14 T H 4.50 
13 V HB 4 W HE3 4.50 
13 V QXG1 4 W HE3 4.50 
13 V QXG1 4 W HA 4.50 
13 V QXG1 4 W HE3 4.50 
13 V QXG2 14 T H 4.50 
13 V QXG2 4 W HA 4.50 
14 T H 4 W HE3 4.50 
14 T H 4 W HE3 4.50 
14 T H 13 V H 4.50 
14 T H 13 V QXG1 4.50 
15 E H 15 E H 4.50 
15 E H 14 T H 4.50 
15 E HA 14 T QXGT 4.50 
15 E HB1 2 G H 4.50 
1 C HB1 16 C H 4.50 
1 C HB2 2 G H 5.50 
4 W HH2 2 G H 5.50 
8 A QXB 13 V QXG2 5.50 
8 A QXB 9 T HA 5.50 
9 T QXGT 12 BF QE 5.50 
12 BF HA2 12 BF QE 5.50 
12 BF HG2 4 W HE3 5.50 
12 BF HG2 13 V H 5.50 
12 BF HG2 13 V QXG1 5.50 
12 BF QE 13 V QXG2 5.50 
12 BF QE 4 W HE3 5.50 
13 V QXG1 2 G H 5.50 
13 V QXG1 3 E H 5.50 
13 V QXG1 15 E H 5.50 
13 V QXG2 4 W HZ2 5.50 
13 V QXG2 5 BY H 5.50 
13 V QXG2 12 BF QE 5.50 
13 V QXG2 14 T H 5.50 
14 T H 13 V QXG2 5.50 
14 T QXGT 2 G H 5.50 
14 T QXGT 15 E H 5.50 
15 E QG 16 C H 5.50 
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Table 39. NOE Distance restraints for peptide 24b. 
Residue Proton Residue Proton Distance 
3 E HA 4 W H 2.70 
4 W H 3 E HA 2.70 
4 W HA 5 BAY H 2.70 
5 BAY HA 6 N H 2.70 
6 N H 5 BAY HA 2.70 
11 K HA 12 BFA H 2.70 
12 BFA H 11 K HA 2.70 
12 BFA HA 13 V H 2.70 
13 V H 12 BFA HA 2.70 
13 V HA 14 T H 2.70 
15 E HA 16 C H 2.70 
1 C HA 2 G H 3.50 
2 G HA1 3 E H 3.50 
2 G HA1 16 C H 3.50 
2 G HA2 3 E H 3.50 
3 E H 2 G HA1 3.50 
3 E H 2 G HA2 3.50 
3 E HB2 4 W H 3.50 
4 W HA 3 E H 3.50 
4 W HA 14 T H 3.50 
4 W QB 14 T H 3.50 
5 BAY HA 12 BFA HB 3.50 
5 BAY QE 4 W HE1 3.50 
5 BAY QE 7 P HA 3.50 
7 P HA 8 A H 3.50 
7 P HG2 8 A H 3.50 
8 A H 9 T H 3.50 
9 T H 8 A H 3.50 
9 T H 10 G H 3.50 
10 G H 9 T H 3.50 
10 G H 9 T HA 3.50 
10 G H 11 K H 3.50 
10 G HA1 11 K H 3.50 
10 G HA2 11 K H 3.50 
11 K H 12 BFA H 3.50 
11 K HB1 12 BFA H 3.50 
12 BFA HB 6 N H 3.50 
12 BFA QXG 13 V H 3.50 
13 V H 12 BFA QXG 3.50 
14 T HA 15 E H 3.50 
15 E H 14 T HA 3.50 
15 E QG 2 G HA2 3.50 
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Residue Proton Residue Proton Distance 
1 C H 2 G H 4.50 
2 G H 1 C H 4.50 
2 G H 3 E H 4.50 
3 E H 2 G H 4.50 
3 E H 4 W H 4.50 
3 E H 14 T H 4.50 
3 E HB1 4 W H 4.50 
4 W H 3 E H 4.50 
4 W H 5 BAY H 4.50 
5 BAY H 4 W H 4.50 
5 BAY H 13 V HA 4.50 
5 BAY HG1 4 W HD1 4.50 
5 BAY QE 4 W HZ2 4.50 
5 BAY QE 6 N H 4.50 
5 BAY QE 12 BFA HD2 4.50 
5 BAY QE 12 BFA QH 4.50 
5 BAY QE 12 BFA QZ 4.50 
5 BAY QXI 6 N H 4.50 
6 N H 5 BAY QXI 4.50 
7 P QD 8 A H 4.50 
8 A HA 9 T H 4.50 
8 A QXB 9 T H 4.50 
9 T H 8 A HA 4.50 
11 K H 10 G H 4.50 
11 K HB2 12 BFA H 4.50 
12 BFA H 11 K HB1 4.50 
12 BFA HB 5 BAY H 4.50 
13 V H 14 T QXGT 4.50 
13 V HA 5 BAY H 4.50 
13 V QQXG 12 BFA HD2 4.50 
13 V QQXG 14 T H 4.50 
14 T H 3 E H 4.50 
14 T HB 15 E H 4.50 
14 T QXGT 15 E H 4.50 
15 E H 14 T H 4.50 
15 E H 14 T HB 4.50 
16 C H 1 C H 4.50 
11 K H 6 N H 5.50 
12 BFA HB 5 BAY HA 5.50 
12 BFA QZ 5 BAY QZ 5.50 
13 V QQXG 4 W HD1 5.50 
13 V QQXG 12 BFA QZ 5.50 
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Table 40. NOE Distance Restraints for Peptide 73. 
Residue Proton Residue Proton Distance 
2 E HA 2 E HB1 2.7 
2 E HA 3 W H 2.7 
3 W H 2 E HA 2.7 
5 Y HA 6 N H 2.7 
5 Y HA 12 F HA 2.7 
6 N H 5 Y HA 2.7 
6 N HA 7 P QD 2.7 
7 P HB1 8 A H 2.7 
8 A H 7 P HB1 2.7 
8 A H 9 T H 2.7 
8 A H 9 T HB 2.7 
9 T H 8 A H 2.7 
9 T H 10 G H 2.7 
9 T HB 8 A H 2.7 
10 G H 9 T H 2.7 
10 G H 11 K H 2.7 
11 K H 10 G H 2.7 
12 F HA 5 Y HA 2.7 
12 F HA 13 X H 2.7 
13 X H 12 F HA 2.7 
14 V HA 15 T H 2.7 
15 T H 14 V HA 2.7 
15 T HA 16 E H 2.7 
16 E H 15 T HA 2.7 
1 G HA1 2 E H 3.5 
1 G HA2 2 E H 3.5 
2 E H 1 G HA1 3.5 
2 E H 1 G HA2 3.5 
2 E HB1 3 W H 3.5 
2 E HB2 3 W H 3.5 
3 W H 2 E HB1 3.5 
3 W H 2 E HB2 3.5 
3 W H 3 W HA 3.5 
3 W HA 4 X H 3.5 
3 W HA 14 V HA 3.5 
3 W HB1 4 X H 3.5 
3 W HB2 4 X H 3.5 
4 X H 3 W HA 3.5 
4 X H 3 W HB1 3.5 
4 X H 3 W HB2 3.5 
5 Y H 12 F HB1 3.5 
5 Y HA 13 X H 3.5 
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Residue Proton  Residue Proton Distance 
5 Y HB2 6 N H 3.5 
5 Y QD 7 P HB1 3.5 
5 Y QD 12 F HB2 3.5 
5 Y QE 7 P HA 3.5 
5 Y QE 7 P HB1 3.5 
5 Y QE 7 P HB2 3.5 
6 N H 11 K H 3.5 
6 N H 12 F HA 3.5 
6 N HA 8 A H 3.5 
6 N HB2 9 T H 3.5 
6 N HB2 10 G H 3.5 
6 N HB2 11 K H 3.5 
7 P HA 5 Y QE 3.5 
7 P HA 8 A H 3.5 
7 P HB1 5 Y QD 3.5 
7 P HB1 5 Y QE 3.5 
7 P HB2 5 Y QE 3.5 
7 P QD 8 A H 3.5 
8 A H 7 P HA 3.5 
8 A H 7 P QD 3.5 
8 A QXB 7 P HB1 3.5 
8 A QXB 9 T H 3.5 
9 T H 8 A QXB 3.5 
9 T H 10 G HA1 3.5 
9 T HA 10 G H 3.5 
9 T HB 11 K H 3.5 
10 G H 9 T HA 3.5 
10 G HA1 5 Y QD 3.5 
10 G HA1 5 Y QE 3.5 
10 G HA1 9 T H 3.5 
10 G HA1 11 K H 3.5 
10 G HA2 5 Y QE 3.5 
10 G HA2 11 K H 3.5 
11 K H 6 N H 3.5 
11 K H 9 T HA 3.5 
11 K H 10 G HA1 3.5 
11 K H 10 G HA2 3.5 
11 K HA 12 F H 3.5 
11 K QB 12 F H 3.5 
11 K QD 12 F H 3.5 
12 F H 11 K HA 3.5 
12 F H 11 K QB 3.5 
12 F H 11 K QD 3.5 
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Residue Proton Residue Proton Distance 
12 F HA 5 Y QD 3.5 
12 F HA 6 N H 3.5 
12 F HB1 13 X H 3.5 
12 F HB2 5 Y QD 3.5 
12 F HB2 13 X H 3.5 
12 F QD 5 Y HB1 3.5 
12 F QD 13 X H 3.5 
13 X H 5 Y HA 3.5 
13 X H 12 F HB1 3.5 
13 X H 12 F HB2 3.5 
14 V HA 3 W HA 3.5 
14 V HA 15 T QXGT 3.5 
14 V QQXG 15 T H 3.5 
15 T H 2 E H 3.5 
2 E HA 3 W HD1 4.5 
2 E QG 3 W H 4.5 
3 W H 4 X H 4.5 
3 W HA 14 V QQXG 4.5 
3 W HA 15 T H 4.5 
3 W HD1 4 X H 4.5 
4 X H 3 W H 4.5 
4 X H 14 V HA 4.5 
4 X H 15 T H 4.5 
5 Y HB1 6 N H 4.5 
5 Y QD 6 N H 4.5 
5 Y QD 7 P HA 4.5 
5 Y QD 7 P HB2 4.5 
5 Y QD 13 X H 4.5 
5 Y QE 6 N H 4.5 
5 Y QE 10 G H 4.5 
6 N H 5 Y HB1 4.5 
6 N H 5 Y QD 4.5 
6 N H 13 X H 4.5 
6 N HA 8 A QXB 4.5 
6 N HB2 8 A H 4.5 
6 N HB2 9 T QXGT 4.5 
7 P HA 5 Y QD 4.5 
7 P HA 9 T H 4.5 
7 P HA 9 T QXGT 4.5 
7 P HB2 5 Y QD 4.5 
7 P HB2 8 A H 4.5 
7 P QD 6 N H 4.5 
8 A H 9 T HA 4.5 
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Residue Proton Residue Proton Distance 
8 A H 9 T QXGT 4.5 
8 A H 10 G H 4.5 
8 A QXB 9 T HA 4.5 
8 A QXB 9 T QXGT 4.5 
8 A QXB 10 G H 4.5 
9 T H 7 P HA 4.5 
9 T HA 8 A H 4.5 
9 T HA 8 A QXB 4.5 
9 T HA 10 G HA2 4.5 
9 T QXGT 8 A H 4.5 
9 T QXGT 8 A QXB 4.5 
9 T QXGT 10 G H 4.5 
9 T QXGT 11 K QD 4.5 
10 G H 5 Y QE 4.5 
10 G H 6 N H 4.5 
10 G H 8 A H 4.5 
10 G H 8 A QXB 4.5 
10 G H 9 T QXGT 4.5 
10 G HA2 5 Y QD 4.5 
10 G HA2 9 T H 4.5 
11 K H 9 T QXGT 4.5 
11 K H 12 F H 4.5 
11 K HA 5 Y QE 4.5 
11 K QD 10 G H 4.5 
11 K QG 12 F H 4.5 
12 F H 11 K H 4.5 
12 F H 11 K QG 4.5 
12 F H 13 X H 4.5 
12 F HA 5 Y QE 4.5 
12 F HB2 5 Y QE 4.5 
13 X H 12 F H 4.5 
14 V HA 3 W HD1 4.5 
14 V HA 4 X H 4.5 
15 T H 3 W HA 4.5 
1 G HA1 14 V QQXG 5.5 
1 G HA2 14 V QQXG 5.5 
7 P HA 8 A QXB 5.5 
8 A QXB 7 P HA 5.5 
11 K HA 10 G H 5.5 
14 V QQXG 1 G HA1 5.5 
14 V QQXG 15 T HA 5.5 
15 T HA 14 V QQXG 5.5 
15 T HA 15 T H 5.5 
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Residue Proton Residue Proton Distance 
15 T HB 14 V QQXG 5.5 
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Table 41. NOE Distance Restraints for Peptide 74. 
Residue Proton Residue Proton Distance 
2 E H 1 G HA2 2.7 
3 W HA 4 X H 2.7 
3 W HA 14 V HA 2.7 
4 X H 3 W HA 2.7 
4 X HA 5 Y H 2.7 
5 Y H 4 X HA 2.7 
5 Y HA 6 N H 2.7 
6 N H 5 Y HA 2.7 
8 A H 9 T H 2.7 
10 G H 9 T H 2.7 
10 G H 11 K H 2.7 
11 K HA 12 F H 2.7 
12 F HA 5 Y HA 2.7 
12 F HA 13 X H 2.7 
13 X H 12 F HA 2.7 
14 V H 13 X HA 2.7 
14 V HA 3 W HA 2.7 
14 V HA 15 T H 2.7 
15 T HA 16 E H 2.7 
1 G HA1 2 E H 3.5 
1 G HA2 2 E H 3.5 
2 E H 1 G HA1 3.5 
2 E H 3 W H 3.5 
2 E H 15 T H 3.5 
2 E HA 3 W H 3.5 
2 E HB1 3 W H 3.5 
2 E HB2 3 W H 3.5 
3 W H 2 E HA 3.5 
3 W H 2 E HB1 3.5 
3 W H 2 E HB2 3.5 
3 W HA 15 T H 3.5 
3 W HE3 14 V H 3.5 
3 W HZ3 13 X HA 3.5 
5 Y H 6 N H 3.5 
5 Y HA 13 X H 3.5 
5 Y HB2 6 N H 3.5 
6 N H 12 F HA 3.5 
7 P HA 8 A H 3.5 
7 P HG2 8 A H 3.5 
7 P QD 8 A H 3.5 
8 A H 7 P HA 3.5 
8 A H 7 P HG2 3.5 
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Residue Proton Residue Proton Distance 
8 A H 7 P QD 3.5 
8 A H 10 G H 3.5 
8 A HA 9 T H 3.5 
9 T H 8 A H 3.5 
9 T H 10 G H 3.5 
9 T HB 11 K HG1 3.5 
10 G H 8 A H 3.5 
10 G H 9 T HA 3.5 
10 G HA1 11 K H 3.5 
10 G HA2 9 T H 3.5 
10 G HA2 11 K H 3.5 
11 K H 6 N HB2 3.5 
11 K H 10 G H 3.5 
11 K H 10 G HA1 3.5 
11 K HG2 12 F H 3.5 
12 F HA 6 N H 3.5 
12 F HB1 3 W HE1 3.5 
12 F HB1 5 Y HA 3.5 
13 X H 6 N H 3.5 
13 X H 12 F HB1 3.5 
13 X HA 5 Y QE 3.5 
13 X HA 14 V H 3.5 
14 V HA 4 X H 3.5 
14 V HB 15 T H 3.5 
14 V QXG2 3 W HE3 3.5 
14 V QXG2 13 X H 3.5 
14 V QXG2 13 X HG 3.5 
15 T H 2 E H 3.5 
15 T HB 16 E H 3.5 
16 E H 15 T HB 3.5 
2 E QG 3 W H 4.5 
3 W HA 14 V H 4.5 
3 W HD1 14 V H 4.5 
3 W HD1 14 V QXG2 4.5 
3 W HE3 14 V QXG1 4.5 
3 W HZ3 14 V H 4.5 
3 W HZ3 14 V QXG2 4.5 
4 X H 15 T H 4.5 
4 X HA 12 F QE 4.5 
4 X HG 3 W HD1 4.5 
4 X HG 5 Y H 4.5 
5 Y H 4 X HG 4.5 
5 Y HB2 12 F HA 4.5 
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Residue Proton Residue Proton Distance 
5 Y HB2 12 F QE 4.5 
5 Y QD 6 N H 4.5 
5 Y QD 10 G H 4.5 
5 Y QD 12 F H 4.5 
5 Y QE 6 N H 4.5 
5 Y QE 12 F H 4.5 
5 Y QE 12 F HA 4.5 
6 N H 5 Y HB2 4.5 
6 N H 11 K H 4.5 
6 N HB2 8 A H 4.5 
6 N HB2 9 T H 4.5 
6 N HB2 10 G H 4.5 
6 N HB2 11 K H 4.5 
7 P HG1 8 A H 4.5 
7 P QB 8 A H 4.5 
7 P QB 10 G H 4.5 
7 P QD 6 N H 4.5 
8 A H 7 P HG1 4.5 
8 A QXB 9 T H 4.5 
9 T H 6 N H 4.5 
9 T H 6 N HB2 4.5 
9 T H 7 P QD 4.5 
9 T H 8 A QXB 4.5 
9 T HA 10 G H 4.5 
9 T HB 11 K HD1 4.5 
9 T HB 11 K QB 4.5 
9 T QXGT 8 A H 4.5 
9 T QXGT 10 G H 4.5 
10 G H 6 N HB2 4.5 
10 G HA1 9 T H 4.5 
11 K H 6 N H 4.5 
11 K H 6 N HB1 4.5 
11 K HD1 12 F H 4.5 
11 K HG1 12 F H 4.5 
11 K QB 12 F H 4.5 
12 F H 11 K HG1 4.5 
12 F H 11 K QB 4.5 
12 F HA 5 Y HB2 4.5 
12 F HB1 13 X H 4.5 
12 F QE 4 X HA 4.5 
12 F QE 5 Y HB2 4.5 
13 X H 5 Y HA 4.5 
13 X HA 3 W HZ2 4.5 
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Residue Proton Residue Proton Distance 
13 X HA 5 Y QD 4.5 
13 X HG 14 V H 4.5 
14 V HA 2 E H 4.5 
14 V HA 3 W HE3 4.5 
14 V HB 3 W HE3 4.5 
14 V QXG1 1 G HA2 4.5 
14 V QXG1 2 E H 4.5 
14 V QXG1 3 W HE3 4.5 
14 V QXG1 15 T H 4.5 
14 V QXG2 3 W HD1 4.5 
14 V QXG2 3 W HZ3 4.5 
14 V QXG2 15 T H 4.5 
15 T H 4 X H 4.5 
15 T H 14 V HB 4.5 
15 T H 14 V QXG1 4.5 
15 T H 14 V QXG2 4.5 
15 T HB 2 E H 4.5 
15 T QXGT 16 E H 4.5 
16 E H 15 T QXGT 4.5 
3 W HE3 14 V HB 5.5 
5 Y HB1 12 F HA 5.5 
6 N H 5 Y HB1 5.5 
6 N H 10 G H 5.5 
8 A QXB 7 P QD 5.5 
8 A QXB 9 T HA 5.5 
8 A QXB 10 G H 5.5 
9 T HA 8 A QXB 5.5 
12 F QE 5 Y HB1 5.5 
14 V QXG1 3 W H 5.5 
14 V QXG2 3 W H 5.5 
15 T QXGT 2 E H 5.5 
15 T QXGT 16 E HE2 5.5 
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Table 42. NOE Distance Restraints for Peptide 76. 
Residue Proton Residue Proton Distance 
1 C HA 2 G H 2.70 
3 E HA 4 W H 2.70 
3 E HB1 3 E H 2.70 
4 W H 3 E HA 2.70 
5 γ4 HA 6 Y H 2.70 
6 Y H 5 γ4 HA 2.70 
6 Y HA 7 N H 2.70 
7 N H 6 Y HA 2.70 
7 N HA 8 P QD 2.70 
10 T H 11 G H 2.70 
11 G H 10 T H 2.70 
14 γ4 HA 15 V H 2.70 
15 V H 14 γ4 HA 2.70 
15 V HA 15 T H 2.70 
16 T H 15 V HA 2.70 
16 T HA 17 E H 2.70 
17 E H 16 T HA 2.70 
2 G H 3 E H 3.50 
2 G HA1 3 E H 3.50 
2 G HA2 3 E H 3.50 
3 E H 2 G H 3.50 
3 E H 2 G HA1 3.50 
3 E H 2 G HA2 3.50 
3 E HB2 4 W H 3.50 
4 W H 5 γ4 H 3.50 
4 W HA 5 γ4 H 3.50 
4 W HA 15 V HA 3.50 
5 γ4 H 4 W H 3.50 
5 γ4 H 4 W HA 3.50 
5 γ4 HA 13 F QD 3.50 
5 γ4 HB 14 γ4 H 3.50 
6 Y HA 13 F QD 3.50 
6 Y HA 14 γ4 H 3.50 
6 Y HB2 7 N H 3.50 
6 Y QE 7 P HA 3.50 
7 P HA 6 Y QE 3.50 
7 P HA 9 A H 3.50 
7 P QB 6 Y QE 3.50 
7 P QD 9 A H 3.50 
7 P QG 9 A H 3.50 
9 A H 8 P HA 3.50 
9 A H 8 P QD 3.50 
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Residue Proton Residue Proton Distance 
9 A H 10 T H 3.50 
9 A HA 9 A H 3.50 
9 A HA 10 T H 3.50 
10 
 
T H 9 A H 3.50 
10 T H 9 A HA 3.50 
10 T H 9 A QXB 3.50 
10 T HA 6 Y QD 3.50 
10 T QXGT 10 T HA 3.50 
10 T QXGT 10 T HB 3.50 
11 G H 12 K H 3.50 
11 G HA1 12 K H 3.50 
11 G HA2 12 K H 3.50 
12 K H 11 G H 3.50 
12 K QB 13 F H 3.50 
13 F H 12 K QB 3.50 
13 F HA 7 N H 3.50 
13 F HA 14 γ4 H 3.50 
14 γ4 H 5 γ4 HB 3.50 
14 γ4 H 13 F HA 3.50 
14 γ4 H 13 F QB 3.50 
15 V H 14 γ4 HB 3.50 
15 V HB 16 T H 3.50 
16 T H 15 V H 3.50 
16 T H 15 V QXG2 3.50 
16 T H 17 E H 3.50 
17 E H 16 T H 3.50 
17 E H 17 E HA 3.50 
18 C H 17 E HA 3.50 
3 E HB1 4 W H 4.50 
4 W HH2 16 T QXGT 4.50 
4 W HZ3 5 γ4 H 4.50 
4 W QB 5 γ4 H 4.50 
5 γ4 H 15 V HA 4.50 
5 γ4 HA 13 F QE 4.50 
6 Y HB1 7 N H 4.50 
6 Y HB2 13 F QD 4.50 
6 Y HB2 13 F QE 4.50 
6 Y QD 7 N H 4.50 
6 Y QD 8 P QD 4.50 
6 Y QD 13 F QD 4.50 
7 N H 6 Y H 4.50 
7 N H 6 Y QD 4.50 
7 N H 6 Y QE 4.50 
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Residue Proton Residue Proton Distance 
7 N H 12 K H 4.50 
7 N HA 9 A H 4.50 
8 P HA 6 Y QD 4.50 
8 P QB 6 Y QD 4.50 
8 P QG 6 Y QE 4.50 
9 A H 11 G H 4.50 
9 A QXB 10 T H 4.50 
10 T H 12 K H 4.50 
10 T HA 11 G H 4.50 
10 T HB 12 K H 4.50 
10 T QXGT 9 A HA 4.50 
11 G H 10 T HA 4.50 
11 G HA1 6 Y QD 4.50 
11 G HA1 6 Y QE 4.50 
12 K H 7 N H 4.50 
12 K H 10 T H 4.50 
12 K HA 6 Y QD 4.50 
12 K HA 6 Y QE 4.50 
12 K HA 13 F H 4.50 
13 F H 12 K HA 4.50 
13 F H 12 K QD 4.50 
13 F QD 6 Y QD 4.50 
13 F QD 14 γ4 H 4.50 
14 γ4 QXD 5 γ4 HB 4.50 
15 V H 14 γ4 QXD 4.50 
15 V HA 5 γ4 H 4.50 
15 V QXG1 4 W HZ3 4.50 
15 V QXG2 2 G HA1 4.50 
15 V QXG2 2 G HA2 4.50 
15 V QXG2 16 T H 4.50 
16 T H 3 E H 4.50 
16 T H 15 V QXG1 4.50 
16 T QXGT 15 V H 4.50 
16 T QXGT 17 E H 4.50 
5 γ4 QXD 6 Y H 5.50 
8 P QD 6 Y QD 5.50 
14 γ4 HB 5 γ4 H 5.50 
15 V QXG1 16 T H 5.50 
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CNS SOFTWARE PATCHES FOR UNNATURAL RESIDUES 
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Parameters for B3F   
 
 ANGLe    CH2E CH1E CH2E    500.00 {sd= 0.031}–-     109.5000 
 
 IMPRoper HA   NH1  CH2E CH2E     500.00 {sd= 0.031}    0      70.0000 
!--------------------------------------------------------------------- 
 
Parameters for B3V and beta linkages 
 
 ANGLe     CH2E C    NH1      500.00 {sd= 0.031}     116.1998 
 
 IMPRoper  HA   HA   C    CH1E     500.00 {sd= 0.031}     0      -70.0000  
 IMPRoper  HA   NH1  CH2E CH1E     500.00 {sd= 0.031}     0       70.0000  
 IMPRoper  CH1E NH1  C    CH2E     500.00 {sd= 0.031}     0      180.0000  
 IMPRoper  C    CH2E NH1  O        500.00 {sd= 0.031}     0        0.0000  
 IMPRoper  NH1  C    CH2E H        500.00 {sd= 0.031}     0        0.0000  
!--------------------------------------------------------------------- 
 
Parameters for B2Y   
 
 ANGLe    CH1E CH2E NH1     500.00 {sd= 0.031}     111.4875 
 
 DIHEdral CH2E CH1E CH2E CY   2.00   3    0.0000 
 
 IMPRoper HA   CH2E C    CH2E         500.00 {sd= 0.031}   0   65.9907 
 IMPRoper CH2E NH1  C    CH1E      500.00 {sd= 0.031}   0  180.0000  
!--------------------------------------------------------------------- 
 
Parameters for BAY  
 
 IMPRoper  HA   NH1  CH1E CH3E      500.00 {sd= 0.031}   0   70.0000  
 IMPRoper  HA   CH2E C    CH1E      500.00 {sd= 0.031}   0  -70.0000  
!-------------------------------------------------------------------- 
 
Parameters for BFA 
 
 IMPRoper  HA    NH1  CH1E CH2E      500.00 {sd= 0.031}    0    70.0000  
!-------------------------------------------------------------------- 
 
Parameters for BVA 
 
 ANGLe     CH1E CH1E CH1E     500.00 {sd= 0.031}     109.5000 
 
 IMPRoper  HA   CH3E C    CH1E      500.00 {sd= 0.031}    0   -70.0000  
 IMPRoper  HA   NH1  CH1E CH1E      500.00 {sd= 0.031}    0    70.0000  
 IMPRoper  HA   C    CH3E CH1E      500.00 {sd= 0.031}    0   -70.0000  
 IMPRoper  HA   CH1E NH1  CH1E      500.00 {sd= 0.031}    0    70.0000  
!-------------------------------------------------------------------- 
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Parameters for ACC and Linkages 
 BOND  CC1E NH1   1000.000 {sd= 0.001}       1.458 
 BOND  CC1E CC2E   1000.000 {sd= 0.001}       1.530 
 BOND  CC2E CC2E      1000.000 {sd= 0.001}       1.520 
 BOND  CC2E HAA        1000.000 {sd= 0.001}       1.080 
 BOND  CC2E HAE        1000.000 {sd= 0.001}       1.080 
 BOND  CC1E HAA        1000.000 {sd= 0.001}       1.080 
 BOND  C    CC1E      1000.000 {sd= 0.001}       1.525 
 
 ANGLe  H    NH1  CC1E   500.00  {sd= 0.031}       125.5 
 ANGLe  NH1  CC1E HAA     500.00  {sd= 0.031}       107.0 
 ANGLe  NH1  CC1E CC2E    500.00 {sd=  0.031}       110.0 
 ANGLe  HAA  CC1E CC2E    500.00 {sd=  0.031}      109.4 
 ANGLe  CC1E CC2E CC1E    500.00 {sd=  0.031}       111.0 
 ANGLe  CC1E CC2E CC2E    500.00 {sd=  0.031}     111.0 
 ANGLe  CC2E CC2E CC2E    500.00 {sd=  0.031}      111.0 
 ANGLe  CC1E CC2E HAA    500.00 {sd=  0.031}      109.4 
 ANGLe  CC2E CC2E HAA      500.00 {sd=  0.031}     109.4 
 ANGLe  CC1E CC2E HAE     500.00 {sd=  0.031}     111.0 
 ANGLe  CC2E CC2E HAE   500.00 {sd=  0.031}    111.0 
 ANGLe  CC2E CC1E CC2E     500.00 {sd=  0.031}     111.0 
 ANGLe  CC2E CC1E C     500.00 {sd=  0.031}     110.0 
 ANGLe  HAA  CC2E HAE     500.00 {sd=  0.031}     107.0 
 ANGLe  HAA  CC1E C     500.00 {sd=  0.031}     107.0 
 ANGLe  CC1E C    O    500.00 {sd=  0.031}     123.9 
 ANGLe  C    NH1  CC1E     500.00 {sd=  0.031}     120 
 ANGLe  CC1E C    NH1     500.00 {sd=  0.031}     120 
 
 
 NONBonded  CC1E      0.0903   3.2072        0.0903   3.2072 
 NONBonded  CC2E      0.0903   3.2072        0.0903   3.2072 
 NONBonded  HAA        0.0045   2.6157        0.0045   2.6157 
 NONBonded  HAE        0.0045   2.6157        0.0045   2.6157 
 
 IMPRoper  NH1  CC1E CC2E CC1E     500.00 {sd=  0.031}    0     180 
 IMPRoper  C    CC1E CC2E CC1E    500.00 {sd=  0.031}    0     180 
 IMPRoper  HAA  CC1E CC2E HAA     500.00 {sd=  0.031}    0     180 
 IMPRoper  HAA  CC2E CC2E HAA     500.00 {sd=  0.031}    0     180 
 IMPRoper  O    C    NH1  H      500.00 {sd=  0.031}    0     180 
 IMPRoper  CC1E C    NH1  CH1E         500.00 {sd=  0.031}    0     180 
 IMPRoper  CH1E C    NH1  CC1E       500.00 {sd=  0.031}    0     180 
 IMPRoper  O    C    NH1  CH1E         500.00 {sd=  0.031}    0     0 
!--------------------------------------------------------------------- 
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Parameters for G4A 
 BOND   CH1E  CD1E   1000.000 {sd=     0.001}      1.516 
 BOND   CD1E  CD1E   1000.000 {sd=     0.001}      1.34 
 BOND   CD1E  C      1000.000 {sd=     0.001}      1.516 
 BOND   CD1E  HA     1000.000 {sd=     0.001}      1.080 
 
 ANGLe  NH1   CH1E  CD1E     500.00 {sd= 0.031}      109.5000 
 ANGLe  HA    CH1E  CD1E     500.00 {sd= 0.031}      109.5000 
 ANGLe  CD1E  CH1E  CH3E     500.00 {sd= 0.031}      109.5000 
 ANGLe  CH1E  CD1E  CD1E     500.00 {sd= 0.031}      120.0000 
 ANGLe  CH1E  CD1E  HA       500.00 {sd= 0.031}      120.0000 
 ANGLe  CD1E  CD1E  HA       500.00 {sd= 0.031}     120.0000 
 ANGLe  CD1E  CD1E  C        500.00 {sd= 0.031}      120.0000 
 ANGLe  C     CD1E  HA       500.00 {sd= 0.031}      120.000 
 ANGLe  CD1E  C     O        500.00 {sd= 0.031}      120.000 
 ANGLe  CD1E  C     NH1      500.00 {sd= 0.031}      120.000 
 
 IMPRoper  HA   CD1E C    CH1E     500.00 {sd= 0.031}    0    0 
 IMPRoper  C    CD1E NH1  O          500.00 {sd= 0.031}    0    0 
 IMPRoper  CD1E C    NH1  CH1E          500.00 {sd= 0.031}    0    180 
 IMPRoper  HA   NH1  CH3E CD1E      500.00 {sd= 0.031}    0    70.0000 
!--------------------------------------------------------------------- 
 
Parameters for MABA 
 
 BOND  NH1 CF       1000.000 {sd= 0.001}       1.373 
 BOND  CF C        1000.000 {sd= 0.001}       1.373 
 
 ANGLe  H NH1 CF       500.00 {sd= 0.031}      119.9118 
 ANGLe  NH1 CF CR1E      500.00 {sd= 0.031}      119.9118 
 ANGLe  CR1E CF C       500.00 {sd= 0.031}      119.9118 
 ANGLe  CF CR1E CF      500.00 {sd= 0.031}      119.9118 
 ANGLe  C CF CR1E       500.00 {sd= 0.031}      119.9118 
 ANGLe  CF C O       500.00 {sd= 0.031}      119.9118 
 ANGLe  C NH1 CF       500.00 {sd= 0.031}      119.9118 
 ANGLe  CF C NH1       500.00 {sd= 0.031}      119.9118 
 
 IMPRoper  CF   CR1E CF   CR1E     500.00 {sd= 0.031}    0    0.0000  
 IMPRoper  CR1E CF   CR1E CF     500.00 {sd= 0.031}    0    0.0000  
 IMPRoper  NH1  C    CF   H     500.00 {sd= 0.031}    0    0.0000  
 IMPRoper  CH2G C    NH1  CF     500.00 {sd= 0.031}    0    0.0000  
 IMPRoper  C    CF   NH1  O     500.00 {sd= 0.031}    0    0.0000  
!--------------------------------------------------------------------- 
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Topologies 
 
residue ACC 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CRA  type=CC1E   charge= 0.000 end 
    atom HA   type=HAA    charge= 0.000 end 
    atom CRB  type=CC2E   charge= 0.000 end 
    atom HB1  type=HAA    charge= 0.000 end 
    atom HB2  type=HAE    charge= 0.000 end 
    atom CRG  type=CC1E   charge= 0.000 end 
    atom HG   type=HAA    charge= 0.000 end 
    atom CRD  type=CC2E   charge= 0.000 end 
    atom HD1  type=HAA    charge= 0.000 end 
    atom HD2  type=HAE    charge= 0.000 end 
    atom CRE  type=CC2E   charge= 0.000 end 
    atom HE1  type=HAA    charge= 0.000 end 
    atom HE2  type=HAE    charge= 0.000 end 
    atom CRZ  type=CC2E   charge= 0.000 end 
    atom HZ1  type=HAA    charge= 0.000 end 
    atom HZ2  type=HAE    charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CRG     bond CRG  HG      bond CRG  CRB     
  bond CRB CRA     bond CRB  HB1     bond CRB  HB2 
  bond CRA CRZ     bond CRA  HA 
  bond CRZ CRE     bond CRZ  HZ1     bond CRZ  HZ2 
  bond CRE CRD     bond CRE  HE1     bond CRE  HE2 
  bond CRD CRG     bond CRD  HD1     bond CRD  HD2       
  bond CRA C       
  bond C   O 
 
improper N CRG CRB CRA 
improper C CRA CRB CRG 
 
!Ring Impropers 
improper HG  CRG CRB HB1 
improper HB1 CRB CRA HA 
improper HA  CRA CRZ HZ1 
improper HZ1 CRZ CRE HE1 
improper HE1 CRE CRD HD1 
improper HD1 CRD CRG HG 
 
  DONO HN   N 
  ACCE O    C 
 
End 
!---------------------------------------------------------------------  
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residue B3F 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH2E   charge= 0.000 end 
    atom HA1  type=HA     charge= 0.000 end 
    atom HA2  type=HA     charge= 0.000 end 
    atom CB   type=CH1E   charge= 0.000 end 
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH2E   charge= 0.000 end 
    atom HG1  type=HA     charge= 0.000 end 
    atom HG2  type=HA     charge= 0.000 end 
    atom CD   type=CF     charge= 0.000 exclude=(CH)  end 
    atom CE1  type=CR1E   charge= 0.000 exclude=(CZ2) end 
    atom HE1  type=HA     charge= 0.000 end 
    atom CE2  type=CR1E   charge= 0.000 exclude=(CZ1) end 
    atom HE2  type=HA     charge= 0.000 end 
    atom CZ1  type=CR1E   charge= 0.000 exclude=(CE2) end 
    atom HZ1  type=HA     charge= 0.000 end 
    atom CZ2  type=CR1E   charge= 0.000 exclude=(CE1) end 
    atom HZ2  type=HA     charge= 0.000 end 
    atom CH   type=CR1E   charge= 0.000 exclude=(CD)  end 
    atom HH   type=HA     charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB 
  bond CB  CG     bond CG  HG1     bond CG  HG2 
  bond CG  CD     
  bond CD  CE1    bond CE1 HE1 
  bond CD  CE2    bond CE2 HE2 
  bond CE1 CZ1    bond CZ1 HZ1      
  bond CZ1 CH 
  bond CZ2 CH 
  bond CE2 CZ2    bond CZ2 HZ2      
  bond CH  HH 
  bond CB  CA     bond CA  HA1     bond CA  HA2 
  bond CA  C       
  bond C   O 
 
  improper HB   N    CA  CG    !chirality CB 
  improper HG1  HG2  CB  CD    !stereo CG 
 
! Hs and CG around the ring 
  improper HE2 CE2 CZ2 CH 
  improper HZ2 CZ2 CH  CZ1 
  improper HH  CH  CZ1 CE1 
  improper HZ1 CZ1 CE1 CD 
  improper HE1 CE1 CD  CE2 
  improper CG  CD  CE2 CZ2 
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! around the ring 
  improper CD  CE1 CZ1 CH  
  improper CE1 CZ1 CH  CZ2 
  improper CZ1 CH  CZ2 CE2 
  improper CH  CZ2 CE2 CD 
  improper CZ2 CE2 CD  CE1 
  improper CE2 CD  CE1 CZ1 
 
  dihedral N   CB  CA  C 
  dihedral CD  CG  CB   N 
  dihedral CE1 CD  CG  CB 
 
  DONO HN   N 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
 
residue B3V 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH2E   charge= 0.000 end 
    atom HA1  type=HA     charge= 0.000 end 
    atom HA2  type=HA     charge= 0.000 end 
    atom CB   type=CH1E   charge= 0.000 end 
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH1E   charge= 0.000 end 
    atom HG   type=HA     charge= 0.000 end 
    atom CD1  type=CH3E   charge= 0.000 end 
    atom HD11 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom HD12 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom HD13 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom CD2  type=CH3E   charge= 0.000 end 
    atom HD21 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom HD22 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom HD23 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB 
  bond CB  CG     bond CG  HG 
  bond CG  CD1    bond CD1 HD11    bond CD1 HD12    bond CD1 HD13 
  bond CG  CD2    bond CD2 HD21    bond CD2 HD22    bond CD2 HD23 
  bond CB  CA     bond CA  HA1     bond CA  HA2 
  bond CA  C       
  bond C   O 
 
  improper HB   N    CA  CG     !chirality CB 
  improper HG   CB   CD1 CD2    !stereo CG 
  improper HA1  HA2  C   CB     !stereo CB 
  improper HD11 HD12 CG  HD13   !methyl CD1 
  improper HD21 HD22 CG  HD23   !methyl CD2 
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  dihedral CD1 CG  CB   N 
  dihedral HD11 CD1 CG  CB   ! UCL methyl stagger 12-MAR-00  
  dihedral HD21 CD2 CG  CB   ! UCL methyl stagger 12-MAR-00  
 
  DONO HN   N 
  ACCE O    C 
end 
!---------------------------------------------------------------------- 
 
residue B2Y 
 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH1E   charge= 0.000 end 
    atom HA   type=HA     charge= 0.000 end 
    atom CB   type=CH2E   charge= 0.000 end 
    atom HB1  type=HA     charge= 0.000 end 
    atom HB2  type=HA     charge= 0.000 end 
    atom CG   type=CH2E   charge= 0.000 end 
    atom HG1  type=HA     charge= 0.000 end 
    atom HG2  type=HA     charge= 0.000 end 
    atom CD   type=CY     charge= 0.000 exclude=(CH)  end 
    atom CE1  type=CR1E   charge= 0.000 exclude=(CZ2) end 
    atom HE1  type=HA     charge= 0.000 end 
    atom CE2  type=CR1E   charge= 0.000 exclude=(CZ1) end 
    atom HE2  type=HA     charge= 0.000 end 
    atom CZ1  type=CR1E   charge= 0.000 exclude=(CE2) end 
    atom HZ1  type=HA     charge= 0.000 end 
    atom CZ2  type=CR1E   charge= 0.000 exclude=(CE1) end 
    atom HZ2  type=HA     charge= 0.000 end 
    atom CH   type=CY2    charge= 0.265 exclude=(CD)  end 
    atom OT   type=OH1    charge=-0.700 end 
    atom HT   type=H      charge= 0.435 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB1     bond CB  HB2 
  bond CB  CA     bond CA  HA       
  bond CA  CG     bond CG  HG1     bond CG  HG2     
  bond CG  CD     
  bond CD  CE1    bond CE1 HE1     bond CE1 CZ1 
  bond CD  CE2    bond CE2 HE2     bond CE2 CZ2 
  bond CZ1 HZ1    bond CZ1 CH 
  bond CZ2 HZ2    bond CZ2 CH 
  bond CH  OT     bond OT  HT 
  bond CA  C       
  bond C   O 
 
! chirality 
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  improper HA  CB  C  CG  !chirality CA 
  improper HG1 HG2 CA CD  !stereo CG 
 
! Hs, OT, and CG around the ring 
  improper HE2 CE2 CZ2 CH 
  improper HZ2 CZ2 CH  CZ1 
  improper OT  CH  CZ1 CE1 
  improper HZ1 CZ1 CE1 CD 
  improper HE1 CE1 CD  CE2 
  improper CG  CD  CE2 CZ2 
 
! around the ring 
  improper CD  CE1 CZ1 CH  
  improper CE1 CZ1 CH  CZ2 
  improper CZ1 CH  CZ2 CE2 
  improper CH  CZ2 CE2 CD 
  improper CZ2 CE2 CD  CE1 
  improper CE2 CD  CE1 CZ1 
 
  dihedral CD  CG  CA  CB 
  dihedral CE1 CD  CG  CA 
  dihedral CZ2 CH  OT  HT   ! UCL Added 12-MAR-00 
 
  DONO HN   N 
  DONO HT   OT 
  ACCE OT  " " 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
 
residue BAY 
 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH1E   charge= 0.000 end 
    atom HA   type=HA     charge= 0.000 end 
    atom CB   type=CH1E   charge= 0.000 end 
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH2E   charge= 0.000 end 
    atom HG1  type=HA     charge= 0.000 end 
    atom HG2  type=HA     charge= 0.000 end 
    atom CD   type=CY     charge= 0.000 exclude=(CH) end 
    atom CE1  type=CR1E   charge= 0.000 exclude=(CZ2) end 
    atom HE1  type=HA     charge= 0.000 end 
    atom CE2  type=CR1E   charge= 0.000 exclude=(CZ1) end 
    atom HE2  type=HA     charge= 0.000 end 
    atom CZ1  type=CR1E   charge= 0.000 exclude=(CE2) end 
    atom HZ1  type=HA     charge= 0.000 end 
    atom CZ2  type=CR1E   charge= 0.000 exclude=(CE1) end 
    atom HZ2  type=HA     charge= 0.000 end 
    atom CH   type=CY2    charge= 0.265 exclude=(CD) end 
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    atom OT   type=OH1    charge=-0.700 end 
    atom HT   type=H      charge= 0.435 end 
    atom CI   type=CH3E   charge= 0.000 end 
    atom HI1  type=HA     charge= 0.000 end 
    atom HI2  type=HA     charge= 0.000 end 
    atom HI3  type=HA     charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB      bond CB  CI 
  bond CB  CA     bond CA  HA       
  bond CA  CG     bond CG  HG1     bond CG  HG2     
  bond CG  CD     
  bond CD  CE1    bond CE1 HE1     bond CE1 CZ1 
  bond CD  CE2    bond CE2 HE2     bond CE2 CZ2 
  bond CZ1 HZ1    bond CZ1 CH 
  bond CZ2 HZ2    bond CZ2 CH 
  bond CH  OT     bond OT  HT 
  bond CI  HI1    bond CI  HI2     bond CI  HI3 
  bond CA  C       
  bond C   O 
 
! Hs, OT, and CG around the ring 
  improper HE2 CE2 CZ2 CH 
  improper HZ2 CZ2 CH  CZ1 
  improper OT  CH  CZ1 CE1 
  improper HZ1 CZ1 CE1 CD 
  improper HE1 CE1 CD  CE2 
  improper CG  CD  CE2 CZ2 
 
! around the ring 
  improper CD  CE1 CZ1 CH  
  improper CE1 CZ1 CH  CZ2 
  improper CZ1 CH  CZ2 CE2 
  improper CH  CZ2 CE2 CD 
  improper CZ2 CE2 CD  CE1 
  improper CE2 CD  CE1 CZ1 
 
  improper HB   N    CA  CI    !chirality CB 
  improper HA   CG   C   CB    !chirality CA 
  improper HI1  HI2  CA  HI3   !methyl CI 
  improper HG1  HG2  CA  CD    !stereo CG 
     
  dihedral  CG  CA  CB  N 
 
  DONO HN   N 
  DONO HT   OT 
  ACCE OT  " " 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
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residue BFA 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH1E   charge= 0.000 end 
    atom HA   type=HA     charge= 0.000 end 
    atom CB   type=CH1E   charge= 0.000 end 
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH3E   charge= 0.000 end 
    atom HG1  type=HA     charge= 0.000 end 
    atom HG2  type=HA     charge= 0.000 end 
    atom HG3  type=HA     charge= 0.000 end 
    atom CD   type=CH2E   charge= 0.000 end 
    atom HD1  type=HA     charge= 0.000 end 
    atom HD2  type=HA     charge= 0.000 end 
    atom CE   type=CF     charge= 0.000 exclude=(CT) end 
    atom CZ1  type=CR1E   charge= 0.000 exclude=(CH2) end 
    atom HZ1  type=HA     charge= 0.000 end 
    atom CZ2  type=CR1E   charge= 0.000 exclude=(CH1) end 
    atom HZ2  type=HA     charge= 0.000 end 
    atom CH1  type=CR1E   charge= 0.000 exclude=(CZ2) end 
    atom HH1  type=HA     charge= 0.000 end 
    atom CH2  type=CR1E   charge= 0.000 exclude=(CZ1) end 
    atom HH2  type=HA     charge= 0.000 end 
    atom CT   type=CR1E   charge= 0.000 exclude=(CE) end 
    atom HT   type=HA     charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB 
  bond CA  CG     bond CG  HG1     bond CG  HG2       bond CG  HG3 
  bond CB  CD     bond CD  HD1     bond CD  HD2       bond CD  CE 
  bond CE  CZ1    bond CZ1 HZ1 
  bond CE  CZ2    bond CZ2 HZ2 
  bond CZ1 CH1    bond CH1 HH1      
  bond CH1 CT 
  bond CH2 CT 
  bond CZ2 CH2    bond CH2 HH2      
  bond CT  HT 
  bond CB  CA     bond CA  HA   
  bond CA  C       
  bond C   O 
 
! Hs and CG around the ring 
  improper HZ2 CZ2 CH2 CT 
  improper HH2 CH2 CT  CH1 
  improper HT  CT  CH1 CZ1 
  improper HH1 CH1 CZ1 CE 
  improper HZ1 CZ1 CE  CZ2 
  improper CD  CE  CZ2 CH2 
 
! around the ring 
192 
  improper CE  CZ1 CH1 CT  
  improper CZ1 CH1 CT  CH2 
  improper CH1 CT  CH2 CZ2 
  improper CT  CH2 CZ2 CE 
  improper CH2 CZ2 CE  CZ1 
  improper CZ2 CE  CZ1 CH1 
 
  improper HB   N    CA  CD    !chirality CB 
  improper HA   CG   C   CB    !chirality CA 
  improper HD1  HD2  CB  CE    !stereo CD 
  improper HG1  HG2  CA  HG3   !methyl CE 
     
  dihedral  CE  CD  CB  N 
 
  DONO HN   N 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
 
residue BVA 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CH1E   charge= 0.000 end 
    atom HA   type=HA     charge= 0.000 end 
    atom CB   type=CH1E   charge= 0.000 end 
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH1E   charge= 0.000 end 
    atom HG   type=HA     charge= 0.000 end 
    atom CD1  type=CH3E   charge= 0.000 end 
    atom HD11 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom HD12 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom HD13 type=HA     charge= 0.000 excl = (HD21 HD22 HD23 HG) end 
    atom CD2  type=CH3E   charge= 0.000 end 
    atom HD21 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom HD22 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom HD23 type=HA     charge= 0.000 excl = (HD11 HD12 HD13 HG) end 
    atom CE   type=CH3E   charge= 0.000 end 
    atom HE1  type=HA     charge= 0.000 end 
    atom HE2  type=HA     charge= 0.000 end 
    atom HE3  type=HA     charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
  bond N   HN 
  bond N   CB     bond CB  HB 
  bond CB  CG     bond CG  HG 
  bond CG  CD1    bond CD1 HD11    bond CD1 HD12    bond CD1 HD13 
  bond CG  CD2    bond CD2 HD21    bond CD2 HD22    bond CD2 HD23 
  bond CB  CA     bond CA  HA 
  bond CA  CE     bond CE  HE1     bond CE  HE2     bond CE  HE3     
  bond CA  C       
  bond C   O 
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  improper HB   N    CA  CG    !chirality CB 
  improper HA   CE   C   CB    !chirality CA 
  improper HG   CB   CD1 CD2   !stereo CG 
  improper HD11 HD12 CG  HD13  !methyl CD1 
  improper HD21 HD22 CG  HD23  !methyl CD2 
  improper HE1  HE2  CA  HE3   !methyl CE 
     
  dihedral CD1 CG  CB   N 
  dihedral HD11 CD1 CG  CB   ! UCL methyl stagger 12-MAR-00  
  dihedral HD21 CD2 CG  CB   ! UCL methyl stagger 12-MAR-00  
  dihedral HE1  CE  CA  CB   ! UCL methyl stagger 12-MAR-00  
 
  DONO HN   N 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
 
residue MABA 
  group 
    atom N    type=NH1  charge=-0.600 end 
    atom HN   type=H  charge= 0.400 end 
    atom CA   type=CF  charge= 0.000 end 
    atom CB   type=CR1E charge= 0.000 end 
    atom HB   type=HA  charge= 0.000 end 
    atom CG   type=CF  charge= 0.000 end 
    atom CD   type=CR1E charge= 0.000 end 
    atom HD   type=HA  charge= 0.000 end 
    atom CE   type=CR1E charge= 0.000 end 
    atom HE   type=HA  charge= 0.000 end 
    atom CZ   type=CR1E charge= 0.000 end  
    atom HZ   type=HA  charge= 0.000 end 
    atom C    type=C  charge= 0.500 end 
    atom O    type=O  charge= -0.500 end 
 
bond N   HN   bond N   CG 
bond CA  CB   bond CA  C  
bond CB  CG   bond CB  HB 
bond CG  CD   
bond CD  CE   bond CD  HD 
bond CE  CZ   bond CE  HE 
bond CZ  CA   bond CZ  HZ 
bond C   O 
 
! Hs around the ring 
  improper HB CB CG CD 
  improper HD CD CE CZ 
  improper HE CE CZ CA 
  improper HZ CZ CA CB 
 
! around the ring 
  improper CA CB CG CD 
  improper CB CG CD CE 
  improper CG CD CE CZ 
  improper CD CE CZ CA 
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  improper CE CZ CA CB 
  improper CZ CA CB CG 
 
  DONO HN   N 
  ACCE O    C 
end 
!--------------------------------------------------------------------- 
 
residue G4A 
  group 
    atom N    type=NH1    charge=-0.600 end 
    atom HN   type=H      charge= 0.400 end 
    atom CA   type=CD1E   charge= 0.000 end  
    atom HA   type=HA     charge= 0.000 end 
    atom CB   type=CD1E   charge= 0.000 end   
    atom HB   type=HA     charge= 0.000 end 
    atom CG   type=CH1E   charge= 0.000 end 
    atom HG   type=HA     charge= 0.000 end 
    atom CD   type=CH3E   charge= 0.000 end 
    atom HD1  type=HA     charge= 0.000 end 
    atom HD2  type=HA     charge= 0.000 end 
    atom HD3  type=HA     charge= 0.000 end 
    atom C    type=C      charge= 0.500 end 
    atom O    type=O      charge=-0.500 end 
 
 
  bond N   HN 
  bond N   CG     bond CG  HG      bond CG  CB      bond CG  CD 
  bond CD  HD1    bond CD  HD2     bond CD  HD3  
  bond CB  CA     bond CB  HB      
  bond CA  C      bond CA  HA       
  bond C   O 
 
! chirality 
  improper HA  CB  C  CG  !chirality CA 
  improper HG1 HG2 CA HG3   !stereo CG 
 
  dihedral HG1 CG  CA  C   ! methyl stagger UCL 12-MAR-00  
 
 
  DONO HN   N 
  ACCE O    C 
end 
!---------------------------------------------------------------------  
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presidue ATOB    ! PEPTide bond link alpha-to-beta, for all except PRO  
                   
  add bond -C +N 
  add angle -CA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CB 
  add angle -C  +N +HN 
  add improper  -C -CA +N -O             ! planar -C 
  add improper  +N -C +CB +HN            ! planar +N 
  add improper -CA -C  +N  +CB           ! angle across peptide plane 
end 
!--------------------------------------------------------------------- 
 
presidue BTOA    ! PEPTide bond link beta-to-alpha, for all except PRO 
                   
  add bond -C +N 
  add angle -CA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CA 
  add angle -C  +N +HN 
  add improper  -C -CA +N -O              ! planar -C 
  add improper  +N -C +CA +HN             ! planar +N 
  add improper -CA -C  +N  +CA            ! angle across peptide plane 
end 
!--------------------------------------------------------------------- 
 
presidue ATOG     ! PEPTide bond link alpha-to-gamma, for all except PRO  
                   
  add bond -C +N 
 
  add angle -CA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CG 
  add angle -C  +N +HN 
 
  add improper  -C -CA +N -O                 ! planar -C 
  add improper  +N -C +CG +HN                ! planar +N 
  add improper -CA -C  +N  +CG               ! angle across peptide plane 
 
end 
!---------------------------------------------------------------------- 
 
 
  
196 
presidue GTOA     ! PEPTide bond link gamma-to-alpha, for all except PRO 
                   
  add bond -C +N 
 
  add angle -CA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CA 
  add angle -C  +N +HN 
 
  add improper  -C -CA +N -O                 ! planar -C 
  add improper  +N -C +CA +HN                ! planar +N 
  add improper -CA -C  +N  +CA               ! angle across peptide plane 
 
end 
!---------------------------------------------------------------------- 
 
presidue ATOG     ! PEPTide bond link alpha-to-gamma cyclic  
                   
  add bond -C +N 
  add angle -CA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CRG 
  add angle -C  +N +HN 
  improper -O -C +N +HN 
  improper -CA -C +N +CRG 
end 
!--------------------------------------------------------------------- 
 
presidue GTOA    ! PEPTide bond link cyclic gamma-to-alpha 
                   
  add bond -C +N 
  add angle -CRA -C +N 
  add angle -O  -C +N 
  add angle -C  +N +CA 
  add angle -C  +N +HN 
  improper -O -C +N +HN 
  improper -O -C +N +CA 
end 
!--------------------------------------------------------------------- 
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APPENDIX D 
1H AND 13C NMR DATA FOR SYNTHETICALLY PREPARED SMALL MOLECULES 
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